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Abstract 
Abstract 
This thesis evaluates the ability of 1H nuclear magnetic resonance (NMR) spectroscopic 
and ultra perfon-nance liquid chromatography-mass spectrometry (UPLC-MS) strategies 
to extract latent biochemical information from complex biofluid matrices from animal 
models and humans. 1H NMR spectroscopy was applied to urine samples to investigate 
time-dependent biochemical changes in acid-base balance studies of metabolic alkalosis 
and metabolic acidosis and in a study of caloric restriction in order to establish normal 
physiological variation in organic acids including tricarboxylic acid (TCA) cycle 
intermediates. A method for profiling organic acids in human urine was developed, 
optimised and validated using UPLC-MS and then applied to targeted and untargeted 
metabolic profiling. 
A combined approach using both techniques was then applied in order to assess the 
relative efficiencies and merits of IH NMR spectroscopy and UPLC-MS for diagnosis 
of unknown inborn errors of metabolism (IEM) diseases using human urine samples in a 
blind fashion. Both NMR and UPLC-MS analytical platforms detected and identified all 
of the I]EM correctly and revealed complementary biochemical information from IIEM 
and controls. This evaluation was further extended and scaled up to assess the capability 
of the technologies for extracting latent biological information from urine samples 
collected in a large human population study. Chernometric methods such as Principal 
Component Analysis (PCA) and Orthogonal Projection to Latent Structure Discriminant 
Analysis (0-PLS-DA) were used to interpret and compare the two spectroscopic data 
types. These statistical methodologies allowed the detection of population specific 
biomarkers and the establishment of key metabolic phenotype differences in selected 
populations. In particular, both analytical approaches were able to discriminate 
Icelandic participants from other populations. The methods developed as part of this 
project should prove useful in widespread metabonomic applications in pharmaceutical 
and disease related areas. 
ii 
Table of contents 
Table of Contents 
Acknowledgments ...................................................................................................................... i 
Abstract ........................................................................................................................................ 
List of Tables ............................................................................................................................. vii 
List of Figures ............................................................................................................................. ix 
Abbreviations ........................................................................................................................... xiii 
Chapter 1: Introduction .............................................................................................................. 
1.1 Aims and objectives ...................................................................................................................... 1 1.2 Metabonomics ............................................................................................................................... 2 1.3 Thesis overview ............................................................................................................................. 7 
Chapter 2: Introduction to Analytical Techniques and Pattern Recognition Methods ...... 10 
2.1 Background to analytical techniques used in metabolic profiling .......................................... 10 
2.1.1 NMR spectroscopy ....................................................................................................................... 13 
Fundamental principles of NMR spectroscopy .............................................................................................. 14 Two-dimensional NMR spectroscopy ............................................................................................................ 19 
2.1.2 Chromatography 
........................................................................................................................... 20 
High performance liquid chromatography (HPLC) ...................................................................................... 20 Ultra Performance Liquid ChromatographyTM (UPLC) ............................................................................... 22 
2.1.3 Mass spectrometry ........................................................................................................................ 27 
2.2 Chemometric analysis ................................................................................................................. 31 
2.2.1 Data pre-processing ...................................................................................................................... 31 
2.2.2 Multivariate, data analysis ............................................................................................................. 34 
Chapter 3: Method Development for Profiling of Organic Acids by Ultra Performance 
Liquid Chromatography (UPLC-MS) ..................................................................................... 40 
3.1 Summary ..................................................................................................................................... 40 
3.1.1 Aims and objectives ...................................................................................................................... 40 
3.2 Introduction ................................................................................................................................. 41 
3.3 Method development .................................................................................................................. 45 
3.3.1 Method optimisation for separation of organic acids .................................................................... 45 
Sample Preparation ....................................................................................................................................... 
45 
Standards ...................................................................................................................................................... 
45 
Chromatographic conditions ......................................................................................................................... 
46 
Mass spectrometry conditions ....................................................................................................................... 
47 
3.3.2 Bioanalytical method validation ................................................................................................... 48 
Preparation of calibration standards and urine samples .............................................................................. 48 
Calibration curves ......................................................................................................................................... 
48 
3.4 Results .......................................................................................................................................... 50 
3.4.1 Method optimisation ..................................................................................................................... 50 
3.4.2 Method validation ......................................................................................................................... 53 
Calibration curves ......................................................................................................................................... 53 
iii 
Table of contents 
A ccuracy and precision ................................................................................................................................. 55 Lower limit of quantification (LLOQ) ........................................................................................................... 55 Matrix effects ................................................................................................................................................. 56 Reproducibilit 
,I............................................................................................................................................... 58 SelectivitYlSpeciflicin ...................................................................................................................................... 59 
3.5 Discussion .................................................................................................................................... 61 3.6 Conclusion ................................................................................................................................... 64 
Chapter 4: 1H NMR Spectroscopic Investigation of Organic Acid Excretion in Young 
Sprague-Dawley Rats ................................................................................................................ 65 
4.1 Summary ..................................................................................................................................... 65 
4.1.1 Aims and Objectives ..................................................................................................................... 65 
4.2 Introduction ................................................................................................................................. 66 
4.2.1 Acid-base balance ....................................................................................................................... .. 68 4.2.2 Kidney anatomy and functions ................................................................................................... .. 70 4.2.3 Re-absorption of bicarbonate ions in kidney .............................................................................. .. 73 4.2.4 Tricarboxylic acid (TCA) cycle intermediates in acid-base balance ............................................. 74 4.2.5 Caloric restriction ......................................................................................................................... 76 4.2.6 Use of 1H NMR spectroscopy in metabolic studies ...................................................................... 77 
4.3 Methodology ................................................................................................................................ 79 
4.3.1 Dose groups and sample collection ............................................................................................... 79 4.3.2 Urinary pH measurements ............................................................................................................ 80 4.3.3 Sample preparation ....................................................................................................................... 80 4.3.4 'H NMR analysis of urine samples ............................................................................................... 81 4.3.5 Data pre-processing ...................................................................................................................... 81 4.3.6 Rationalisation for choice of metabolites ...................................................................................... 
81 
4.3.7 Urinary mean excretion plots ........................................................................................................ 85 
4.4 Results .......................................................................................................................................... 88 
4.4.1 Metabolic alkalosis ....................................................................................................................... 
88 
Visual analYsis of NMR spectra .................................................................................................................. .. 88 Urinary pH .................................................................................................................................................. .. 
90 
Urinary excretion profiles of metabolites during metabolic alkalosis ......................................................... .. 91 
4.4.2 Metabolic acidosis ........................................................................................................................ 
94 
Visual anal , vSis of 
1H NMR spectra ............................................................................................................. .. 94 
Urinary pH .................................................................................................................................................. .. 
96 
Urinary excretion profiles of metabolites during metabolic acidosis .......................................................... .. 97 
4.4.3 Caloric restriction study .............................................................................................................. 
101 
Visual analysis of 1H NMR spectra ............................................................................................................. 
101 
Urinary pH .................................................................................................................................................. 
103 
Urinary excretion profiles of metabolites during caloric restriction ........................................................... 104 
4.5 Discussion .................................................................................................................................. 
107 
4.5.2 Effect of acid-base balance on excretion of metabolites ............................................................. 
108 
Metabolic alkalosis and acidosis ................................................................................................................. 
108 
Caloric restriction ....................................................................................................................................... 
110 
4.6 Conclusion ................................................................................................................................. 
113 
Chapter 5: Assessment of the Relative Efficiencies of 1H NMR Spectroscopy and UPLC- 
MS for the Diagnosis of Inborn Error Organic Acidurias ................................................... 114 
5.1 Summary ................................................................................................................................... 
114 
5.1.1 Aims and objectives .................................................................................................................... 
114 
5.2 Introduction ............................................................................................................................... 
115 
5.2.1 Inborn Errors of Metabolism (lEM) ............................................................................................ 115 
5.2.2 Methods for diagnosing 1EM ...................................................................................................... 
115 
iv 
Table of contents 
5.2.3 Established methods for the identification of IEM ..................................................................... 117 
5.3 Methodology .............................................................................................................................. 121 
5.3.1 NMR analysis of clinical samples and controls .......................................................................... 121 
Urine sample preparation ........................................................................................................................... 121 One-elimensional 1H NMR spectroscopý ...................................................................................................... 121 
Two-dimensional 1H NMR spectroscopy ..................................................................................................... 122 
5.3.2 NMR analysis of standards ......................................................................................................... 124 
Standard solution preparation .................................................................................................................... 124 ID 'H NMR analYsis of standard solutions ................................................................................................. 124 
5.3.3 Data pre-processing and chemometric analysis .......................................................................... 125 5.3.4 UPLC-MS analysis ..................................................................................................................... 126 
Sample Preparation ..................................................................................................................................... 126 Chromatographic conditions ....................................................................................................................... 126 Mass spectrometry conditions ..................................................................................................................... 126 Data pre-processing and chemometric analysis .......................................................................................... 
127 
5.4 Results ........................................................................................................................................ 128 
5.4.1 Metabonomic investigation of inborn errors of metabolism using 400 MHz 'H NMR 
spectroscopy ................................................................................................................................ 128 
Visual analýysls of urine NMR spectra of IEM and controls ........................................................................ 
128 
Principal component analysis (PCA) of IEM and controls ......................................................................... 
136 
5.4.2 Metabonomic investigation of inborn errors of metabolism using 800 MHz 1H NMR 
spectroscopy ................................................................................................................................ 
139 
Visual analysis of NMR spectra of IEM ...................................................................................................... 
139 
Visual anal - NIsis 
of NMR spectra of controls ................................................................................................ 
143 
PCA analysis of 1EM and controls .............................................................................................................. 
146 
5.4.3 Comparison of IEM and controls using 400 MHz and 800 MHz 'H NMR spectroscopies ........ 149 
Visual analysis of urine NMR spectra of 1EM and controls ........................................................................ 
149 
Principal component analysis of IEM and controls .................................................................................... 
152 
5.4.4 UPLC-MS analysis of inborn errors of metabolism .................................................................... 
154 
Visual analysis of chromatograms of IEM samples ..................................................................................... 
154 
Visual analysis of chromatograms of controls ............................................................................................ 
158 
Identification and characterisation of metabolites in samples of IEM ........................................................ 
161 
PCA analysis of UPLC-MS data from IEM samples and controls .............................................................. 
175 
5.5 Discussion .................................................................................................................................. 
180 
5.5.1 Identification ............................................................................................................................... 
180 
5.5.2 Use of 1H NMR spectroscopy for identification of IEM ............................................................. 
183 
5.5.3 Use of UPLC-MS for identification of IEM ............................................................................... 
185 
5.6 Conclusion ............................................................................................................................ *. *** 
188 
Chapter 6: NMR Spectroscopy and UPLC-MS Based Metabonomic Approaches for 
Detection of Urinary Metabolic Differences in Human Populations ................................... 189 
6.1 Summary ................................................................................................................................... 
189 
6.1.1 Aims and objectives .................................................................................................................... 
189 
6.2 Introduction ............................................................................................................................... 
190 
6.2.1 INTERSALT study ..................................................................................................................... 
190 
6.2.2 Use of metabonomics in epidemiology studies ........................................................................... 
191 
6.3 Methodology .............................................................................................................................. 
194 
6.3.1 114 NMR analysis of INTERSALT urine samples ..................................................................... 
196 
Experimental ...................................................................................................................................... *******" "" 
Data analysis of 1H NMR spectroscopy ...................................................................................................... 
197 
6.3.2 UPLC-MS analysis of urine samples .......................................................................................... 
199 
Experimental ............................................................................................................................................... 
199 
Data analysis of UPLC-MS ......................................................................................................................... 
201 
6.3.3 Validation and characterisation of urinary biomarkers ............................................................... 2U2 
V 
Table of contents 
Experimental ............................................................................................................................................... 202 
6.4 Results 
........................................................................................................................................ 205 
6.4.1 11-1 NMR analysis of urine samples ............................................................................................. 205 
Exploratory analysis ................................................................................................................................... 205 Discriminant analývsis of 1H NMR data ....................................................................................................... 211 
6.4.2 UPLC-MS analysis of urine samples .......................................................................................... 218 
Exploratory analývsis of UPLC-MS data ...................................................................................................... 218 Discriminant analYsis of UPLC-MS data .................................................................................................... 224 
6.4.3 Validation and characterisation of urinary biomarkers ............................................................... 230 
Validation of unknown metabolites ............................................................................................................. 230 Characterisation of unknown metabolites in urine samples ftom Iceland ................................................... 231 
6.5 Discussion .................................................................................................................................. 234 
6.6 Conclusion ................................................................................................................................. 237 
Chapter 7: General Discussion, Conclusions and Future Directions .................................. 238 
7.1 General discussion .................................................................................................................... 238 7.2 Conclusion ................................................................................................................................. 248 
7.3 Future work ............................................................................................................................... 249 
References ................................................................................................................................. 251 
Appendices ................................................................................................................................ 
279 
Appendix 1: Materials and Suppliers ................................................................................................... 279 
Appendix 2: Composition of phosphate buffer for urine sample preparation for NMR spectroscopy 
.................................................................................................................................................... 
281 
Appendix 3: MS and MS/MS Spectra of Unknown Metabolites ........................................................ 282 
Appendix 4: Abstract I ........................................................................................................................... 
286 
Appendix 5: Abstract 11 ......................................................................................................................... 
288 
vi 
List of tables 
List of Tables 
Table 1.1: Applications and examples of metabonomics ............................................................................. 5 
Table 1.2: The relative strengths and weaknesses of NMR spectroscopy and mass spectrometry for 
metabonomic applications ........................................................................................................... 6 
Table 2.1: Nuclear spin quantum numbers (1) of some nuclei .................................................................... 14 
Table 2.2: Examples of standard 2D NMR experiments (Claridge, 1999) ............................................... 19 
Table 2.3: Resolution, speed, sensitivity and back pressure improvement with 1.7 [im particle size (UPLQ 
in comparison to 3 and 5 [tm particle size (HPLQ for a constant column length ..................... 23 
Table 3.1: UPLC gradient conditions for 0.1 % formic acid in water (mobile phase A) and acetonitrile 
(mobile phase B) ....................................................................................................................... 46 
Table 3.2: MS and MS/MS conditions for analysing samples of standards and urines in both negative and 
positive modes ........................................................................................................................... 47 
Table 3.3: Retention time of standards of organic acids (50 ýtg/ml) detected in negative mode ................ 51 
Table 3.4: Precision and accuracy of the developed bioanalytical method for quantifying the organic acids 
adipate, cis-aconitate and methylmalonate in human urine samples ......................................... 56 
Table 3.5: Matrix effect of the developed bioanalytical. method for quantifying the organic acids adipate, 
cis-aconitate and methylmalonate in human urine samples ....................................................... 57 
Table 4.1: Examples of urinary metabolites referenced as markers in toxicology studies ......................... 67 
Table 4.2: The primary acid-base disorders ............................................................................................... 70 
Table 4.3: Dose regime/ diet restriction and pre and post dose urine collection time points for metabolic 
alkalosis, acidosis and caloric restriction studies ....................................................................... 80 
Table 4.4: 1H NMR resonances integrated for quantification of urinary metabolites ................................ 85 
Table 4.5: two-way ANOVA statistical analysis and pair-wise student t-test between both low and high 
treatment groups and between controls and treatment groups for time period 0-312 hours for 
urinary pH during metabolic alkalosis ....................................................................................... 91 
Table 4.6: Maximum % change of metabolites of high dose compared to controls and two-way ANOVA 
statistical analysis for time period 0-312 hours for metabolites during metabolic alkalosis ..... 93 
Table 4.7: two-way ANOVA statistical analysis between controls and both low and high treatment groups 
and pair-wise student t-test between both low and high treatment groups and between controls 
and treatment groups for time period 0-312 hours for urinary pH during metabolic acidosis ... 97 
Table 4.8: Maximum % change of metabolites of high dose compared to controls and two-way ANOVA 
statistical analysis for time period 0-288 hours for metabolites during metabolic acidosis ..... 100 
Table 4.9: two-way ANOVA statistical analysis between controls and caloric restriction groups of 25% 
and 50% and between controls and 100% restricted group for I day only .............................. 104 
Table 4.10: Two-way ANOVA statistical analysis for time period 0-168 hours for metabolites during 
caloric restriction samples collected from ad libitum food intake rats and rats restricted with 
50%, 25% food intake and 100% restricted for a day then returned to the diet of controls ..... 106 
Table 5.1: A selection of inborn errors of metabolism that have been detected using 
'H NMR 
spectroscopy and/or hyphenated mass spectrometry ............................................................... 
120 
Table 5.2: UPLC gradient conditions for 0.1% formic acid in water (mobile phase A) and acetonitrile 
(mobile phase B) ..................................................................................................................... 
126 
Table 5.3: NIS and MS/MS conditions for analysing samples of standards and urines in both negative and 
positive modes ......................................................................................................................... 
127 
Table 5.4: Retention time and m/z ratio in negative mode for standards of organic acids measured using 
UPLC-MS ................................................................................................................................ 
154 
vii 
List of tables 
Table 5.5: Separation of IEM urine samples from controls using PCA analysis from both NMR and 
UPLC-MS techniques .............................................................................................................. 187 
Table 6.1: Demographics of urine samples of 194 participants from part of the INTERSALT study for 
initial 1H NMR and UPLC-MS analysis .................................................................................. 194 
Table 6.2: UPLC gradient conditions for 0.1% formic acid in water (mobile phase A) and acetonitrile 
(mobile phase B) ..................................................................................................................... 200 
Table 6.3: NIS conditions for analysing samples of standards and urines in both negative and positive ESI 
modes using Micromass LCT Premier .................................................................................... 200 
Table 6.4: Urine samples of 420 participants from part of the INTERSALT study for repeated UPLC-MS 
analysis .................................................................................................................................... 
202 
Table 6.5: NIS and MSIMS conditions for analysing urine samples in both negative and positive ESI 
modes using Micromass Q-TofTM Premier ............................................................................ 
204 
Table 6.6: Mass to charge ratio/retention time couples of positive correlation from O-PLS-DA analysis 
for discriminating ions for Iceland from other countries and UK ............................................ 
228 
Table 6.7: Retention time/mass to charge ratio couples of positive correlation from O-PLS-DA analysis 
for discriminating ions for China from remaining countries ................................................... 
228 
Table 6.8: Data base and literature search for possible biomarkers which discriminate Iceland from other 
countries .................................................................................................................................. 
233 
Table 6.9: The average weight of coffee consumed (Kg) annually by each person in each country, 
obtained from international coffee organisation ...................................................................... 
237 
viii 
List of Noures 
List of Figures 
Figure 1.1: A flow diagram showing the description of the chapters in the thesis ....................................... 7 
Figure 2.1: The effect of an external magnetic field (BO) on the population difference in the energy states for a spin - 1/2 nucleus ............................................................................................................... 15 
Figure 2.3: van Deernter plot, illustrating the evolution of particle size of UPLC columns compared to 
HPLC ......................................................................................................................................... 24 
Figure 2.4: Comparison of a 10 min section of UPLC chromatograrn with a HPLC chromatogram ........ 25 
Figure 2.5: An example of different types of UPLC chromatogram for a control urine sample; total ion 
chromatograrn (TIC), base peak ion chromatogram (BPI) and extracted ion chromatogram (EIC) 
for m/z 178 ................................................................................................................................ 26 
Figure 2.6: An example of negative mode MS and MS/MS spectra for authentic isovalerylglycine ......... 30 
Figure 2.7: An example of principal component analysis of 1H NMR data of two human control urines 
and two urine samples of inborn errors of metabolism (IEM) of isovaleryl aciduria (IVG) and 
mevalonic aciduria (MEV) ........................................................................................................ 35 
Figure 2.8: An example of a loadings plot from an O-PLS-DA model of HgC12-treated versus control rat 
urines using 1H NMR spectroscopy ........................................................................................... 37 
Figure 2.9: An example of STOCSY plot for metabolites of acetaminophen (paracetamol) in urine 
samples ...................................................................................................................................... 39 
Figure 3.1: Extracted ion chromatograms of organic acids in the control urine sample after spiking 
50gg/ml ..................................................................................................................................... 52 
Figure 3.2: Calibration plots of adipate, cis-aconitate, and methylinalonate .............................................. 54 
Figure 3.3: PCA scores and loadings plots of urines of three different controls, each of them prepared 12 
times and injected in a randomised order .................................................................................. 58 
Figure 3.4: PCA scores and loadings plots of urines 3 different controls with nilz < 200, each of them 
prepared 12 times and injected in a randomised order .............................................................. 59 
Figure 3.5: Extracted chromatograms of cis-aconitate obtained from (A) blank urine I with IS; (B) blank 
urine I without IS; (C) urine 2 containing cis-aconitate at 50 gg/ml; (D) urine I containing cis- 
aconitate at 50 [tg/ml; (E) standard solution of cis-aconitate at 50 gg/ml ................................. 60 
Figure 4.1: The structure of a mammalian nephron .................................................................................... 
72 
Figure 4.2: Mechanism of bicarbonate reabsorption in the proximal tubule .............................................. 74 
Figure 4.3: The tricarboxylic acid (TCA) cycle ......................................................................................... 
75 
Figure 4.4: PCA analysis of rat urine samples from caloric restriction study (A) scores plots of principal 
component I (PC 1) (X axis) and PC 2 (Y axis) of controls and 50% food restricted group, (B) 
loadings plot, (C) loadings plot after removing spectral regions of citrate, 2-oxoglutarate and 
taurine ........................................................................................................................................ 
84 
Figure 4.5: Series of 600 MHz 1H NMR spectra of urine samples collected at 48 and 144 hours post-dose 
from (A) control rat at 48 hours (B) treated with 0.1 M NaHC03 at 48 hours (C) treated with 
0.1 M NaHC03 at 144 hours (D) treated with 0.35M NaHC03 at 48 hours (E) treated with 
0.35M NaHC03at 144 hours after treatment . ........................................................................... 
89 
Figure 4.6: Mean urinary pH values of samples collected from control rats and rats treated with low and 
high doses of NaHC03 .............................................................................................................. 90 
Figure 4.7: Mean urinary excretion rates of (A) citrate, (B) 2-oxoglutarate, (C) succinate, (D) fumarate, (E) 
trans-aconitate, (F) hippurate, (G) N-methyl nicotinamide (NMND) and (H) N-methylnicotinic 
acid (NMNA) for samples collected from control rats and rats treated with low and 
high doses 
of NaHC03 ............. ................................................................................................ 
92 
Figure 4.8: Series of 600 MHz 1H NMR spectra of urine samples collected at 48 and 144 hours post-dose 
from (A) control rat at 48 hours (B) treated with 0.07 M NH4Cl at 48 hours (Low dose) (C) 
ix 
List of flRures 
treated with 0.07 M NH4Cl at 144 hours (Low dose) (D) treated with 0.28 M NH4Cl at 48 hours (high dose) (E) treated wIth 0.28 M NH4CI at 144 hours (high dose) . ............................ 95 Figure 4.9: Mean urinary pH values of samples collected from control rats and rats treated with low and high doses of NH4Cl .................................................................................................................. 96 
Figure 4.10: Mean urinary excretion rates of (A) citrate, (B) 2-oxoglutarate, (C) succinate, (D) furnarate, (E) trans-aconitate, (F) hippurate, (G) N-methyl nicotinamide (NMND) and (H) N- 
methylnicotinic acid (NMNA) for samples collected from control rats and rats treated with low 
and high doses of NH4Cl ........................................................................................................... 98 
Figure 4.11: Series of 600 MHz 'H NMR spectra of urine samples collected at 48 and 144 hours post- dose after (A) administration of ad libitum (control), and animals dietary restricted by (B) 25% 
at post 48 hours (C) 50% at post 48 hours (D) 100% (1 day only) at post 48 hours (E) 25% at 
post 144hours (F) 50% at post 144 hours (G) at 100% (1 day) post 144 hours ....................... 102 
Figure 4.12: Mean urinary pH of samples collected from control rats (C) and animals of dietary restricted by 25%, 50% or 100% (24 hours only then returned to ad libitum diet) . ................................ 103 
Figure 4.13: Mean urinary excretion rates of (A) citrate, (B) 2-oxoglutarate, (C) succinate, (D) furnarate, 
(E) trans-aconitate, (F) hippurate, (G) N-methyl nicotinamide (NMND) and (H) N- 
methylnicotimc acid (NMNA) for samples collected from ad libitum food intake rats and rats 
restricted with 50%, 25% food intake and 100% restricted for a day then returned to the diet of 
controls. Each time point represents the time emerged excretion from the previous 
measurement starting at -24 hrs pre-dose ................................................................................ 105 
Figure 5.1: 400 MHz 1H NMR spectra (6H 4.5-0.5) of urine samples from unknown inborn errors of 
metabolism .............................................................................................................................. 130 
Figure 5.2: 400 MHz 1H NMR spectra OH 5.0-8.5) of urine samples from unknown inborn errors of 
metabolism .............................................................................................................................. 131 
Figure 5.3: 400 MHz 1H NMR spectra(8H4.5-0.5) of urine samples from age-matched controls .......... 133 
Figure 5.4: 400 MHz 1H NMR spectra(8H5.0-8.5) of urine samples from age-matched controls .......... 134 
Figure 5.5: Score plots of principal component (PC) I (X axis) versus PC2 (Y axis) for NMR data of 
urine samples obtained from inborn errors and control samples acquired by 400 MHz 1H NMR 
spectroscopy using (A) mean centred data (B) mean centred data after removal of MMA and 
lVG samples (C) unit variance scaling (D) unit variance scaling after removing MMA and IVG 
samples .................................................................................................................................... 137 
Figure 5.6: Loadings plots of principal component I (PC 1) (X axis) versus PC2 (Y axis) (corresponds to 
Figure 5.5 A and B) for NMR data of urine samples obtained from inborn errors and control 
samples acquired by 400 MHz 1H NMR spectroscopy using A) mean centred data (B) mean 
centred data after removal of MMA and IVG samples ............................................................ 138 
Figure 5.7: 800 MHz 1H NMR spectra(6H4.5-0.5) of urine samples with inborn errors of metabolism 141 
Figure 5.8: 800 MHz 1H NMR spectra(8H5.0-8.5) of urine samples with inborn errors of metabolism 142 
Figure 5.9: 800 MHz 1H NMR spectra (6 4.5-0.5) of urine samples from age-matched controls ............ 144 
Figure 5.10: 800 MHz 1H NMR spectra(8H5.0-8.5) of urine samples from age-matched controls ........ 145 
Figure 5.11: Score plots of principal component I (PC 1) (X axis) versus PC 2 (Y axis) for NMR data of 
urine samples obtained from inborn errors and control samples acquired by 800 MHz 1H NMR 
spectroscopy using A) mean centred data (B) mean centred data after removal of MMA sample 
(C) unit variance scaling .......................................................................................................... 147 
Figure 5.12: Loadings plots of principal component I (PC 1) (X axis) versus PC2 (Y axis) (corresponds to 
5.11 A and B) for NMR data of urine samples obtained from inborn errors and control samples 
acquired by 800 MHz 1H NMR spectroscopy using A) mean centred data (B) mean centred 
data after removal of MMA sample ........................................................................................ 148 
Figure 5.13: Comparison of 400 MHz and 800 MHz 1H NMR spectra of urine samples of (A) 
methylmalonic aciduria (B) mevalonic aciduria (C) isovaleryl aciduria (D) alkaptonuria (E) 
ornithine transcarbarnylase defiency (OTC) and (F) control ................................................... 151 
x 
List of fikures 
Figure 5.14: Score plots of PC I (X axis) versus PC2 (Y axis) for NMR data of urine samples of inborn errors of metabolism and controls obtained from both 400 MHz and 800 MHz 1H NMR 
spectroscopies using A) mean centred data (B) mean centred data after removal of outliers (C) 
unit variance scaling ................................................................................................................ 153 
Figure 5.15: Negative mode Base Peak Intensity (BPI) chromatograms between 0.4 -7 min for each of the blinded IEM urine samples ................................................................................................ 156 
Figure 5.16: Positive mode Base Peak Intensity (BPI) chromatograms between 0.4 -7 min for each of the blinded IEM urine samples ...................................................................................................... 157 
Figure 5.17: Negative mode Base Peak Intensity (BPI) chromatograms between 0.5 -7 min for each of the blind control urine samples ................................................................................................ 159 
Figure 5.18: Positive mode Base Peak Intensity (BPI) chromatograms between 0.5 -7 min for each of the blind control urine samples ..................................................................................................... 160 
Figure 5.19: Extracted ion chromatograms, MS and MS/MS spectra for authentic methylmalonic acid and IEM urine sample I ................................................................................................................. 162 
Figure 5.20: Extracted ion chromatograms, MS and MS/MS spectra for authentic mevalonolactone and 
IEM urine sample 2 ................................................................................................................. 164 
Figure 5.2 1: Extracted ion chromatograms, MS and MS/MS spectra for authentic isovalerylglycine and 
IEM urine sample 3 ................................................................................................................. 166 
Figure 5.22: Extracted ion chromatograms, MS and MS/MS spectra for authentic i sovalerylcarni tine and 
IEM urine sample 3 ................................................................................................................. 167 
Figure 5.23: Extracted ion chromatograms, MS and MS/MS spectra for authentic homogentisic acid and 
IEM urine sample 4 ................................................................................................................. 169 
Figure 5.24: Extracted ion chromatograms, MS and MS/MS spectra for authentic orotic acid and IEM 
urine sample 5 ......................................................................................................................... 171 
Figure 5.25: Extracted ion chromatograms, MS and MS/MS spectra for authentic orotic acid and IEM 
urine sample 5 ......................................................................................................................... 172 
Figure 5.26: Extracted ion chromatograms, MS and MS/MS spectra for authentic uridine and IEM urine 
sample 5 ................................................................................................................................... 173 
Figure 5.27: Score plots of principal component I (PC 1) (X axis) versus PC2 (Y axis) for negative mode 
UPLC-MS data of urine samples obtained from IEM and control samples using (a) mean 
centred data (b) unit variance scaling (C) unit variance scaling after removal of MMA sample 
176 
Figure 5.28: Loading plot of PCI (X axis) versus PC2 (Y axis) negative mode UPLC-MS data 
(corresponding to Figure 5.27 (A)) of urine samples obtained from IEM patients and controls 
using mean centring ................................................................................................................. 177 
Figure 5.29: Score plots of principal component I (PC 1) (X axis) versus PC 2 (Y axis) for positive mode 
UPLC-MS data of urine samples obtained from inborn errors and control samples using (a) 
mean centred data (b) unit variance scaling (C) unit variance scaling after removal of the MMA 
sample ...................................................................................................................................... 
178 
Figure 5.30: Loading plot of PCI (X axis) versus PC2 (Y axis) for positive mode UPLC-MS data 
(corresponding to Figure 5.29 (A)) of urine samples obtained IEM samples and controls using 
mean centring .......................................................................................................................... 
179 
Figure 5.3 1: Metabolic pathway of valine and isoleucine metabolism .................................................... 180 
Figure 5.32: Metabolic pathway of peroxisomal cholesterol metabolism ................................................ 181 
Figure 5.33: Metabolic pathway of leucine metabolism, adapted from .................................................... 182 
Figure 5.34: Metabolic pathway of tyrosine metabolism, adapted from .................................................. 182 
Figure 5.35: Metabolic pathway for urea formation, adapted from .......................................................... 183 
Figure 6.1: A flow diagram illustrating the method used for analysis of INTERSALT study urine samples 
................................................................................................................................................. 
195 
xi 
List of figures 
Figure 6.2: Principal component analysis (PCA) of mean- centred 1H NMR data of 194 urine samples from nine countries (A) scores map; data coloured according to country (B) loadings map ... 206 
Figure 6.3: Principal component analysis (PCA) of urine 1H NMR data from nine countries after removal 
of four outliers samples containing ethanol (A) scores map using mean centring; 1H NMR 
data coloured according to country (B) loadings map of mean-centred 1H NMR data ........... 207 
Figure 6.4: One dimensional STOCSY analysis of Iceland population for the selected variable at 
4.445ppm 
................................................................................................................................. 208 
Figure 6.5: The scores map of PCA of urine 'H NMR urine data from nine countries after removal of four 
outliers samples containing ethanol using unit variance scaling . ............................................ 209 
Figure 6.6: Principal component analysis of urine 1H NMR data of Iceland and China after removal of 
outliers samples containing ethanol (A) scores map using mean centring; 1H NMR data 
coloured according to country (B) loadings map of mean-centred IH NMR data (C) scores map 
using unit variance scaling . ..................................................................................................... 210 
Figure 6.7: O-PLS model for the discrimination of 1H NMR urine spectra of Iceland versus all other 
populations (a) cross-validated scores for the discrimination between two groups (black - Iceland, red - other countries) (b) loading coefficient plot ...................................................... 213 
Figure 6.8: O-PLS model for the discrimination of IH NMR urine spectra of China versus other countries 
(a) cross-validated scores for the discrimination between two groups (black - China, red - other 
countries) (b) loading coefficient plot ..................................................................................... 214 
Figure 6.9: O-PLS model for the discrimination of 1H NMR urine spectra of Iceland and a similar 
geographical and environmental western country UX (a) cross-validated scores for the 
discrimination between two groups (black - Iceland, red - U. K) (b) loading coefficient plot. 
216 
Figure 6.10: O-PLS model for the discrimination of 'H NMR urine spectra of China and a similar 
geographical and environmental eastern country Japan (a) cross-validated scores for the 
discrimination between two groups (black - China, red - Japan) (b) loading coefficient plot. 217 
Figure 6.11: Principal component analysis (PCA) of urine UPLC-MS data from nine countries (A) scores 
plot of mean centring data (B) Loadings plot of mean-centring data (c) scores plot of unit 
variance scaling data ................................................................................................................ 
220 
Figure 6.12: Principal component analysis (PCA) of urine UPLC-MS data of Iceland and China (A) 
scores map using mean centring (B) loadings map of mean-centred UPLC-MS data (C) scores 
map using unit variance scaling ............................................................................................... 
221 
Figure 6.13: Comparison of Negative mode Base Peak Intensity (BPI) chromatograms between 0.4 -7 
min for urine samples of participant from Iceland and china . ................................................. 
222 
Figure 6.14: PCA scores map of urine UPLC-MS data of western countries Colombia, Iceland, Italy, 
USA and UK using unit variance scaling ............................................................................... 
223 
Figure 6.15: PCA scores map of urine UPLC-MS data of eastern countries India, Japan and China using 
unit variance scaling ................................................................................................ **----** 
224 
Figure 6.16: O-PLS model for the discrimination of UPLC-MS data of Iceland versus all other countries, 
the signal orientation indicates the higher (positive orientation) or lower (negative orientation) 
concentration of metabolites with respect to Iceland ............................................................... 
225 
Figure 6.17: O-PLS model for the discrimination of UPLC-MS data of China versus all other countries, 
the signal orientation indicates the higher (positive orientation) or lower (negative orientation) 
concentration of metabolites with respect to China ................................................................. 
226 
Figure 6.18: O-PLS model for the discrimination of UPLC-MS data of Iceland and UK, the signal 
orientation indicates the higher (positive orientation) or lower (negative orientation) 
concentration of metabolites with respect to Iceland ............................................................... 
227 
Figure 6.19: Extracted ion chromatograms of urine samples of participant from Iceland and china for (A) 
at nVz 495.2 and (B) at nVz 511.2 .................................................................................... ***, *, **229 
Figure 6.20: Bar chart of mean intensity values of nz/z 495.2 and nz/z 511.2 for all nine countries ......... 230 
Figure 6.21: MS/MS spectra of a urine sample of Iceland with nVz 495.2 and nilz 511.2 ....................... 231 
xii 
Abbreviations 
Abbreviations 
1D One Dimensional 
2D Two Dimensional 
ACN Acetonitrile 
APCI Atmospheric Pressure Chemical lonisation 
ATP Adenosine Triphosphate 
BPI Base Peak Ion Chromatogram 
COSY Correlated Spectroscopy 
8H 1H NMR chemical shift 
DMA Dimethylamine 
EIC Extracted Ion Chromatogram 
ESI Electro Spray Ionisation 
FDA Food Drug Agency 
FID Free Induction Decay 
FT Fourier Transform 
GC Gas Chromatography 
1H Hydrogen 
H20 Water 
HMBC Heteronuclear Multiple Bond Correlation 
HMQC Heteronuclear Multiple Quantum Coherence 
HPLC High Perfon-nance Liquid Chromatography 
hr Hour 
Hz Hertz 
I Spin quantum number of a nucleus 
INTERSALT INTERnational study of SALT and blood pressure 
J Spin-spin coupling constant 
LB Exponential line broadening factor 
LC Liquid Chromatography 
LOD Limit of Detection 
A] microlitre 
min Minutes 
MS Mass Spectrometry 
Mw Molecular Weight 
M/Z Mass to charge ratio 
NMR Nuclear Magnetic Resonance 
O-PLS-DA Orthogonal Projection to Latent Structures - Discriminant Analysis 
PC Principal Component 
PCA Principal Component Analysis 
PLS-DA Projection to Latent Structures - Discriminant Analysis 
PPM Parts Per Million 
Q-TOF Quadrupole-Time Of Flight 
RT Retention Time 
xiii 
Abbreviations 
SIMCA Soft Independent Modelling Of Class Analogy 
SPE Solid Phase Extraction 
S/N Signal to Noise 
STOCSY Statistical Total Correlation Spectroscopy 
TCA Tri Carboxylic Acid 
TIC Total Ion Current Chromatogram 
TNL4L Trimethylamine 
TMAO Trimethylamine-N-oxide 
TOCSY TOtal Correlation SpectroscopY 
TOF Time Of Flight 
TSP sodium 3-(trimethylsilyl)- I -propionate 
UPLC Ultra Performance Liquid Chromatography 
UK United kingdom 
USA United States of America 
xiv 
C'hy ter I 
Chapter 1: Introduction 
1.1 Aims and objectives 
The overall aim of this project is to evaluate the ability of a range of specific IH NMR 
spectroscopy and ultra-performance liquid chromatography-mass spectrometry (UPLC- 
MS) based approaches to extract meaningful biochemical information from complex 
biofluid matrices derived from animal models of toxicity and from human studies. 
The specific objectives of this project are: 
1. To develop, optimise and validate a new approach for profiling urinary organic 
acids and other metabolites using UPLC-MS bioanalytical method, and to apply 
these to targeted and untargeted metabolic profiling. 
2. To apply 1H NMR spectroscopy to investigate the time-related changes of organic 
acids including TCA cycle intermediates and to distinguish the possible non-toxic 
or confounding physiological effects of toxic intervention caused by metabolic 
alkalosis, metabolic acidosis as well as caloric restriction on the metabolic 
composition of urine in rat models. 
To assess the relative performance of 1H NMR spectroscopy and UPLC-MS for 
diagnosis of patients with unknown inborn errors of metabolism from urine 
samples. 
4. To evaluate the applicability of 1H NMR spectroscopy and UPLC-MS analytical 
platforms for scale-up to large scale human population epidemiological studies by 
investigating a series of human population samples with varying ethnic 
backgrounds. 
To apply chernometric tools such as principal component analysis (PCA) and 
orthogonal projection to latent structure discriminant analysis (0-PLS-DA) to NMR 
and UPLC-MS datasets for detection of population specific biomarkers and to 
establish key metabolic phenotype differences in selected populations using the 
developed methodologies. 
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1.2 Metabonomics 
Metabonomics provides a means of probing biological processes in complex organisms 
by studying metabolic endpoints, and has been defined as "the quantitative 
measurement of the time-related metabolic response of living systems to 
pathophysiological stimuli or genetic modification"(Nicholson et al., 1999). Measuring 
changes in metabolite concentrations (metabolic profiling) is a powerful approach for 
assessing gene function which has identified different phenotypes (Brindle et al., 2002, 
Phelps et al., 2002). Metabolic profiling is usually conducted on biofluids that can be 
obtained non-invasively (urine) or relatively easily e. g. blood serum. The potential 
applications of metabonomics include evaluating the biochemical composition of 
biofluids and tissues for control animals and humans, characterising diseases in patients 
and animals, drug safety testing and nutrition studies. Metabonomics has several 
advantages over other "-omics" techniques including rapid sample preparation and 
acquisition, minimally invasive, low cost per sample but most importantly generating 
'real' endpoints evidence of perturbed metabolites. High resolution 1H nuclear magnetic 
resonance (NMR) spectroscopy and mass spectrometry (MS) are two of the most 
powerful technologies employed to investigate the biochemical composition of biofluids 
and tissues (Lenz et al., 2007b, Lindon et al., 2008, Wang et al., 2006a, Wishart et al., 
2008). 
Biofluid spectral profiles contain a vast array of latent information about many factors 
such as the species, age, sex and diet of the organism from which a sample derives. 
Changes in biofluid profiles in response to toxic or disease-induced stress may 
incorporate latent information about the type of toxic insult or mechanism of toxicity 
(Lindon et al., 2003a). Much of this latent infori-nation can be extracted from multi- 
parametric spectral datasets by use of multivariate analysis (MVA) that reduces the 
dimensionality of the dataset to make it more interpretable. Unsupervised and 
supervised pattern recognition (PR) techniques can be used to discern patterns in 
complex datasets. One simple unsupervised technique used extensively in 
metabonomics is principal component analysis (PCA) which establishes any intrinsic 
clustering within a dataset by mapping samples according to their properties without a 
prior knowledge of sample class. Widely used supervised methods include projection to 
latent structures-discriminant analysis (PLS-DA) and orthogonal projection to latent 
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structures discriminant analysis (0-PLS-DA). These supervised methods of analysis use 
4. class information given for a dataset to optimise the separation between two or more 
sample classes (Trygg et al., 2007). 
Metabonomics has been successfully applied to investigate a wide range of 
physiological and environmental effects that can have an influence on the metabolic 
composition of human and animal biofluids (Table 1.1). Both NMR spectroscopy and 
MS based metabonomics techniques have been used to distinguish many physiological 
effects including diet (Griffin et al., 2000), diurnal effects (Bollard et al., 2001, Lenz et 
al., 2007b, Plumb, 2003), hormonal variation (Bollard et al., 2001), interspecies 
differences and similarities (Holmes et al., 1996, Holmes et al., 1997a), strain 
differences (Gavaghan et al., 2000, Plumb, 2003) and gender related differences (Lenz 
et al., 2007b, Plumb, 2003). The importance of gut microfloral effects on humans have 
been studied extensively using germ-free animals (Nicholls et al., 2003), different 
animal colonies (Robosky et al., 2005), parasitic infections in animals (Wang et al., 
2004, Wang et al., 2006b) and using probiotics (Martin et al., 2007, Martin et al., 2008) 
and antibiotics (Anthony et al., 1993, Anthony et al., 1992, Connor et al., 1994). 
NMR based metabolic profiling has been used to investigate many diseases including 
inherited metabolic disorders, organ failure and cancers (Howells, 1992, Nicholson et al., 
1989b, Yang et al., 2004). NMR spectroscopy analysis of biofluids, particularly urine, 
to detect inborn errors of metabolism is a more powerful method than the widely used 
conventional method of gas chromatography-mass spectrometry (GC-MS), which can 
be time consuming and involve considerable sample preparation (Lindon et al., 1999, 
Lindon et al., 2007, Wevers et al., 1999). Both NMR spectroscopy and MS analytical 
techniques have been used to investigate a variety of other diseases using biofluids such 
as urine, plasma and cerebrospinal fluid (CSF). These include diabetes (Toye et al., 
2007, Williams et al., 2005), coronary heart disease (Brindle et al., 2002), Alzheimer's 
disease (Frolich et al., 1998, Ghauri et al., 1993a, Pocernich et al., 2003), multiple 
sclerosis (Lutz et al., 2007) and cancer turnours (Barton et al., 1999, Howells, 1992, 
Marangon et al., 2008, Moka et al., 1997). 
Numerous studies have used metabonomics to evaluate many toxins including the liver 
toxins hydrazine (Holmes et al., 1998b, Nicholls et al., 2001, Wu et al., 2005), carbon 
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tetrachloride (Robertson et al., 2000, Wu et al., 2005), cc-Napthylisothiocynate 
(Beckwith-Hall et al., 1998, Robertson et al., 2000) and galactosamine (Beckwith-Hall 
et al., 1998, Coen et al., 2007a, Ishihara et al., 2006) and the kidney toxins mercury 11 
chloride (Gartland et al., 1989, Nicholson et al., 1985), p-aminophenol (Gartland et al., 
1990b) and uranyl nitrate (Gartland et al., 1990a). The interest in the use of 
metabonomics to evaluate drug adverse effects is highlighted by the Consortium On 
MEtabonomic Toxicology I (COMET 1) project which was formed to develop 
methodologies to generate a metabonomic database using 1H nuclear magnetic 
resonance (NMR) spectroscopy of mouse and rat urine and blood serum for preclinical 
toxicological screening of candidate drugs (Lindon et al., 2003b). As part of this project, 
the analytical reproducibility of metabonomic data which were acquired from different 
laboratories was assessed and found to be highly reproducible and robust (Keun et al., 
2002b). Additionally, COMET has shown the possibility of building predictive and 
informative models of toxicity using NMR-based metabonomics data. This successful 
outcome is implemented by a construction of a computer based expert system for the 
prediction of target organ toxicity, generated from the databases of a wide range of 147 
model toxins (Lindon et al., 2003b). The follow-up program COMET 2 is currently in 
progress which aims to enhance the knowledge gained from COMET I by detailed 
testing of metabonomic hypotheses using NMR spectroscopy, liquid chromatography- 
mass spectrometry (LCMS), and appropriate in vitro and in vivo labelling studies for 
understanding the detailed biochemical mechanism in model system of specific toxins 
such as galactosamine and 2-bromoethanamine (BEA). 
Apart from human and other mammalian systems, metabonomics has also been applied 
in fields such as environmental pollution. The potential benefits of this tool has been 
highlighted in studies of caterpillar haemolymph (Phalaraksh et al., 1999), soil 
pollution (Bundy et al., 2002, Jones et al., 2008) and heavy metal toxicity in rodents 
'fin et al., 
2001). Furthermore, metabonomic data have been successfully integrated (Grif 
with data from other molecular biology platforms such as genomics (Griffin et al., 
2004), transcriptomics (Coen et al., 2004, Hirai et al., 2004) and proteomics 
(Rantalainen et al., 2006). This integration of different technology platforms offers 
complementary information of metabolic responses and thus enhances 
insight 
understanding of in vivo model systems. 
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Table I. I: Applications and examples of metabonomics Technique- Reference: colour coded, CSF: Cerebrospinal t1uld, both techniques 'H NMR spectroscopy and HPLC-MS 
Application Examples Biofluid Biomarkers 
- Analytical 
References techniques 
Citrate, Formate, (Bollard et al., 2001, 
Diurnal Taurine Creatinine' Lenz et al., 2007b, 
variation 
Urine , Allantoin, 2- Plumb, 2003, Plumb 
oxoglutarate et al., 2005a, Williams et al., 2005) 
Hormonal 
Urine Trimethylamine 
variation (TMA) (Bollard et al., 2001) 
2-oxoglutarate, 
Strain Taurine, Hippurate, 
(Bollard et al., 2005b, 
Urine Formate P/l/mb, 200'?, P111/11b Investigation differences , Betaine, Succinate, 1H NMR et al., 2005a, 
of Acetate spectroscopy, 
Williams et al., 2005) 
physiological Hippurate, FiPLC-t%1S. (Bollard et al., 2005b, status 
Gender Succinate, 2- 
UPLC-MS Lenz et al., 2007b, 
differences Urine oxoglutarate, Plumb, 2003, Plumb Dimethylglycine et al., 2005a, 
(DMG) Williams et al., 2005) 
Interspecies (Beckwith-Hall et al., 
variation 
Urine 1998, Bollard et al., 
2005b) 
Gut 
nýdcrobial Hippurate 
(Bollard et al., 2005b, 
Nicholls et al., 2003) 
effects 
Inborn 
errors of Urine 
Organic acids and See Chapter 5, Table 
amino acids 5.1 
metabolism 
(Barton et al., 1999, 
Howells, 1992, 
Cancer Tissue Lipoprotems "Varall" , on et al., Plasma 2008, Moka et al., 
1H NMR 1997, Yong et id., Classification 
spectrometry, -1004) of disease (Toye et al., 2007, Diabetes Urine Glucose Williams et al., 2005) 
Coronary 
heart Serum Triglycerides (Brindle et al., 2002) 
disease 
Alzheimer's CSF Citrate (Ghauri et al., 1993a) disease 
organic acids and Kidney 
amino acids 1H NMR Table Ch r4 S t Classification ee ap e , 
of Toxicity Liver 
Urine Taurme, bile acids, 
organic acids and 
spectrometry 4.1 
amino acids 
Heavy 
metal 1H NMR - Environmental toxicity Tissue spectrometry, 
pollution Soil Maltose (Bundy et al., 2002) 
pollution 
(Rantalainen et al., 
Proteomics Plasma 2006) 
1H NMR 
Integration of Transcripto 
Tissue 
Plasma 
spectrometry, (Coen et al., 2004, 
metabonomiCs Plant nucs 
I extract 
GenomicS I Tissue 
rýýn 
et al., 2004) 
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Although both NMR spectroscopy and MS have been widely used for metabonornic 
applications, the real benefits of each technique are not entirely appreciated. Table 1.2 
presents a comparison of both these complementary analytical techniques. Many of 
these analytical instruments, including high-field NMR spectroscopy and Fourier 
transforrn mass spectrometers (FT-MS) may have high initial expense involved in the 
purchase and NMR spectroscopy requires specifically adapted infrastructure. Both 
analytical platforms require experienced users and trained chemometricians for data 
analysis. Targeted approaches by both NMR spectroscopy and MS may be more 
sensitive than global analysis. Compared to transcriptomics, automated peak 
annotations using these analytical platforms are not possible at present and thus will not 
be suitable for large scale use in the developing world or even with some sectors of the 
healthcare system. 
Table 1.2: The relative strengths and weaknesses of NMR spectroscopy and mass 
spectrometry for metabonomic applications, adapted from Lindon et al. (Lindon et al., 
2008) 
1H NMR spectroscopy MS spectrometry 
Detection limits Micromolar at typical Picomolar 
observation frequency (600 
MHz) but nanomolar using cryo 
probes 
Universality of metabolite If metabolite contains hydrogen, Usually needs a more targeted 
detection it will be detected (other nuclei approach. There can be problems 
can be used but are not as with poor chromatographic 
sensitive) separation due to lack of ionisation 
or ion suppression (this is reduced 
when using UPLQ. 
Ability to run both positive and 
negative detection give extra 
information 
Sample handling Whole sample analysed in one Different LC columns and 
measurement conditions needed for different 
classes of metabolites 
Amount of sample used Typically 200-400 ýtl, but much Low gl range 
less with micro probes (5- 10 [d) 
Sample recovery Technique is non-destructive Technique is destructive but only 
small amounts used 
Analytical reproducibility Very high Fair 
Sample preparation Minimal Often simple sample preparation 
Ease of molecular High, both from databases of Difficult, often needs extra 
identification authentic material and by self- experiments such as tandem 
consistent analysis of ID and spectrometry MS/MS. 
2D spectra 
Robustness of instruments High Low 
Analysis of tissue samples Yes, tissue extractions and Yes, if tissues are extracted 
intact tissue analysis 
Availability of databases Several are available on the For LC-MS, only mass values can 
web be compared. Some fragmentation 
databases are now available. 
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1.3 Thesis overview 
Figure 1.1 shows the chapters and their inter-relationships in this thesis. Chapters 2-7 of 
this thesis detail and compare analytical investigations evaluating of the ability of 1H 
NMR spectroscopy and UPLC-MS platfon-ns for extracting latent biological 
information from animal models and human urine samples. Multivariate analysis of 
pattern recognition tools including PCA and O-PLS-DA were used to analyse the 
datasets from both 1H NMR spectroscopy and UPLC-MS. 
Chapter I 
Introduction to Metabonomics 
Chapter 2 
Introduction to Analytical Techniques 
and Pattern Recognition Methods 
Chapter 3 
Method Development for Profiling 
Urinary Organic Acids 
Using UPLC-MS 
Chapter 5 
Assessment of the Relative Efficiencies 
of 1H NMR Spectroscopy and UPLC-MS 
for the Diagnosis of Inborn Error 
Organic Acidurias 
Chapter 4 
IH NMR Spectroscopy Investigation 
of Organic Acid Excretion in Young 
Sprague Dawiey Rats 
Chapter 6 
IH NMR Spectroscopy and UPLC-MS 
Based metabonomic Approaches for 
Detection of Urinary metabolic 
Differences in Human Populations 
Chapter 7 
General Discussion, Conclusions and suggestions for further research 
Figure 1.1: A flow diagram showing the description of the chapters in the thesis 
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Chapter 2 describes in detail the background and principles of analytical techniques 
NMR spectroscopy and mass spectrometry, pre-processing steps for both NMR and MS 
data and chemometric pattern recognition methods used in this thesis such as principal 
component analysis (PCA), projection to latent structures-discriminant analysis (PLS- 
DA), orthogonal projection to latent structures discriminant analysis (0-PLS-DA) and 
statistical total correlation spectroscopy (STOCSY). 
Chapter 3 describes the development and optimisation of a bioanalytical method for the 
profiling of organic acids in human urine using the relatively new analytical technique 
of UPLC-MS. Although this method was optimised for profiling urinary organic acids, 
which eluted in less than 5 mins, the chromatography gradient was also ramped to a 
higher organic solvent acetonitrile (ACN) ratio up to 95% with total time of 12 mins, to 
elute the majority of hydrophilic and hydrophobic metabolites in urine. Thus this 
method could be used for separation of other classes of metabolites for untargeted 
metabolic profiling studies. This method was applied to analysis of urine samples of 
inborn errors of metabolism (IIEM) (Chapter 5) in a blind fashion and untargeted 
metabolic profiling of the large human population study INTERSALT (Chapter 6). 
Chapter 4 analyses the differences in the temporal changes in urinary metabolite 
composition due to possible adverse drug side-effects. 1H NMR spectroscopy was used 
to investigate the temporal relationship between organic acids including TCA cycle 
intermediates citrate, 2-oxoglutarate, succinate and fumarate to distinguish the possible 
non-toxic or confounding physiological effects of xenobiotic intervention of rat models 
from toxicology studies of chemically induced metabolic acidosis, metabolic alkalosis 
as well as caloric restriction. 
In Chapter 5, urine samples of patients with unknown inborn errors of metabolism (I]EM) 
and age-matched controls were analysed by both 
1H NMR spectroscopy and UPLC-MS 
in order to identify and characterise metabolic profiles of I]EM. Initially the 
investigation was carried out using 400 MHz 
1H NMR spectroscopy without any prior 
knowledge of the diagnosis. Subsequently the urine samples were analysed by both 800 
MHz 1H NMR spectroscopy and UPLC-MS to obtain both confirmatory and 
complementary information. 
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Chapter 6 describes the capabilities of 1H NMR and UPLC-MS technologies for 
extracting latent metabolite information from a subset of urine samples from a large 
human population which forms part of the INTERSALT study. Initially, urine samples 
for this study obtained from 194 participants from nine countries were analysed by both 
IH NMR and UPLC-MS technologies. Multivariate analysis methods were applied to 
selected populations in order to identify those metabolites responsible for characterising 
people from the different countries. Subsequently, this study was repeated with a larger 
number of samples to identify urinary biomarkers which discriminated Icelandic 
participants from other populations since Iceland was the greatest metabolic outlier in 
this population study. 
Chapter 7 of this thesis brings together the above studies in a general discussion and 
describes the ongoing evaluation of the ability of 1H NMR spectroscopy and UPLC-MS 
approaches for extracting significant biological information from animal models and 
human urine samples. The use of UPLC-MS for obtaining complementary biological 
latent information is described. Furthen-nore, future directions were also discussed 
including identifying metabolites using more advanced Fourier-transform mass 
spectrometry (FIFMS) and integrating both IH NMR spectroscopy and UPLC-MS 
datasets to investigate correlation patterns of metabolites. 
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Chapter 2: Introduction to Analytical Techniques 
and Pattern Recognition Methods 
2.1 Background to analytical techniques used in 
metabolic profiling 
A variety of analytical techniques are currently used for metabolic profiling to generate 
information-rich data sets as a basis for metabonomic investigations. The main 
approaches are high resolution 1H nuclear magnetic resonance (NMR) and mass 
spectrometry (MS), usually coupled to chromatography. 
Nuclear magnetic resonance (NMR) spectroscopy: over the last two decades, 
with the major improvements in resolution and sensitivity, NMR spectroscopy has 
become a key analytical technique for the detection, characterisation and quantification 
of xenobiotic and endogenous metabolites in biofluids and the investigation of many 
diseases including inherited metabolic disorders (Holmes et al., 1994, Lindon et al., 
1999, Nicholson et al., 1989b), organ failure (Lindon et al., 1999) and cancers (Barton 
et al., 1999, Howells, 1992). The primary advantages of this technique are its non- 
destructive and non-selective nature and its ability to measure analytes in biofluids 
quickly and accurately, with minimal sample preparation. 
In practical terms, typical 600 MHz IH NMR spectroscopy using a standard room 
temperature probe can obtain adequate signal-to-noise (S/N) spectra on ca 0.5 ml of 
sample within five minutes. The development of cryogenic probes has shown that NMR 
S/N can be improved by cooling the NMR radio frequency detector and preamplifier to 
-20K (Styles et al., 1984). Reducing thermal noise in this way provides up to a 
four-fold 
improvement in probe sensitivity on a single scan and 16 fold improvement in real time 
sensitivity for multi-scan experiments, which can greatly reduce the experimental time. 
Furthermore, due to this higher sensitivity, cryogenic technologies allow the detection 
of lower abundance metabolites in the biofluids with volume or mass limited 
circumstances than could be expected of conventional NMR techniques (Griffin et al., 
2002, Keun et al., 2002a). 
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Two-dimensional (2D) NMR spectroscopy is useful for elucidating the connectivities 
between signals, thus aiding the identification of the molecular structures of metabolites 
(Gerhard et al., 2003). These include correlation spectroscopy (COSY) and total 
correlation spectroscopy (TOCSY), providing connectivity information of protons in a 
molecule. Another type of 2D experiment, J-resolved Q-res) provides information on 
the multiplicity and coupling pattern of resonances. 
The addition of magic-angle spinning (MAS) NMR spectroscopy to the NMR toolbox 
allows intact tissues and cells to be examined with small amounts of material (ca 15-20 
mg) and enables, for example, direct examination and characterisation of turnours, 
(Bollard, 2000, Garrod, 1999, Moka et al., 1997). The development of the hyphenated 
technique liquid chromatography (LC)-NMR has had substantial impact on the ability to 
simplify complex biofluid spectra by use of the liquid chromatographic separation step. 
This has proved particularly advantageous for structural elucidation of drug metabolites 
in toxicology studies (Dear et al., 2000). 
Mass spectrometty (MS): Mass spectrometry has been widely used in metabolic 
identification of both plant extracts (Goodacre et al., 2003, Koulman et al., 2007) and 
mammalian studies (Huskova et al., 2004, Jiang et al., 2007, Shackleton et al., 1997). 
Direct infusion of biofluids provides a rapid way to obtain a metabolite 'fingerprint' 
from a sample. However, direct infusion analysis of complex liquid samples into a mass 
spectrometer often causes problems such as ion signal suppression due the simultaneous 
presence of compounds. 
In the 1970s, mass spectrometry coupled to a separation technique, gas chromatography 
(GC-MS), was used as the prime analytical tool for metabolic profiling analysis of low 
molecular weight species of steroids, acids and drug metabolites in biological samples 
(Horning et al., 1971). This technique is still being used to detect suspected or known 
metabolic disturbances (Cartigny et al., 2006, Song et al., 2008) or plant and microbial 
metabolic fingerprinting (Jonsson et al., 2004, Tolstikov et al., 2002), but requires 
extensive sample preparation methods that include sample extraction and derivatisation 
(Chace, 2001). 
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High performance liquid chromatography (HPLC) is widely used to separate out 
different compounds, including non-volatile molecules, from a complex sample mixture. 
The combination of HPLC with MS is currently the most widespread separation 
technique utilised in metabonomics as this does not require derivatisation of the sample 
as required in GC-MS. HPLC-MS has now emerged as an additional technique for 
generating metabonomic data, often detecting a different, and complementary, range of 
metabolites to NMR spectroscopy. This technique has been applied to the investigation 
of toxicity in rats (Lafaye et al., 2003, Lenz et al., 2004, Plumb et al., 2002), to the 
discrimination of strain, gender and diurnal variation in mice and to disease models in 
rats (Plumb, 2003). 
More recently, the application of ultra performance liquid chromatography coupled to mass 
spectrometry (UPLC-MS) to generate metabonomic profiles in toxicity or phenotyping has 
begun to be explored (Granger et al., 2007, Plumb et al., 2005a, Plumb et al., 2006a). This 
advanced analytical system also provides an alternative platform in proteornics to detect and 
quantify proteins in human serum in a multiplexed fashion without the need for antibodies 
(Kay et al., 2007). Increased resolution of this method has improved identification and 
separation of plasma drug metabolites in pharmacokinetics studies (Pedraglio et al., 2007, 
Qin et al., 2008). UPLC uses columns packed with 1.7 micron particles and enables elution 
of sample components in much narrower, more concentrated bands, resulting in better 
chromatographic resolution, improved separation and hence increased sensitivity. 
Both IH NMR spectroscopy and MS are extremely powerful technologies for the 
identification and quantitative analysis of compounds of both endogenous and 
xenobiotic origin and have been used extensively in probing the composition of 
complex mixtures, biofluids (urine, bile, plasma) and tissue extracts (Lindon, 2004). 
NIS can be analytically more sensitive than NMR spectroscopy, but it generally requires 
a pre-processing separation method for different classes of substances using either 
liquid or gas chromatography. The most recent separation method of ultra performance 
of liquid chromatography-mass spectrometry (UPLC-MS) gives improved peak 
resolution and sensitivity and has been used to generate metabonomic profiles reflecting 
physiological status, toxicity, disease processes and phenotype (Lenz et al., 2007a, 
Plumb et al., 2006a). The complementary NMR and UPLC-MS approaches are now 
described in more detail in the following section. 
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2.1.1 NMR spectroscopy 
The first observations of the NMR phenomenon were discovered in bulk matter in 1945 
independently by two separate groups of physicists led by Bloch (Bloch, 1946) and 
Purcell (Purcell et al., 1946). With the later observation of different resonance 
frequencies for nuclei in a molecule (the chemical shift) came the realisation that NMR 
spectroscopy would be useful for chemical structure, and thus NMR spectroscopy has 
evolved to become a powerful analytical technique for molecular structural analysis in 
organic chemistry. In the last three decades, the applications of NMR range far and wide, 
from the determination of structures of protein molecules in solvents (Massiah et al., 
2001, Nael et al., 2007) to whole body imaging with magnetic resonance imaging (MRI) 
scanners in clinical studies (McCarville, 2008, Nael et al., 2007, Tan et al., 2008). 
NMR is a non-destructive technique requiring minimal sample preparation. These 
qualities make it an attractive tool (where applicable) for a range of investigations 
including high-throughput analysis, or in situations where samples are precious (Lindon, 
2004). The theory of NMR spectroscopy has been thoroughly documented in many text 
books (Claridge, 1999, Kemp, 1986). A brief review of the fundamental principles of 
NMR and the information it reveals from one and two dimensional experiments for 
structural elucidation such as chemical shifts, integration, coupling constants and 
relaxation times are outlined below. 
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Fundamental principles of NMR spectroscopy 
Spin angular moment of nuclei 
The NMR phenomenon is based on the fact that nuclei of certain atoms have magnetic 
properties that can be utilized to yield chemical information. 
Nuclei of certain atoms possess an intrinsic quantised angular momentum called spin, 
characterised by a spin quantum number (I). Atoms with odd mass numbers possess 
half-integer spin quantum numbers; those with odd atomic numbers and even mass 
numbers have integral values for I. Nuclei with both even atomic and mass numbers 
have zero spin and therefore cannot exhibit nuclear magnetic resonance. Examples of 
values of I for some nuclei are listed in Table 2.1. 
Table 2.1: Nuclear spin quantum numbers (1) of some nuclei 
Spin Quantum No (I) 
0 
1/2 
1 
3/2 
5/2 
3 
Nucleus 
4 He, 12C, 160 
'H, 13C, 15 N., 19 F, 31 p 
2 H, 14 N 
1113,23 Na , 
35CI, 37C, 
170,27 Al 
11B 
The spin angular momentum (1) is derived from the spin quantum number (I) 
h 
2)r 
Where h= Planck's constant (6.6 X 10-34 jS) 
The spinning nuclei possess angular momentum, and charge and the motion of this 
charge gives rise to an associated magnetic moment g which is also a vector and lies in 
the same direction as 1. 
g=yl 
Where y= magnetogyric ratio, a unique constant for each nucleus, measuring the 
intrinsic magnet property of a nucleus. The number of allowed orientation for the spin 
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angular momentum (1) is restricted and given by (21 +1), e. g. for nuclei I= 1/2, only two 
directions are allowed. For nuclei such as 1H or 13C, there are only two spin states to be 
considered, denoted m=+ 1/2and m=- 1/2. 
Behaviour of nuclei in a static magneticfteld 
In the absence of a magnetic field, all 21 +I possible orientations of a nucleus have 
equal energies. When the nucleus is placed in an external, static magnetic field (B"), the 
energy levels are no longer degenerate since the nuclei can be regarded as being aligned 
with and/or against the field. For example: a proton nucleus (1H) with I= 1/2has two 
possible orientations with two different energies, a lower energy for alignment with the 
field at a higher energy state for nucleus opposed to the field as shown Figure 2.1. 
Increasing energy 
/ 
0 T/4o( N 
No extemal field 
ttittl 
Applied field present 
ff 
Magnetic field Bo 
, e! ý, E a hv 
Figure 2.1: The effect of an external magnetic field (BO) on the population difference in the 
energy states for a spin -1/2 nucleus, adapted from (Kemp, 1986) 
The lower energy state, labelled as the (X-state, corresponds to m=+ 1/2 and the upper 
state, labelled as the P-state, corresponds to m= -1/2. The energy difference (AE) 
between two states corresponds to a precise electromagnetic frequency, v, known as the 
Larmor frequency. 
AE = h. v 
Where h is Plank's constant 
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A population of nuclei at equilibrium will be unequally distributed between the energy 
states, leading to the existence of a net magnetisation. The energy states are populated 
according to the Boltzmann equation with a slight majority of nuclei naturally 
occupying the lower energy state (cc). 
Na -äE 
Nß -= exp 
kT 
Where N,, and Np are numbers of nuclei in the (x- and P- states, k is the Boltzmann 
constant and T is absolute temperature in Kelvin (K). 
At thermal equilibrium, the population difference between the two levels is extremely 
small (I in 30000) and this is why NMR spectroscopy is insensitive in comparison to 
other spectroscopic techniques such as infrared (IR) and ultraviolet (UV). 
Chemical shift 
The electron density around each nucleus varies according to the types of nuclei and 
bonds in the molecule. The electron cloud surrounding the nucleus creates a magnetic 
field B, opposing the main B. field and therefore the effective field, at each nucleus will 
vary. This phenomenon is called shielding and results a shift in the resonance frequency 
known as chemical shift (5). The more dense the electron cloud, the higher the strength 
of the induced B', the less effective is the magnetic field (B") experienced by the 
nucleus and thus a higher field has to be applied to bring them to resonance. Likewise, 
low electron density deshields the nucleus, causing resonances to appear at a lower field 
applied. The resonance frequencies in a typical NMR spectrum thus help to identify the 
chemical structure of a compound in a sample. 
To avoid chemical shift value being magnetic field dependent, they are converted into 
parts per million (ppm) values. These ppm values are calculated relative to that of an 
internal standard compound such as tetramethylsilane (TMS) or 3- 
(trimethylsilyl)propionic-2,2,3,3-d4acid (TSP). The ppm scale is usually denoted by the 
symbol 8, with the internal standard compounds given a value of 5= OR For 
1H NMR 
spectra almost all protons have lower shielding than TMS or TSP. Thus their chemical 
shift values are higher, increasing as shielding decreases. 
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The chemical shift of metabolites are also potentially sensitive to temperature, pH 
and/or metal ion concentrations (Potts et al., 2001). Compounds containing titratable 
groups may have variations in the chemical shifts because of the differences in 
ionisation of groups adjacent to the nuclei. Thus, in biofluids, the organic acid citrate 1H 
NMR chemical shifts show variations across urine samples (Miyataka et al., 2007, Potts 
et al., 2001). Chemical shift variability can also be caused by differences in metal ion 
concentrations between samples, particularly divalent cations which bind to citrate 
(Potts et al., 2001). 
Spin-spin coupling 
The interaction of a nucleus with its neighbouring magnetic nuclei can also be observed 
in NMR spectra. This effect is known as spin-spin coupling which can cause splitting of 
the signal for each type of nucleus into two or more lines (multiplets) rather than a 
single line, giving structural information about interaction between neighbouring nuclei 
with different chemical environments. The spacing between the lines of the multiplet is 
called the spin-spin or scalar coupling constant (J), which is independent of the 
magnetic field and measured in Hz. The J-coupling between two nuclei is transmitted 
via the intervening bond electrons and is thus very dependent in the number and type of 
such bonds. 
Signal intensity 
The relative intensity of a signal in 1H NMR spectroscopy is proportional to number of 
protons contributing to the signal. The concentration of a compound can thus be 
calculated by the addition of a known concentration of reference compound. The typical 
external reference compounds used in 
1H NMR experiments are tetramethylsilane (TMS) 
for organic solvents and trimethylsilyl-2,2,3,3-tetradeuteropropionic acid (TSP) for 
aqueous studies. 
Spin relaxation 
The spin relaxation process allows excited nuclear spins to return to equilibrium 
by loss 
of energy. There are two different relaxation processes: spin-lattice 
(longitudinal) 
relaxation and spin-spin (transverse) relaxation. 
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Spin-lattice relaxation is defined by a time T, that relates to rate at which nuclei reach 
thermal equilibrium populations since these results in changes in magnetisation along 
BO, this is sometimes called longitudinal relaxation. Spin-spin relaxation (characterised 
by a time T-, ) occurs by mutual swapping of energy between spins. T2 occurs in the 
plane perpendicular to BO, and hence is called transitional relaxation. Both TI and T2 
values can be measured using special pulse sequence and the derived values can be used 
to probe molecular dynamics and flexibility. 
Practical aspects of NMR spectroscopy 
Early NMR experiments were carried out using continuous wave (CW) methods. In this, 
the sample is held in a fixed strong magnetic field, and the radio frequency is slowly 
scanned. In some instruments, the source frequency was held constant, and the field is 
scanned. This is a highly inefficient process as most time was taken up by scanning 
between few sharp peaks. A typical scan time was 500 s. 
Modem NMR spectrometers use radiofrequency pulses to disturb and manipulate this 
net magnetisation and record how it evolves over time as the population of nuclei return 
to equilibrium. The simplest experiment is to apply a single RF pulse to tip the 
magnetisation with the transverse plane (so called 90' pulse). This induces a oscillating 
decaying voltage in a coil placed there. This is known as Free induction decay (FID) 
which is then deconvolved using Fourier Transformation (FT) to produce frequency- 
domain spectra that are interpretable. A typical scan now takes 1-3 s and these can be 
added together to improve the signal-noise ratio. Suitable pulse sequence manipulations 
can reveal a range of molecular properties including internal connectivity and structure, 
molecular dynamics and molecular interaction amongst many others (Claridge, 1999). 
Figure 2.2 shows an example of a 1H NMR spectrum of a human control urine sample. 
Lactate 
Alanine 
DMA 14 
1 
--Creatimine RVOW4"m Urea TMAO o 
"GlOie itrate 
suloate III I' I 'I I- I' Ii ''I ''I .... 1 -7-7- 
1.1 7.0 6.0 to 3.0 2.0 to PH 
Figure 2.2: An example of a 400 MHz 1H NMR spectrum of a control human urine sample. 
Abbreviations: DMA, dimethylarnine; TMAO, trimethylamine-N-oxide 
18 
Chapter 2 
Two-dimensional NMR spectroscopy 
Two-dimensional (213) NMR spectra are provided by a pulse sequence involving two 
variable time periods leading to two frequency axes after double Fourier transformation. 
2D NMR spectra are often shown as contour plots of the peaks in these two axes. One 
axis (/2) usually contains conventional chemical shifts and the other axis (f]) may 
contain other chemical shift or coupling information. The position of the signal on the 
map correlates the chemical shift of the one axis with the information given on the other 
axis. The correlation can be either homonuclear (e. g. IH-1H) or heteronuclear (e. g. 'H- 
13C) 
. Examples of common 2D NMR experiments are shown in Table 2.2. 
Table 2.2: Examles of standard 2D NMR exnerimenk (Cla. ridv,,, - 1999) 
Experiment Nuclei Types of information, 
observed applications 
COSY (Correlation 
H 
Assigning 1H and 1H signals 
Spectroscopy) usually through no more than three 
bonds, based on J couplings 
Allows identification of all the 
2D-TOCSY (Total Correlation IH protons belonging to a common 
Spectroscopy) coupled spin system (4- and 5- 
bond 1H to 1H correlation) 
NOESY(Nuclear Overhauser I H 
Gives evidence for spatial 
proximity of 1H to 1H nuclei using Enhancement Spectroscopy) 
nuclear Overhauser effect. 
Separates chemical shifts from 
J-RES (J-resolved) IH or 
13c couplings and determines 
multiplicities and coupling 
constants 
Assigns signals in proton and 
HMQC (Heteronuclear Multiple 13C 1H carbon spectra, starting from 13 1 Quantum Coherence) , C H to known signals (one-bond 
correlation), based on 
IJCH 
Assigns 1H and 
13C 
signals on the 
HMBC (Heteronuclear Multiple 13C 1H, basis of long range couplings (2- 
Bond Correlation) and 3- bond 1H to 
13C 
correlation). 
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2.1.2 Chromatography 
Chromatography encompasses a broad range of physical methods used to separate 
and/or to analyse complex mixtures. Liquid chromatography involves passing a mixture 
dissolved in a solvent (mobile phase) through a column packed with sorbents (stationary 
phase) which separates the substance (analyte) to be measured from other molecules in 
the mixture. The affinity of a molecule to adsorptive materials in the stationary phase as 
the mixture moves over the column depends on a molecule's hydrophobic character, 
size, shape and ion exchange property of the analyte. 
Solid-phase extraction (SPE) is a simple separation method that uses a solid phase and a 
liquid phase to isolate analytes of interest from a wide variety of matrices, including 
urine and blood. This technique is based on the principles of liquid chromatography, i. e. 
the separation of the analytes depends on the mode (e. g. hydrophobic, polar, ionic or a 
combination of both) and strength of their interaction with the sorbent and the eluting 
solvent (Krishnan et al., 1994). It is usually used to clean up a sample prior to a more 
detailed chromatographic, NMR spectroscopic or other analytical method, facilitating 
the identification and quantification of unknown metabolites in complex mixtures or 
allowing optimising to avoid loss of important analytes in lower level concentrations 
(Stanley et al., 2005, Wilson et al., 2005). SPE is commonly performed using small 
disposable cartridges containing a stationary phase (sorbent) of which normal phase, 
reversed phase, anion exchange and cation exchange are typical examples, but the 
approach can also be used in plate fon-n (i. e. 96-well plates). 
High performance liquid chromatography (HPLQ 
The fundamental basis for HPLC consists of passing a sample (analyte mixture) in a 
high pressure mobile phase through a column (stationary phase). As the analytes pass 
through the column, they interact with the two phases, mobile and stationary 
differentially, such that their passage occurs at different rates. The difference in rates is 
primarily due to different polarities for the analytes. The analytes that have the 
least 
amount of interaction with the stationary phase or the most amount of 
interaction with 
the mobile phase will exit the column faster. Repeated interactions along the 
length of 
the column effect a separation of the analytes. 
Changes in the polarity and pH of the 
mobile phase are other variables that can affect the efficiency of 
the HPLC separation, 
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as they affect the interactions of the analytes with the stationary phase. The mobile 
phase polarity is generally the opposite of the stationary phase. Thus, various mixtures 
of analytes can be analysed by changing the polarities of the stationary phase and the 
mobile phase. There are two types of mobile phase elution; isocratic and gradient. 
Isocratic elution involves a mobile phase of constant composition irrespective of the 
number of components it contains, whereas the gradient elution separates analytes while 
the mobile phase composition is changed. The latter mobile phase elution provides 
better separation in early eluting analytes than the former. 
There are different types of columns including reverse phase, normal phase and 
hydrophilic interaction liquid chromatography (HILIC). The majority of metabolic 
profiling applications use reverse phase columns, which consist of a non-polar 
stationary phase and a moderately polar aqueous mobile phase i. e. acetonitrile (ACN). 
Samples are introduced to the column in mostly aqueous solvent. The common 
stationary phase is silica with bonded straight chain alkyl group such asC18H37, C8HI7, 
C4H9 andC2H5. These reverse phase columns, particularlyCl8andC8columns, are used 
for both polar and non-polar samples, with polar molecules eluting more readily than 
non-polar compounds. Normal phase columns again separate analytes based on polarity, 
but using a polar stationary phase and a non-polar mobile phase. These columns are 
mainly used to separate analytes in polar nature samples. The recent addition of HILIC 
columns is a special case of non-nal phase chromatography,, used primarily for the 
separation of very polar compounds including amino acids or drug metabolites in 
complex biofluids (Idborg et al., 2005). 
Reduction in column dimensions enhances mass sensitivity to picomole and even 
attomole ranges and such micro-methods have been successfully used in LC methods 
where small amounts of samples are available for analysis or separation. HPLC methods 
are now being developed using nano columns, which require less solvent for the same 
resolving power as the ordinary columns, since analytes can be eluted at a lower flow 
rate and less sample is also needed (Lanckmans et al., 2006). 
Choosing the right column is essential for obtaining good HPLC results. In addition to 
the type of bonded phase, the pore size of the particles of the stationary phase can 
have 
a significant effect, as they allow certain sized analytes to pass through at 
different rates. 
Mobile phase additives such as formic acid also provide significant 
improvement on the 
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shape of peaks and reduce the matrix effects. Furthermore, the dimensions of the 
column can be varied to allow different sample sizes to be analysed. The work 
presented in this thesis was carried out on aC 18 reverse phase column with addition of 
0.1% of formic acid to the mobile phases of water and ACN. After separation on the LC 
column, the sample is often pass through a ultraviolet (UV) detector. Many organic 
compounds absorb UV light of various wavelengths and the amount of absorption 
depends on the amount of substance passing through the UV beam at a particular time. 
The UV spectrum gives additional information about the chemical composition of the 
sample. There are different types of UV detectors available for HPLC including a fixed 
or variable wavelength array and diode array which measure a spectrum of wavelengths 
simultaneously. 
Components eluting from the HPLC column are then introduced to the mass 
spectrometer via a specialised interface which eliminates the solvent and generates gas 
phase ions. The two most common mass spectrometer ionisation approaches used for 
HPLC-MS are electrospray ionisation (ESI) and atmospheric pressure chemical 
ionisation (APCI). This will be discussed further in section 2.1.3. 
Ultra Performance Liquid ChromatographyTM (UPLQ 
The applications described in the work in this thesis rely on ultra performance liquid 
chromatography (UPLC), which retains the practicality and principles of conventional 
HPLC while increasing the overall speed, sensitivity, and resolution (Table 2.3). This 
technology uses a hybrid silica-polymer column with porous 1.7 [tm particles. The 
efficiency of the column can be approximated by the following equation: 
HETP = Au 
1/3 
+B+ cu 
u 
Where HETP - the height equivalent to a theoretical plate 
A- Eddy diffusion 
B- Longitudinal diffusion 
C- Slow mass transfer in both the stationary and mobile phases 
u- Linear velocity 
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The contributions to plate height (HETP) can be shown by the Van deernter plot. The 
use of smaller particles results in a very flat van Deernter plot (Figure 2.3), which 
relates the variance in length of a column to the linear mobile phase velocity. The van 
Deernter curves (Swartz, 2005, Van Deemter et al., 1995) are used to predict and 
determine the flow rate of mobile phase, and hence the flow rate at which column 
efficiency will be maximised. As the particle size decreases, the corresponding height 
equivalent to theoretical plate (HETP), which is numerically equal to the absorption bed 
length divided by the number of theoretical plates in the absorption bed, also decreases, 
resulting in higher column efficiency (Novakova, 2006). This increase in column 
efficiency in turn increases mass sensitivity, analytical resolution and speed (Novakova, 
2006, Plumb et al., 2004). 
With 1.7 ýtrn particles, the highest efficiencies are available over a much wider range of 
flow rates than with larger particles. As a result, the UPLC system has an operating 
range with the best combination of speed and efficiency. 
Table 2.3: Resolution, speed, sensitivity and back pressure improvement with 1.7 Pm 
particle size (UPLQ in comparison to 3 and 5 gm particle size (HPLQ for a constant 
column length. (Adapted from presentation provided by R. Plumb, Waters Corporation) 
Resolution Speed Sensitivity 
Back Pressure 
Improvement Improvement Improvement 
1.7 vs.. 5ttm 1.7 X 3X 1.7 X 25 X 
particles 
1.7 vs. 3gm 1.3 X 2X 1.3 X 6X 
particles 
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Figure 2.3: van Deemter plot, illustrating the evolution of particle size of UPLC columns 
compared to HPLC (Novakova, 2006, Swartz, 2005) 
Additionally, smaller particle sizes (< 2gm) require much higher operating pressures, 
since back pressure is proportional to flow rate and the UPLC system is designed as the 
first commercially available instrument to withstand pressures exceeding 10,000 psi 
(Swartz, 2005). 
Figure 2.4 shows a 10 min section from both a UPLC chromatogram and a HPLC 
chromatogram from a serum sample. Compared to HPLC, UPLC produces narrower 
chromatographic peaks, resulting in improved separation, increased peak capacity, 
lower ion suppression, improved signal-to-noise ratio, and thus increased sensitivity. 
Sample run time is reduced significantly, allowing for higher sample-throughput. In the 
case of the serum sample shown here, run time was reduced from 60 min to 25 min 
using UPLC. 
24 
Chapter 2 
UPLC TIC 
lOrviin EIC 
separadon 
M/z 8 12 rn. /Z 951 !C 
signalinals* 
nVz 524 
EIC 
: Le 
IN - 690 
HPLC 
m/, - 951 
mir 812 S/N -- 70 
j-_, 
OýL 
Tirrw Time 
n in 32 34 38 
lOnfin 
Figure 2.4: Comparison of a 10 min section of UPLC chromatogram with a HPLC 
chromatogram. With UPLC, separation of metabolites is improved, decreasing ion 
suppression, leading to improved signal to noise (S/N), accuracy and sensitivity. Modified 
from (Want et al., 2007). 
TIC: total ion chromatogram, EIC: extracted ion chrornatograrn 
A chromatogram from either HPLC or UPLC represents time in the x-axis and signal 
intensity in the y-axis. Figure 2.5 shows an example of a total ion chromatogram (TIC), 
a base peak chromatograrn (BPI) and an extracted ion chromatogram (EIC) from a 
UPLC analysis of a human control urine sample. The TIC monitors the entire range of 
masses of all ions being detected at any one time. BPI is similar to TIC with the entire 
range of masses being detected, but it monitors only the most intense peak (the base 
peak) at any one time. BPI represents clearer resolved peaks compared to TIC since a 
large background with a lot of the smaller peaks that sum together in a TIC is ignored. 
EIC monitors masses of ions, usually with the detection of a very specific mass. Figure 
2.5 shows the extracted ion chromatogram for hippurate (nVz 178) in the urine sample. 
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Figure 2.5: An example of different types of UPLC chromatogram for a control urine 
sample; total ion chromatogram (TIC), base peak ion chromatogram (BPI) and extracted 
ion chromatogram (EIC) for m/z 178 
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2.1.3 Mass spectrometry 
Mass spectrometry is an analytical tool used for deten-nining the mass of a molecule by 
measuring the mass-to-charge ratio (nz/z) of its charged ions. The mass spectrometer is 
divided into three fundamental parts: the ionisation source, analyser, and detector. These 
are kept under high vacuum to aid the passage of the ions through the instrument. A 
sample under investigation is first introduced to the ionisation compartment/chamber, 
where the sample is ionised, for later electrostatic acceleration to the analyser. The 
sample can be introduced directly into the ionisation source, or can undergo 
chromatography beforehand. Different methods are utilised for producing ions 
including cationisation, deprotonation, electron ejection and electron capture. The ions 
are then extracted into the analyser of the mass spectrometer where they are separated 
according to their mass-to-charge ratios (Wz). The separated ions are detected and 
stored as signals in a data system where the n-Vz ratios are listed with their relative 
abundance for presentation in the fon-nat of an nz/z spectrum. The principles and 
developments of mass spectrometry have been documented in many text books (Howe 
et al., 2006, Siuzdak, 2006). 
Ionisation: Although many ionisation sources are currently available, the ionisation 
method used for the analysis depends on the type of sample under investigation and the 
mass spectrometer available. Typical ionisation techniques include electron ionisation 
(EI), chemical ionisation (0), electrospray ionisation (ESI), atmospheric pressure 
chemical ionisation (APCI) and matrix assisted laser desorption ionisation (MALDI) 
(de Hoffinann et al., 2003, Siuzdak, 2006). Among these, the ionisation sources used for 
the majority of biomolecular analyses are electrospray ionisation (ESI) (Fenn et al., 
1989) and matrix assisted laser desorption ionisation (MALDI) (Tanaka et al., 1988), 
both are 'soft' ionisation methods. In ESI analysis, the analyte solution 
flow passes 
through an electrospray needle, where a high electrode potential difference 
is applied 
and highly charged droplets are sprayed through the needle. 
The solvent is evaporated 
from the droplets using a drying gas (nitrogen). The droplets diminish in size and 
charged are released. These then enter the mass spectrometer. 
MALDI analysis uses 
excess of a matrix compound, usually a 
UV-absorbing weak organic acid, to co- 
crystallise the analyte compound. The 
MADLI sample matrix then vaporises on 
irradiation of laser rays, aiding the vaporisation of the sample. 
Both ESI and MALDI 
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are easily adapted to liquid chromatography and have good sensitivity, to low picomole 
concentration. However, ESI is more suitable for identification of lower molecular 
weight molecules in biofluids compared to MALDI since the ionisation technique has 
no matrix interference, which can be a problem for lower weight compounds (less than 
700 Da), and it is easily adaptable to tandem mass analysers (MS/MS) for structural 
elucidation. MALDI is used more in proteornics applications (Gonnet et al., 2003, 
Mueller et al., 2007, Yanes et al., 2007). In most ionisation methods, both positively and 
negatively charged sample ions can be generated, depending on the proton affinity of 
the sample. Positive mode is applied for samples have functional groups that readily 
accept a proton (H') whilst negative mode for the samples with functional groups that 
readily lose a proton. 
Analysers: The main function of the analyser is to separate the ions formed in the 
source according to their nilz ratios. The analyser is a vital component for the 
performance of any mass spectrometer with respect to scan speed, accuracy, mass range, 
tandem analysis capabilities and resolution. Over the last fifteen years, mass analysers, 
have undergone numerous modifications in order to interface with ionisation sources 
such as ESI and MALDI. There are many different analysers currently available 
including the quadrupole, ion trap, time-of-flight (TOF), Fourier transform (FT) and 
combinations such as quadrupole-time-of-flight (Q-TOF), triple quadrupole and 
quadrupole ion trap (Q-Trap). These have different properties including the nzlz range 
that can be scanned and the mass accuracy that can be achieved. Mass spectrometers 
can be used with a reference compound to improve mass accuracy. The mass scans of 
the reference compound are collected and averaged for correction of mass drifts due to 
temperature changes. Common reference compounds are leucine enkephalin (nilz 555) 
and reserpine (nzlz 608) which fall in the middle of the mass range scanned (usually nilz 
50-1000) for metabolite profiling studies, and ionise in both positive and negative 
modes. Leucine enkephalin was used as a reference compound for the work in this 
thesis. The work presented in this thesis was carried out on both TOF and Q-TOF mass 
spectrometers. The quadrupole and TOF analysers are described below. 
Quadrupole: The quadrupole consists of four circular, parallel metal rods, connected in 
parallel to a radio frequency (RF) and a direct current (DC) potential. 
It filters ions 
based on their nz1z ratio and allows selection of a particular ion 
by varying the voltages. 
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Only ions of a particular nilz will reach the detector for a given ratio of voltages, others 
will collide with the rods. Quadrupole mass analyzers can easily tolerate with high 
pressures, are relatively low cost and easily interfaced with both ESI and APCI. These 
analysers have a significant mass range up to nilz 4000, which allows for the analysis of 
compounds including proteins and other biornolecules. Application of quadrupole 
analysers for LC-MS analysis provides good reproducibility, greater sensitivity than 
conventional mass spectrometers and can be used in large scale studies. However, they 
are limited in mass accuracy and resolution compared to other analysers. 
Time-of-flight (TOF): Time-of-flight analysis is used to determine the time taken for 
ions to reach a detector while travelling over a known distance. A group of ions are 
accelerated by an electrical field to the same amount of energy with the velocity 
depending on their nzlz. The lighter ions reach the detector first because of their greater 
velocity, while the heavier ions take longer due to their lower velocity. Thus time-of- 
flight can be used to determine the nVz of a molecule. TOF delivers high mass accuracy 
and high mass resolution compared to quadrupole analyser. It is an extremely versatile 
instrument which can be employed for the analysis of a wide range of compounds and 
complex biological samples. 
Q-TOF: Q-TOF mass spectrometers are relatively new and combine a quadrupole with 
a TOF analyser. This combination provides the benefits of tandem mass spectrometry 
(MS/MS) with selectivity and flexibility for collision experiments as described below. 
This is an ideal combination for sophisticated applications with the advantages of TOF 
analyser including sensitivity in scan mode, fast scan, accurate mass, and resolution, 
thus being ideal for metabolic profiling of biofluids and providing structural information 
of unknown compounds. 
Tandem mass spectrometry (MSIMS): These experiments are performed 
by colliding a 
selected ion of interest with inert gas molecules such as argon and 
helium and the 
resulting fragment ions are analysed. MS/MS experiments 
facilitate the structural 
elucidation of complex biornolecules. Using a 
Q-TOF, high mass accuracy can be 
achieved for both precursor (parent 
ion) and product ions in MS/MS studies. For 
example, in a typical study, the identification of metabolites 
in biofluids will be carried 
out by the comparison of retention times 
from the chromatography and the mass 
fragmentation patterns of reference compound and the molecule of 
interest. 
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Figure 2.6 shows an example of a typical mass spectrum (MS) and MS/MS spectrum of 
an authentic compound, isovalerylglycine, obtained from a Q-TOF mass spectrometer. 
The average mass spectrum shows a prominent peak of the parent ion at n? lz 158. The 
MS/MS spectrum of authentic isovalerylglycine shows a fragment ion of glycine ("Vz 
74.0) and another fragment ion at nVz 114.1 from a loss of theC02(44 Da) from the parent 
ion. 
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Figure 2.6: An example of negative mode MS and MS/MS spectra for authentic 
isovalerylglycine. m1z 158.0 corresponds to the [M-H-] ion of isovalerylglycine, while the 
ion m1z 74.0 corresponds to glycine, adapted from 
Figure 5.21. 
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2.2 Chemometric analysis 
2.2.1 Data pre-processing 
Analysis of 1H NMR and UPLC-MS data generated in metabolic profiling studies is 
facilitated by multivariate pattern recognition techniques to extract the latent biological 
information. Prior to performing any multivariate analysis, both 1H NMR and UPLC- 
MS data set are usually pre-processed and transformed to make them amenable, robust 
and accurate. Commonly used pre-processing steps include data reduction or binning, 
scaling and normalisation. 
Data reduction or binning 
Methods of 1H NMR and UPLC-MS data reduction usually include integration of 
spectral regions of a set width (bins). This solves the problem of minor variations in 
NMR chemical shift and chromatography retention times of certain metabolites, due to 
variation in pH and solvent effects respectively. 
For NMR spectroscopic data, a 1H NMR spectrum with a chemical range8HO. 5-9.5 
can be divided into frequency windows of width typically either 0.001 or 0.01 or 0.04 
ppm, integrating signal intensity within these segments. However, NMR data are not 
always binned; full resolution with peak alignment is an alternative for a small data set. 
Similar bin approaches have been applied for UPLC-MS data by the Waters 
MarkerLynx software and there the data can be binned by either chromatographic 
retention time or nVz range or both. 
For a series of NMR and mass spectra, the resulting data set can be simplified into N*K 
matrix, where N is observations (NMR or mass spectra) and K represents variables of 
chemical shift range with integrated spectral region for NMR data or intensity as a 
function of both retention time/mass to charge ratio for MS data. 
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Scaling 
The pattern recognition techniques of principal component analyses (PCA) and 
orthogonal projection to latent structure discriminant analysis (0-PLS-DA) are sensitive 
to the scaling method selected. There are many methods currently being used for scaling 
of the data, but the most common methods are use of mean centred data without scaling 
or after applying unit variance (UV) or pareto scaling. Mean centring is the subtraction 
of the mean variable vector from all its elements whereas unit variance scaling involves 
the subtraction of mean vector followed by division of the standard deviation. Pareto 
scaling is similar to UV scaling, however, instead of standard deviation, square root of 
the standard deviation is used as a scaling factor. 
In order to express a simple geometrical understanding of the concept of scaling, the 
initial variance of a variable is interpretable as the size or length of that variable. In UV- 
scaling, variables are centred and scaled to unit variance which means that long 
variables are shrunk and short variables are stretched, such that all variables will rest on 
equal footing. No small variable is allowed to dominate the model since all variables 
have same length. UV scaling is generally recommended to use when there is no prior 
information about the data and the variables are not measured in the same units. Mean- 
centring implies that the variables are centred but not scaled. This facilitates the 
interpretation of the model and in certain cases it removes the numerical instability. 
Pareto scaling is intermediate between the two extremes of mean centring and UV 
scaling and gives each variable a variance equal to its initial standard deviation. 
Normalisation 
Biofluids, particularly urine, show very distinctive variations in overall concentrations, 
depending on dilution factors resulting from water intake, food deprivation and drug 
effects (Lindon et al., 2007) . The pre-processing step of normalisation 
minimises the 
effects of variation in urine concentrations across the samples 
by scaling the spectra to 
the same virtual overall concentration, allowing metabolite concentration across 
samples to be displaced in comparable ratios (Craig et al., 
2006a, Lindon et al., 2007). 
One common normalisation method currently used 
for NMR based metabonomics is 
normalisation to a constant sum, setting each observation 
(spectrum) to unit total 
intensity by expressing the intensity of each 
bin as a fraction of the total spectral 
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integral. However, the constant sum normalisation method has limitations and might fail 
for datasets of urine samples from toxin-treated animals since it is considered to 
approximate the relative concentration of metabolites (Craig et al., 2006a). Dieterle et 
al. developed the probabilistic quotient normalisation which scales an NMR spectrum 
on the basis of probable dilutions (Dieterle et al., 2006). The probable dilution is 
achieved by looking at the distribution of the quotients of the amplitudes of a test 
spectrum by those of a reference spectrum. 
Much of the NMR data in this thesis was pre-processed using constant sum 
normalisation, for both 1H NMR data of urine samples of inborn errors of metabolism 
(Chapter 5) and a large human population INTERSALT study (Chapter 6). The 
probabilistic quotient normalisation method was used to analyse 
IH NMR data of rat 
urine models from toxin-treated animal models of metabolic acidosis, metabolic 
alkalosis as well as caloric restriction (Chapter 4). 
For the UPLC-MS data, MarkerLynx TM software uses two different approaches similar 
to the method used for NMR analysis, based on normalisation to either total area to a 
constant sum or total height to a constant sum. Both the normalisation of total 
height to 
constant sum and total area to a constant sum were applied and the resulting 
data did not 
show any significant difference. Therefore, the normalisation of total 
height to constant 
sum was used in the work presented in this thesis. 
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2.2.2 Multivariate data analysis 
Principal component analysis (PCA) 
Principal component analysis (PCA) is a multivariate technique that maps samples, 
without prior knowledge of sample class, according to their properties by dimension 
reduction. This unsupervised method expresses most variance within in the data set 
using a smaller number of principal components (PCs). Each PC is orthogonal and 
therefore independent of each other, thereby each successive PC explains the maximum 
amount of variation remaining in the data set. The first PC contains the maximum 
variance of the data set and subsequent PCs containing correspondingly less variance. 
Thus, a PCA plot of first two or three PCs gives the best information content of the data 
set with the benefit of reduced dimensionality. 
The data matrix is converted into two matrices known as scores and loadings. Scores 
represent each sample spectrum and summarise the relationship among the observations, 
whereas loadings summarise the variables (properties) of the patterns seen in the scores 
plot. PCA analysis can provide a visual diagrammatic overview of the samples used in 
the multivariate analysis. This technique is generally used as an initial step to see how 
the samples are clustered together and to identify any outliers. 
Figure 2.7 shows an example of a PCA analysis of IH NMR spectra of two control urine 
samples and urine samples of inborn errors of metabolism (IEM) isovaleryl aciduria 
JVG) and mevalonic aciduria (MEV), one for each IEM. The scores plot (Figure 2.7 
(A)) shows the first two principal components with three different type of samples; 
controls, IVG and MEV in each cluster. Each diamond shape point represents a single 
NMR spectrum. The loadings plot in Figure 2.7 (B) shows the sample on the top left is 
attributed to concentration of mevalonic acid and mevalonolactone OH 1-26,8H 1.39,8H 
1.84,8H 2.3 8 and 6H 3.75) whereas the separation of the sample on the top right is 
attributed to concentration of metabolite isovalerylglycine OH 0.96,8H 3.77,8H 2.2). 
The separation other two samples on the bottom left from the top is due to the 
metabolites of TMAO OH 3.27), isovalerylglycine, mevalonic acid and 
mevalonolactone. The metabolite creatinine (8H3.05,8H4.06) is present in all samples 
and its concentration vanes between all four samples. Figure 2.7 (C) shows the 
1H 
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NMR spectra of urine samples and the spectra which are highlighted represent the 
dominant variable which influence the separation of the samples in the PCA score plot. 
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Figure 2.7: An example of principal component analysis of 'H NMR data of two human 
control urines and two urine samples of inborn errors of metabolism (IEM) of isovaleryl 
aciduria (IVG) and mevalonic aciduria (MEV), one for each with bin size of 0.1 ppm (A) 
A scores Plot of principal component 1 (PC 1) versus PC 2 for the separation of the three 
different types of samples; controls, IVG and MEV (B) a loadings plot represents the 
separation of the sample on the top left is attribute the variation of metabolites of 
mevalonic acid and mevalonolactone (8H 1.26,8H 1.39,80.84, BH2.38 and 8H3.75) where 
as the sample on the top right is due to metabolite isovalerylglycine (8HO. 96,8H3.77,8H 
2.2). The separation of samples on the bottom left from the top is due to metabolites of 
TMAO (BH3.27), isovalerylglycine, mevalonic acid and mevalonolactone. (C) A stack plot 
of 1H NMR spectra of urine samples of two controls, IVG and MEV (each 'H NMR 
spectra colour coded according to those in scores plot), the highlighted regions in spectra 
contribute towards the separation of samples in the score plot. 
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Projection to latent structures - discriminant analysis (PLS-DA) 
Projection to latent structure by means of partial least squares - discriminant analysis 
(PLS-DA) is an extension of PCA analysis in order to maximise the separation of 
between groups of observations. This method relates two data matrices X and Y, where 
* matrix comprises the spectroscopy variables (IH NMR spectra or nzlz spectra) and the 
* matrix is a set of dummy variables that describes the class membership for each 
variation. This supervised method maximises the covariance between X and Y matrices 
by modelling X to correlate with Y. The interpretation of scores and loadings plots of 
PLS-DA analysis is the same as that described for PCA. 
Orthogonal projection to latent structure discriminant analysis (O-PLS- 
DA) 
This supervised pattern recognition method is an extension of PLS-DA, developed by 
Trygg (Trygg et al., 2002). An O-PLS model can be seen as a factor analysis model, 
where the variation in the matrix X (the NMR spectra or nVz spectra) and the matrix Y 
(the descriptive variables) is separated into three parts. The first part contains the 
variation common to X and Y, the second one contains the specific variation for X, so- 
called structured noise, and the last one contains residual variance. The main advantage 
in interpretation using OPLS-DA compared to PLS-DA thus lies in the ability of OPLS- 
DA to separate predictive from non-predictive (orthogonal) variation. 
For metabonomic applications, each line of the X matrix is an NMR spectrum or mass 
spectrum corresponding to one sample and each column of Y defines a class (or group) 
whose values are dummy variables as used in discriminant analysis. Figure 2.8 shows 
an example of loadings plot from O-PLS-DA analysis of HgC12- treated versus Sprague- 
Dawley rat urines using 1H NMR spectroscopy. The plot reveals the discriminatory 
metabolites which are responsible for separating the HgC12- treated group from controls 
(Cloarec, 2005a). The upper section of the loadings plot represents the metabolites 
increased in intensity where as the lower part represents the metabolites decrease in 
intensity. The colour scale in the loadings plot corresponds to the variable weights and 
allows for the identification of significant metabolites 
for the discrimination between 
groups. 
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Figure 2.8: An example of a loadings plot from an O-PLS-DA model of H902-treated 
versus control rat urines using 'H NMR spectroscopy. The lower image is an enlargement 
of the upper image. The plot represents the average spectral difference between the two 
groups; the upper section of the plot represents metabolites increased in intensity whereas 
the lower section represents metabolites decreased in intensity by the treatment. The 
colour code represents the correlation (r 2) to the discriminant variable, reproduced from 
(Cloarec, 2005a) 
37 
Chapter 2 
Statistical total correlation spectroscopy (STOCSY) 
Statistical total correlation spectroscopy (STOCSY) is a recent development for aiding 
the identification of potential biomarkers in metabonomics studies based on NMR 
spectroscopic data. This analysis takes advantage of the linear correlation between all 
peak intensities for a given molecule across a set of spectra to generate a pseudo-two- 
dimensional NMR spectrum that displays the correlation behaviour among the 
intensities of the various Peaks of molecules. For example, protons within the same 
molecules should have a correlation of r=I in a perfect scenario where there is no 
overlap with resonances from other molecules or any noise. 
STOCSY has been introduced by Cloarec et al. (Cloarec, 2005b) and has been 
successfully applied to varied metabonomics studies including insulin restricted diet 
(Cloarec, 2005b), toxicology (Coen et al., 2007b, Holmes, 2006), drug metabolism 
(Keun, 2008) and drug metabolite signatures (Holmes, 2007). Its concept is based on the 
assumption that intensities of peaks (resonances) should be correlated when the 
concentration of the molecule varies across a set of samples. Figure 2.9 shows an 
example of STOCSY plot of metabolites of acetaminophen (paracetamol) in urine 
samples from the large scale human population study INTERMAP. The covariance 
between the selected variable and all other variables is plotted with a colour code 
corresponding to the degree of correlation of selected peak and other variables across 
the spectrum and projected on the spectrum that has the maximum for this variable. For 
example, the N-acetyl proton signal of acetarninophen glucuronide resonance 8H2.17 
(the 'driver' peak) shows strong correlation (red/orange data points) with all other 
acetaminophen glucuronide metabolite resonances at 8H3.62,8H 3.89,8H5.1,8H7.13, 
and8H7.36. Thus, the identification of correlated signals aids the structural elucidation 
of acetaminophen glucuronide. The application of STOCSY in the thesis was used to 
identify the endogenous metabolite N-methylnicotinic acid (NMNA) and is shown in 
Chapter 5 (section 5.4.1.1). 
38 
Chapter 2 
1D STOCSY 'driver' peak 
AG(H2) 
8 
AG(HI. ) 
AG(Hs. ) 
II 
A 
I I I I 
"1 
________ I 
a 7 6 5 4 3 2 
NAC(H, 
r2 
10 
09 
08 
07 
0.6 
0,5 
OA 
03 
0.2 
01 
o 
WH 
Figure 2.9: An example of STOCSY plot for metabolites of acetaminophen (paracetamol) 
in urine samples. The colour code corresponds to the degree of correlation of 
selected peak resonance 8H 2.17 and other variables across the spectrum and 
projected on the spectrum that has the maximum for this variable. (A) The N- 
acetyl proton signal resonance at BH2.17 shows strong correlation (red/orange data 
points) with all other acetaminophen glucuronide metabolite resonances atBH3.62, 
8H3.89,8H5.1,8H7.13, and 8H7.36. (B) Expansion for the aromatic region showing 
signals for acetaminophen and its related metabolites. (C) Expansions for the 8H 
2.17 N-acetyl resonances of acetaminophen metabolites (Holmes et al., 2007) 
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Chapter 3: Method Development for Profiling of 
Organic Acids by Ultra Performance Liquid 
Chromatography (UPLC-MS) 
3.1 Summary 
Profiling of urinary organic acids using reliable and reproducible analytical techniques 
can yield information on the status of many different metabolic pathways, thereby 
allowing early diagnosis and guiding therapy for a range of pathological conditions. 
This study was carried out to develop and optimise a novel bioanalytical method for the 
profiling of organic acids in human urine using ultra performance liquid 
chromatography-mass spectrometry (UPLC-MS). The current method was also 
validated for the quantification of organic acids in human urine by evaluating the 
following fundamental parameters accuracy, precision, selectivity, matrix effects and 
reproducibility. 
3.1.1 Aims and objectives 
1. To develop and optimise a UPLC-MS bioanalytical method for profiling urinary 
organic acids. 
2. To generate calibration models for standards at different concentrations and 
compare these with control urine samples taken from different sources after spiking 
with known concentrations of organic acids. 
3. To validate the optimised method for the quantification of organic acids in human 
urine by evaluating fundamental parameters such as accuracy, precision, selectivity, 
reproducibility and matrix effects. 
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3.2 Introduction 
Organic acids are water-soluble compounds containing one or more carboxyl groups as 
well as other functional groups such as amine, keto and hydroxyl. Organic acids are key 
metabolites involved in many of the fundamental metabolic process of the body. 
Derived from dietary protein, fat and carbohydrate, organic acids are used by the body 
to generate cellular energy and to provide the building blocks necessary for cell function 
(Bralley et al., 2001). Profiling of urinary organic acids using reliable and reproducible 
analytical techniques can yield infori-nation on the pathophysiological status of many 
different metabolic pathways and allow early diagnosis and treatment for inborn errors 
of metabolism. The measurement of organic acids in urine allows the simultaneous 
assessment of mitochondrial energy production efficiency, neurotransmitter metabolism, 
clinically significant microflora imbalances in the gut, and metabolic toxicity problems 
(Bralley et al., 2001). Analysis of organic acids in urine is a powerful technique in the 
diagnosis of inborn errors of metabolism e. g. for organic acidurias (Seymour et al., 
1997). This class of diseases are characterised by either the excretion of excessive 
amounts of urinary organic acids that are ordinarily present or the presence of organic 
acids that are normally not detected or are at very low levels. 
Analytical methodologies have been developed to date for profiling urinary organic 
acids using gas chromatography-mass spectrometry (GC-MS) (Hagen et al., 1999, Liu 
et al., 2004, Suh et al., 1997) or high performance liquid chromatography-mass 
spectrometry (HPLC-MS) (Buchanan et al., 1990, Chong et al., 1989, Kajita et al., 
1993, Simms et al., 2004). Although the GC-MS method is used to analyse organic 
acids in human urine, it requires sample pre-preparation methods such as derivatization 
techniques and extraction methods. These additional sample preparation steps make 
GC-MS less suitable for high-throughput applications such as the large scale screening 
of clinical samples. HPLC-MS procedure requires minimal sample pre-preparation and 
is faster as compared to GC-MS. 
Ultra performance liquid chromatography (UPLQ is a recent 
introduction into the field 
of bioanalysis, offers greater sensitivity, enhanced spectral quality and 
faster separations, 
and thereby allowing the researchers to 
detect many more metabolites (Plumb et al., 
2004). This technology uses a hybrid silica-polymer column with porous 
1.7 [im 
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particles. The use of smaller particles and high pressure increases column efficiency, 
which in turn increases mass sensitivity, analytical resolution speed and reproducibility 
(Al-Dirbashi et al., 2006, Nordstrom et al., 2006). UPLC-MS has been used to profile 
and quantify endogenous and exogenous metabolites in biofluids such as urine 
(Stephanson et al., 2007), serum (Nordstrom et al., 2006) and plasma (Al-Dirbashi et al., 
2006, Ma et al., 2007). 
Validation of an analytical method is important in order to have confidence that the 
method used for quantification of metabolites in biological fluids is accurate and precise. 
The linearity range of analytical instruments is normally assessed by a standard 
calibration curve, which illustrates the relationship between the instrument response and 
the known concentration of the analyte. A standard calibration curve for each analyte in 
the biofluid sample is generated by measuring the area ratio of the analyte and the 
internal standard for known different concentrations. Stable-isotope-labelled 
compounds are commonly used as internal standards (IS) in quantitative analysis of 
biofluids in GC-MS (Chang et al., 2002) and HPLC-MS (Jemal et al., 2003, 
Matuszewski, 2006) . The primary reason 
for using an IS in a bioanalytical analysis is to 
compensate for variations in injections, sample preparation, instrumental parameters 
and matrix effects (Chang et al., 2002, Jemal et al., 2003, Matuszewski, 2006). From 
the standard calibration curve for each analyte, the following fundamental parameters 
have been evaluated here in order to validate the method for quantification of organic 
acids in human urine. The Food Drug Agency (FDA) guidance requires the evaluation 
of these fundamental parameters as a part of quantitative LC-MS method development 
(FDA, 2001). 
Accuracy and precision: The accuracy is defined by the closeness of the experimental 
results to the true value as determined by the replicate analyses of samples that contain 
known amounts of the analyte of interest. The precision expresses the closeness of the 
agreement among a series of experiment measurements when the method 
is applied to 
multiple sampling of the same homogeneous sample. 
Limit of detection (LOD): This is defined as the 
lowest analyte concentration that the 
bioanalytical procedure can reliably differentiate from background noise. 
The accepted 
LOD is typically three times higher than the noise level (S/N = 
3). 
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Lower limit of quantification (LLOQ): This is the lowest amount of an analyte in a 
sample that can be quantitatively determined with suitable precision and accuracy. The 
acceptance for the LLOQ of an analyte is less than 20% of the coefficient of variation 
(%CV) of the LOD or ten times higher than LOD (Koal et al., 2006) 
Matrix effects: Matrix effects in LC-MS bioanalysis have been widely addressed in the 
literature (Chambers et al., 2007, Fu et al., 1998, Jemal et al., 2003, Matuszewski, 2006, 
Matuszewski et al., 1998). A matrix effect is defined as the effect of any co-eluting 
residual matrix components on the ionisation of the target analyte, resulting either in ion 
suppression or ion enhancement. It can be greatly inconsistent and can be difficult to 
control or predict. Matrix effects are caused by numerous factors including endogenous 
metabolites particularly phospholipids, dosing media, formulation agents and mobile 
phase modifiers (Chambers et al., 2007). The presence of a matrix effect can 
significantly decrease the response of the analyte, resulting in adverse effects of 
accuracy and precision of the bioanalytical method. Therefore, it is important to assess 
matrix effects in urine samples from different individuals. The high resolution of the 
advanced UPLC technology provides a significant improvement with respect to matrix 
effects, through improved separation from endogenous components, compared to the 
traditional high performance liquid chromatography (HPLQ (Chambers et al., 2007). 
Reproducibility: This is the ability of a scientific method or result to be accurately 
reproduced or replicated. It also represents precision of the method under the same 
operating conditions over a short period of time. 
Selectivity: The ability of the analytical method to differentiate and quantify the analyte 
in the presence of the other components in the sample. These could include metabolites, 
impurities, degradants, or matrix components. 
In this study, a bioanalytical method was developed and optimised for profiling urinary 
organic acids using UPLC-MS. Initially, a study was carried out on reference solutions 
for eighteen selected organic acids with the aim of recording retention times and mass 
spectra. The selected eighteen organic acids are typical urine metabolites including 
simple molecules, longer chain molecules, unsaturated molecules and molecules with 
aromatic rings. The same chromatography and mass spectrometry conditions were then 
used to analyse control urine samples after spiking with organic acids 
in order to 
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examine any changes in retention time. This method was also validated for the 
quantification of organic acids in human urine. Three organic acids were selected, one 
from each category of simple, longer and unsaturated molecules in order to assess 
whether these structurally different types of molecule behaved differently. 
Methylmalonate was selected as a simple molecule, adipate as a longer chain molecule 
and cis-aconitate as an unsaturated molecule. The method was validated by spiking 
standards of these three selected organic acids at different concentration levels into 
control urine samples from different individuals using the same chromatographic and 
mass spectrometry conditions. 
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3.3 Method development 
3.3.1 Method optimisation for separation of organic acids 
Initially, a reference study was carried out on standard solutions of the eighteen selected 
organic acids (Table 3.3) that are normally found in human urine. The chromatographic 
conditions, and in particular the gradient elution profiles of the mobile phases, were 
optimised through several trials in order to separate all the organic acids. The analytes 
were detected using electrospray ionisation (ESI) mass spectrometry in both negative 
and positive modes. The same chromatographic and mass spectrometry conditions were 
then applied to a control urine sample after spiking standard compounds to a final 
concentration of 50[tg/ml in order to confirm that the retention time was not affected by 
matrix effects. In this study, the isotope-labelled compound, succinic acid-1,4- 13 C2. ) was 
used as IS in order to normalise the response of selected organic acids. 
Sample Preparation 
Standards 
Adipate, methyl succinate, suberate, (S)-2-hydroxybutyrate, 3-hydroxybutyrate, citrate, 
cis-aconitate, 2-ketoglutarate, succinate, furnarate, malate, 3-hydroxy-3-methylglutarate, 
methylmalonate, 5-hydroxyindoleacetate, orotate, urocanic acid, 3-ureidopropionic acid, 
trans-aconitate and succinate-1,4-1 3 C2 were purchased from Sigma-Aldrich (Dorset, 
U. K). UPLC grade water (Riedel-de-Ha6n) and acetonitrile (Riedel-de-Haýn) were also 
purchased from Sigma-Aldrich (Dorset, U. K). 
The stock solutions for the standards (I mg/ml) were prepared by dissolving organic 
acids and the internal standard (IS) succinic acid- 1,4- 
13 C2 in UPLC grade water with I% 
acetonitrile (ACN) and were stored at -40 'C. These stock solutions were then diluted 
with the appropriate volume of UPLC grade water to give working standards of 
50 
[tg/ml for each organic acid and 25 [tg/ml for the IS. The standards were transferred 
into 
96 well plates for analysis. 
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Urine samples 
Control urine samples of 3 healthy volunteers (one male and two female) aged between 
25-35 years were obtained and stored at -40' C until analysis. A 150 gl aliquot of each 
urine sample was added to 150 gl Of H20 to make the total volume 300 gl. The samples 
were centrifuged at 16089 g for 10 minutes to remove particulates. 250 gI of diluted urine 
was transferred into 96 well plates and then spiked with each standard solution of 50 
Rg/ml. 
Chromatographic conditions 
Chromatographic separations were performed on a Waters 2.1 mm x 100 mm. 
ACQUITYTm 1.7 ýtnl C18 BEH column maintained at 40 'C. The samples were 
maintained at 4 *C prior to injection of 2 [tI on to the column. Reversed phase 
chromatography conditions were employed using a 12 min gradient with mobile phase 
A 0.1 % formic acid (FA) in water and mobile phase B being 0.1 % FA in acetonitrile 
(ACN). The gradient conditions are shown in Table 11. The flow rate was 0.5 ml/min. 
Table 3.1: UPLC gradient conditions for 0.1% formic acid in water (mobile phase A) and 
acetonitrile (mobile phase B) for 12 min. 
Time (min) 
Mobile phase A (%) 
(H20 +0.1 % FA) 
Mobile phase B (%) 
(ACN +0.1% FA) 
0.0 100 0 
1.0 85 15 
3.0 50 50 
6.0 5 95 
9.9 5 95 
10.1 100 0 
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Mass spectrometry conditions 
Electrospray (ESI) mass spectrometry experiments were performed on a LCT 
orthogonal acceleration time of flight mass spectrometer (Micromass, Manchester) 
operated in both positive and negative modes. The instrument was operated in W optics 
mode with 12000 resolution using dynamic range extension (DRE). The mass 
spectrometer was calibrated across the mass range 100-1000 Da using a solution of 
sodium formate. All analyses were acquired using the lock spray to ensure accuracy and 
reproducibility; 200 pg/ýiL leucine-enkephalin in H20ACN (50: 50) was used as lock 
mass with a flow rate 30 ýtUmin. Data were collected in centroid mode, the lockspray 
-rýý nequency was set at 5 s, and data were averaged over 10 scans. The MS conditions for 
analysing samples of standards and urines in both modes are shown in Table 3.2. 
Table 3.2: MS and MS/MS conditions for analysing samples of standards and urines in 
both negative and positive modes on LCT mass spectrometer 
Parameters Negative mode Positive mode 
Capillary voltage (KV) 2.4 2.9 
Cone voltage (V) 35 30 
Desolvation gas (LAhr) 900 958 
Desolvation gas temperature (*C) 400 350 
Cone gas (LAhr) 0 0 
Cone gas temperature (OC) 120 120 
Data acquisition rate (s) I I 
Interscan delay (s) 0.1 0.1 
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3.3.2 Bioanalytical method validation 
The method was validated using three randomly selected organic acids adipate, cis- 
aconitate and methylmalonate spiked into control diluted urine samples. In order to 
validate the method for quantification of these organic acids in human urines, a 
calibration curve was constructed for each control urine (a urine processed with the IS) 
and five urine samples covering the total range I- 50 gg/ml of spiked organic acids. 
Preparation of calibration standards and urine samples 
Calibration standards for adipate, cis-aconitate, and methylmalonate were prepared by 
serial dilution with UPLC grade H20 of the initial stock solutions. These standards 
covered 5 different concentrations over the range of 1-50 [tg/ml for each of the three 
organic acids (1,10,20,40 and 50 [tg/ml). 
Calibration standards of organic acids with the IS were spiked into 50 [tl aliquots of 
three diluted control urines for adipate and only two control urines were used for both 
cis-aconitate and methylmalonate due to time constraints. Each spiked organic acid in 
urine was obtained as a single batch at each concentration level of 1,10,20,40 and 50 
[t g/ml. 
Calibration curves 
Peak areas of organic acids and the internal standard (IS) were calculated by integrating 
the peak of each analyte using Markerlynx software (Waters). The calibration curve for 
each organic acid was generated using the analyte to IS area ratios with three replicate 
injections at each concentration level for both the standard solutions and the control 
urines. The six-point best linear fit calibration curve including the non-spiked control 
urine sample (control urine with only IS) for each organic acid was obtained by a linear 
regression equation y= mx +c where y is the area ratio of analyte to the IS and x is the 
concentration of the analyte. 
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Accuracy and precision: The accuracy and the precision were calculated for both 
standards and the controls urines with spiked known concentrations of organic acids at 
all five different concentration levels. 
The accuracy (expressed as % error) was calculated by 
(mean value of observed concentralion), 
(spiked concentrafion) 
100 
Precision (expressed as % coefficient of variation (% CV)) was calculated by 
( standard valueof observed value) 
(mean value of observered concentration) 
100 
Limit of detection: The limit of detection (LOD) was evaluated as the signal-to-noise 
level that gave a ratio for urine samples containing spiked organic acids at 3: 1, this is 
the standard limit required by the FDA guidelines (FDA, 2001). 
Matrix effect: The matrix effect was calculated by dividing the measured concentration 
for each organic acid in the urines by the actual concentration in the urine after spiking 
them. 
Selectivity/specificity: To ascertain the selectivity/specificity of the method, six 
different samples of human urines and standards were analysed with and without IS. 
Reproducibility: Analytical reproducibility was assessed by multivariate statistical 
analysis using SIMCA-P software (version 11.5; Umetrics, Sweden). The acquired data 
were pre-processed using Markerlynx software. The data were normalised to total 
height. The resulting two-dimensional data (mass to charge ratio/ retention time pairs) 
were exported into SIMCA-P software (version 11.5; Umetrics, Sweden) as a marker 
table for further chemometric analysis. Three control samples were prepared and 
analysed 12 times each. Principal components analysis (PCA) was performed on the 
intensity values for the mass to charge ratio/ retention time pairs using unit variance 
scaling. 
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3.4 Results 
3.4.1 Method optimisation 
Human urine contains several thousand components, many of which remain 
uncharacterised. The vast majority of these are moderately or highly polar compounds 
such as organic acids which vary from individual to individual; hence, it was necessary 
to optimise chromatographic conditions especially the composition of organic mobile 
phase, to achieve good separation and elution of as many organic acids as possible in 
the urine samples. 
The method was developed and optimised to give both good separation and ionisation 
of the standards of organic acids as shown in Table 3.3. An in-house gradient method 
was used as a base and several trials were carried out with different gradient elution 
profiles to achieve good resolution and separation of all organic acids, symmetrical peak 
shapes for the analytes and the IS as well as the timing of the gradient changes. It was 
found that the mixture of H20/acetonitrile: 85: 15 - 50: 50 over 1-3 minutes eluted the 
greatest number of organic acids. Further increases in the composition of acetonitrile 
(50-95%) over 3-10 minutes resulted in the elution of the remaining hydrophilic and 
hydrophobic compounds present in urine. This was the method adopted for analysing 
organic acids in urine (Table 3.1). 
MS negative ion mode was chosen for MS detection as it empirically gave a more 
information-rich data set than positive ion mode. The organic acid standards analysed in 
this study have carboxylic acids as functional groups. The carboxylic acid readily loses 
a proton so will be charged using negative mode electron spray ionisation (ESI). 
Therefore all organic acids were detected in negative mode. 
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Table 3.3: Retention time of standards of organic acids (50 Ag/ml) detected in negative 
mode, listed in increasing molecular weight order. 
Organic Acids 
(50 gg/ml) 
Calculated 
monoisotopic 
mass in 
negative mode 
Retention 
Time 
(min) for 
standard 
solution 
Retention 
Time (min) 
for 
standards 
after 
spiking in 
urine 
Shift 
difference 
(min) 
2-hydroxybutyrate 103.0395 1.8 1.77 0.03 
3-hydroxybutyrate 103.0395 1.51 1.52 0.01 
Fumarate 115-0032 1.07 1.06 0.01 
Methylmalonate 117.0188 1.57 1.54 0.03 
Succinate 117.0188 1.35 1.32 0.03 
Succinate- 1,4- 13 C2 (IS) 119.0256 1.43 1.43 0.00 
Methylsuccinate 131.0345 3.15 3.23 0.08 
3-ureidopropionic acid 131.0457 0.78 0.77 0.01 
Malate 133.0137 0.71 0.70 0.01 
Urocanic acid 137.0351 0.79 0.79 0.00 
(x-ketoglutarate 145.0137 0.78 0.76 0.02 
Adipate 145.0501 3.34 3.38 0.04 
Orotate 155.0093 0.71 0.71 0.00 
3-hydroxy-3-methylglutarate 161.045 1.81 1.80 0.01 
Cis-aconitate 173.0086 1.34 1.34 0.00 
Suberate 173.0814 4.31 4.31 0.00 
5-hydroxyindoleacetate 190.0504 3.66 3.62 0.04 
Citrate 191.0192 1.04 1.04 0.00 
Figure 3.1 shows extracted ion chromatograms (EIC) of organic acids in a control urine 
sample after spiking at 50 ýtg/ml using the same chromatographic and mass 
spectrometric conditions developed during the method optimisation. The retention time 
of each organic acid spiked in the urine (Table 3.3, Figure 3.1) shifted only slightly 
(maximum 0.08 min) to its standard solution (Table 3.3). This shows that overall 
retention time of selected organic acids were unaffected by matrix effects. The retention 
times did not shift any more than 0.05 mins for repeated runs of both standards and 
control urines. However, it was noted that the retention times of succinate and 
succinate- 1,4- 13 C2 (IS) were slightly different (0.08 min). The EIC of several spiked 
compounds in urine particularly succinate- 1,4- 
13 C2,, cis-aconitate, suberic acid and 5- 
hydroxyindoleacetate, showed other peaks in the samples (Figure 3.1). These could be 
endogenous metabolites with same nilz values as the standard compounds. 
All organic 
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acids ionised well in the negative mode since the intensity peak of each organic acid 
was significantly higher than the noise level. 
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Figure 3.1: Extracted ion chromatograms of organic acids in the control urine sample 
after spiking 50gg/ml. *- same nilz compound in the urine 
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3.4.2 Method validation 
In order to validate the method for quantification of organic acids in human urine, 
calibration curves for the organic acids. adipate, cis-aconitate and methylinalonate were 
generated and the following fundamental parameters selectivity, accuracy, precision, 
matrix effect and reproducibility were evaluated. 
Calibration curves 
Calibration curves for adipate, cis-aconitate, and methylmalonate were constructed from 
three replicate runs of calibration standards and control urine samples from different 
individuals after spiking with known concentrations of the selected standards. The 
evaluation of the linearity of the calibration curves were obtained for all three organic 
acids. 
Figure 3.2 shows the calibration curves of adipate, cis-aconitate and methylmalonate. 
The six-point best linear fit calibration curve including the zero sample (control urine 
with IS) and five spiked standards of concentration of 1,10,20,40 and 50 ýtg/ml for 
adipate and cis-aconitate and four-point best linear for methylmalonate with spiked 
standards of concentration of 10,2010 40 and 50 ýtg/ml was obtained by linear regression: 
Iy= 
mx+c I 
The calibration curves for adipate and cis-aconitate used I ýtg/ml as the lowest 
concentration point. However, the limit of detection (LOD) was evaluated as 10 gg/ml 
for both organic acids, since the signal-to-noise ratio for urine samples containing I 
gg/ml of spiked organic acids were less than 3: 1, which is the standard limit required by 
the FDA guidelines (FDA, 2001). For methylmalonate, 10 gg/ml was the lowest 
concentration (data not shown). The intercept of urine samples after spiking adipate and 
cis-aconitate did not go through zero since the control urines contained low 
concentrations of these metabolites. The points for control urine I after spiked 50 gg/ml 
of adipate were scattered (Figure 3.2) as compared to control urine 3. This could be due 
to problem with injections (i. e. variations in volume injected) or the matrix effect of the 
sample. Co-eluting peaks may suppress/enhance the signal, which results 
in the 
variation of observed concentration of adipate. 
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Accuracy and precision 
The validation parameters such as precision (% coefficient of variation (%CV)) and 
accuracy (% error) were evaluated between the LOD 10 gg/ml and upper concentration 
of 50 ýtg/ml across the linear dynamic range of each analyte as shown in Table 3-4. 
Both % relative standard error (RSD) and % error for adipate were less than 20 % in 
control urine samples, although the % RSD for 20 ýtg/ml for one out of three urine 
samples (urine sample 2) was 21.12 %. For both cis-aconitate and methylmalonate, 
the % CV and % error were less than 20 % in all concentrations evaluated. 
lDv, -c I, ision and accuracy of adipate, cis-aconitate and methylmalonate in all control urines 
were less than 20 % for the lower limit of quantification (LLOQ) and less than 15% for 
other points. However, methylmalonate shows an error of 17.17 % for the 40 gg/ml in 
urine sample 2, but 5.93 % for urine 1. This method therefore passed the validation 
criteria for adipate, cis-aconitate and partially for methyl malonate. 
Lower limit of quantification (LLOQ) 
The LLOQ was defined as the lowest concentration sample which would give 
acceptable accuracy and precision and was also found to be 10 gg/ml for all three 
organic acids; adipate, cis-aconitate and methylmalonate in urine. 
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Table 3.4: Precision and accuracy of the developed bioanalytical method for quantifying 
the organic acids adipate, cis-aconitate and methylmalonate in human urine samples 
Concentration 
Organic Samples (mg/ml) % RSD % Error 
acid (n=3) (Precision) (Accuracy) Actual Calculated 
10 8.8 0.9 10 12 
20 19.6 2.4 12 8 Urine 1 
40 35.8 4.6 13 12 
50 53.8 10.3 19 17 
10 10.0 0.9 9 5 
20 23.4 ± 4.5 19 21 Adipate Urine 2 
40 39.2 ± 5.4 14 11 
50 49.3 ± 7.6 15 11 
10 9.9 1.7 17 11 
20 22.2 ± 2.3 10 12 Urine 3 
40 37.5 ± 4.6 12 8 
50 51.2 ± 4.9 10 7 
10 10.1 ± 0.8 8 6 
20 18.8 ± 1.8 10 8 Urine 1 
40 40.9 ± 0.8 2 2 
Cis- 50 49.7 ± 4.2 8 6 
aconitate 10 10.1 ± 0.4 4 3 
20 18.671 ± 2.08 11 8 Urine 2 
40 41.069 ± 6.31 15 12 
50 49.661 ± 4.7 9 7 
10 8.9 1.8 21 18 
20 20.7 1.4 7 6 
Urine 1 40 42.4 2.6 6 6 
Methyl 50 50.0 1.4 3 4 
malonate 10 9.6 1.2 13 8 
20 17.4 ± 2.5 14 13 
Urine 2 40 34.2 ± 6.4 19 17 
50 53.7 ± 13.6 25 18 
Matrix effects 
Calculated ion suppression or enhancement values for all organic acids at each 
concentration level are shown in Table 3.5. A calculated concentration of 100% 
indicates that the response in the mobile phase and in the urine samples were the same 
and no matrix effect was observed. A value of more than 100% indicates an ionization 
enhancement and a value of less than 100% indicates ionization suppression. In this 
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method development study, the matrix effects in terms of either ionisation suppression 
or ionisation enhancement was in the range of 0.3% to 17.2% for organic acids adipate, 
cis-aconitate and methyl malonate in different control urine samples with the 
concentration range of 10 - 50 gg/ml. 
Table 3.5: Matrix effect of the developed bioanalYtical method for quantifying the organic 
acids adipate, cis-aconitate and methylmalonate in human urine samples 
Organic Samples Concentration (gg/ml) Calculated T f t i ype o ma r x 
acid (n=3) Actual Calculated concentration effect 
10 8.8 0.9 88.0 12.0% Suppression 
20 19.6 2.4 98.0 2.0% Suppression Urine 1 
40 35.8 4.6 89.5 10.5% Suppression 
50 53.8 10.3 107.5 7.5% Enhancement 
10 10.0 0.9 99.7 0.3% Suppression 
20 23.4 ± 4.5 117.2 17.2% Enhancement Adipate Urine 2 
40 39.2 ± 5.4 98.1 1.9% Suppression 
50 49.3 ± 7.6 98.5 1.5% Suppression 
10 9.9 1.7 98.7 1.3% Suppression 
20 22.2 2.3 110.8 10.8% Enhancement 
Urine 3 
40 37.5+-4.6 93.8 6.2% Suppression 
50 51.2 ± 4.9 102.4 2.4% Enhancement 
10 10.1 ± 0.8 100.9 0.9% Enhancement 
20 18.8 ± 1.8 94.0 6.0% Suppression Urine 1 
40 40.9 ± 0.8 102.3 2.3% Enhancement 
Cis- 50 49.7 ± 4.2 99.4 0.6% Suppression 
aconitate 10 10.1 ± 0.4 101.0 1.0% Enhancement 
20 18.671 ± 2.08 93.4 6.6% Suppression Urine 2 
40 41.069 ± 6.31 102.7 2.7% Enhancement 
50 49.661 ± 4.7 99.3 0.7% Suppression 
10 8.9 1.8 88.7 11.3% Suppression 
20 20.7 1.4 103.3 3.3% Enhancement 
Urine 1 
40 42.4 2.6 105.9 5.9% Enhancement 
Methyl 50 50.0 1.4 95.9 4.1 % Suppression 
malonate 10 9.6 1.2 96.5 3.5% Suppression 
20 17.4 2.5 87.0 13.0% Suppression 
Urine 2 
40 34.2+-6.4 85.6 14.4% Suppression 
50 53.7 ± 13.6 107.4 7.4% Enhancement 
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Reproducibility 
Analytical reproducibility was assessed by multivariate statistical analysis using 
SIMCA-P software (version 11.5; Umetrics, Sweden). Three urine samples from 
healthy volunteers including a male and two females were prepared once and analysed 
12 times each. The principal components analysis (PCA) scores plot in Figure 3.3 
shows that repeated samples are clustered together for each control urine sample, 
indicating that the analytical variation was much smaller than the detected normal 
physiological variation in urine composition of controls. The loadings plot showed that 
the separation of the male urine sample from female samples was attributed to the 
variation of hippurate, p-cresol sulphate and a biomarker with RT- "Vz 4.01357.1425. 
The separation of female I and female 2 from others was attributed to variation of 
biomarkers with RT nz/ -z5.97421.1057 and 
4.03527.2 respectively. 
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Figure 3.3: PCA scores and loadings plots of urines of three different controls, each of 
them prepared 12 times and injected in a randomised order 
\ 4 Hippurale 
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Another PCA model was constructed to examine the organic acid distribution between 
those three control urines. This was achieved by plotting the PCA model (Figure 3-4) 
after removing biomarkers with nzlz above 200 since the nilz of most organic acids are 
less than 200 Da. The loadings plot shows that the separation of male was attributed to 
variation of p-cresol sulphate and the separation female 2 was attributed to variation of 
cis-aconitate and also p-cresol sulphate. The concentration of hippurate and citrate are 
higher in the urine samples of the male and female I sample compared to female 2. 
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Figure 3.4: PCA scores and loadings plots of urines 3 different controls with m1z < 200, 
each of them prepared 12 times and injected in a randomised order 
Selectivity/Specificity 
Figure 3.5 shows selectivity/specificity of cis-aconitate. No significant interfering peaks 
from the standard solution were found at the retention time and in the extracted 
chromatograms of either the analyte or IS. There were also no interfering peaks from 
the urine at the retention time and extracted ion chromatogram of IS. 
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Figure 3.5: Extracted chromatograms of cis-aconitate obtained from (A) blank urine 1 
with IS; (B) blank urine I without IS; (C) urine 2 containing cis-aconitate at 50 gg/ml; (D) 
urine 1 containing cis-aconitate at 50 gg/ml; (E) standard solution of cis-aconitate at 50 
gg/ml 
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3.5 Discussion 
A bioanalytical method was developed for the profiling of organic acids in human urine 
using UPLC-MS. Initially, a reference study was carried out on standard solutions of 
eighteen selected urinary organic acids with the aim of detecting them by UPLC-MS 
and recording retention times and mass spectra. All selected organic acids were detected 
in the negative mode as the carboxylic acid of each organic acid readily loses a proton 
using negative mode electron spray ionisation (ESI). The same chromatographic and 
mass spectrometry conditions were then applied to control urine samples after spiking 
the selected organic acids in order to confin'n that the retention time of each organic 
acid was not affected by matrix effects. 
The UPLC system uses columns packed with 1.7 micron particles and high pressure, 
enabling the elution of sample components in much narrower, more concentrated bands, 
resulting in better chromatographic resolution, very good separation and hence increased 
sensitivity. Additionally, all organic acids were eluted with in 5 mins, therefore this method 
reduces the sample analysis time as compared to other conventional methods such as GC- 
NIS and HPLC-MS. 
Sample preparation for the derivatisation method and longer assay times is the main 
disadvantage of GC-MS, making GC-MS less suitable for high through-put screening. 
Using HPLC-APCI-MS for profiling organic acids is a complex procedure and hence is less 
suitable for screening large numbers of samples. The main advantages of the UPLC-MS 
method developed here over these published methods are the reduction of sample 
preparation steps, the reduced volume of urine required for the analysis and the shorter 
experiment time, rendering the approval suitable for high-throughput screening. In this 
experiment urine samples were prepared by the dilution of water (1: 1) and a2 ý11 aliquot 
of diluted urine after spiking organic acids was injected each time with a total 
experimental time of 12 min 
The method was validated for quantification of three selected organic acids adipate, cis- 
aconitate and methylmalonate by evaluating the fundamental parameters of accuracy, 
precision, matrix effects, selectivity and reproducibility. The calibration curves for each 
organic acid were linear over the concentration range of 10-50 gg/ml in both standards 
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and urine samples with the correlation coefficients (r 2) being > 0.9 1. This method 
passed the validation criteria for adipate and cis-aconitate as accuracy (expressed as % 
error) and precision of the lower limit of quantification (LLOQ) was less than 20% and 
the other concentrations were less than 15%. However, methylmalonate shows an error 
of 17.17% for the 40 ýtg/ml concentration in one of the control urine samples and 
therefore only partially fulfils the validation criteria. All three organic acids showed that 
LLOQ was 10 gg/ml in this method. Ideally, this value should have been 10 times 
higher than the LOD which was also 10 gg/ml in this study (Koal et al., 2006). 
It is important to check matrix effects when developing bioanalytical methods since the 
results obtained strongly depend on the response of the instrument. In this experiment, 
the calculated ion suppression or enhancement values (< 20%) for all organic acids at 
each concentration level showed that the quantification procedure was not significantly 
affected by matrix effects. High concentrations of sodium chloride (NaCl) plays an 
important role of matrix effect in urine (Boer et al., 1998). The sources of NaCl could 
be from urine samples, glassware and buffers. A number of literature studies have 
demonstrated that matrix effects can be largely eliminated by the use of isotope-labelled 
internal standards (IS) (Jemal et al., 2003, Matuszewski et al., 1998, Matuszewski et al., 
2003). 
The developed method shows a good analytical reproducibility since the analytical 
variation is much smaller than the detected normal physiological variation in urine 
composition of controls. The separation between control urines was attributed to 
variation of p-cresol sulphate, hippurate, citrate and cis-aconitate and unidentified 
molecules with RT-nz/z 527.2,421.1 and 357.1. The selectivity/specificity obtained in 
this method was good since no significant interfering peaks from the standard solution 
were found at the retention times in urine samples. 
Various methods for profiling urinary organic acids have been reported in the literature 
using either gas chromatography-mass spectrometry (GC-MS) (Hagen et al., 1999, Liu 
et al., 2004, Suh et al., 1997), high performance liquid chromatography- mass 
spectrometry (HPLC-MS) (Kajita et al., 1993) or capillary electrophoresis (CE) 
(Willetts et al., 1996). However, UPLC-MS has not been used for profiling urinary acids 
yet. A few HPLC-MS methods have described the quantification of urinary organic 
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acids. These methods presented different analyte extraction strategies using different 
chromatography columns. Bishop et al. validated a bioanalytical method for 
quantification of zwitterionic organic acids using weak-anion exchange chromatography. 
The validated method showed a linearity (r2> 0.99), accuracy <15% and precision < 
12%. Keevil et al. also conducted a method for quantification of urinary oxalate using 
LC-MS/MS with anion exchange chromatography. Ion exchange chromatography offers 
excellent retention of small biological polar compounds as compared to reverse phase 
chromatography. The calibration curve was linear (r 2=0.99) with accuracy was <5% 
and precision <6%. There was minimal matrix effects observed in both studies due to a 
high concentration of non-volatile salts in the mobile phases. However, the 
quantification was not affected by the ion suppression, indicating the effectiveness of 
internal standards to correct the matrix effect. Magera et al. quantified urinary 
methylmalonic acid using HPLC-MS/MS with r2=0.99 and precision less than 8.5%. 
However, the sample preparation employed a derivatisation step of butanolic HCI which 
produced MS/MS fragments similar to methylmalonic acid derivative MS/MS 
fragments. This method is not desirable for metabolic profiling studies due to laborious 
sample preparation steps. 
This was an exploratory study showing reasonable results for the validation of three 
organic acids adipate, cis-aconitate and methylmalonate. The current method still fulfils 
the FDA validation criteria, although quantification of urinary organic acids was carried 
out on reverse phase C18 column without using any ion exchange chromatography or 
derivatisation steps. The linearity of the calibration curves could be improved in order 
to enhance the value of r2, accuracy and precision. Future work should be carried out on 
different UPLC columns such as high strength silica (HSS) columns, which have 
become available recently for analysing polar compounds. The method could be 
validated using a wider concentration range of standard compounds (more than six 
different concentrations ranging from 100 ng/ml - 100 ýtg/ml) with at least five control 
urines from different sources in order to obtain more accurate value of LLOQ. 
Additionally, different isotope-labelled internal standards (IS) of different 
concentrations could be used in order to obtain improved values of accuracy, precision 
and ion suppression or ion enhancement thereby enhancing the linearity of calibration 
curves. Liang et al. showed that appropriate concentration of IS could improve the 
linearity of calibration curves (Liang et al., 2003). 
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3.6 Conclusion 
The developed method is rapid, reproducible, reliable and sensitive for profiling urinary 
organic acids. Although this current method was optimised for the profiling of urinary 
organic acids, which all eluted in less than 5 mins, the UPLC gradient was ramped to a 
higher organic solvent acetonitrile (ACN) concentration (95%) over the with total time 
of 12 mins. This eluted the majority of hydrophilic and hydrophobic metabolites in 
urine. Therefore this method is also suitable for separation other classes of organic acids 
such as amino acids (studied in inborn errors of metabolism (EEM), Chapter 5) and 
could be used for untargeted metabolic profiling in all studies (IIEM, Chapter 5, and 
large human population study INTERSALT, Chapter 6). 
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Chapter 4: lH NMR Spectroscopic Investigation 
of Organic Acid Excretion in Young Sprague- 
Dawley Rats 
4.1 Summary 
This study was carried out to identify the temporal changes in the metabolite 
composition of urine in order to distinguish possible confounding physiological effects 
of toxic intervention due to metabolic alkalosis, metabolic acidosis and caloric 
restriction, which can all be associated with drug administration. 1H NMR spectroscopy 
was used to investigate the temporal relationship between energy metabolism related 
tricarboxylic acid (TCA) cycle intermediates citrate, 2-oxoglutarate, succinate and 
furnarate and other metabolites hippurate, trans-aconitate, N-methylnicotinic acid 
(NNWA), and N-methyl nicotinamide (NMND), which are key metabolites observed in 
many toxicology studies (Table 4.1), in urine samples of rat models of metabolic 
alkalosis, acidosis and caloric restriction. 
Aims and Objectives 
1. To use 1H NMR spectroscopy to identify the time related changes in the metabolic 
composition of urine in rat models of chemically induced metabolic acidosis, 
metabolic alkalosis as well as caloric restriction and to construct excretion profiles 
for the selected cohort of metabolites. 
2. To quantify excretion rates of specific organic acids in various physiological states. 
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4.2 Introduction 
Certain drugs on the market have the potential to cause both chronic and acute adverse 
effects in patients (Nebeker et al., 2004). Specific adverse effects include metabolic 
acidosis and alkalosis, which can manifest severe physiological symptoms such as 
seizures, coma, and in some cases death. Drugs such as topiramate (Delpirou-Nouh, 
2007) and lorazepam. (Arbour et al., 2000) are known to cause metabolic acidosis and 
alkalosis. Acetazolamide causes renal tubular acidosis (Ikeda et al., 2002), a class of 
acidosis with impaired renal hydrogen ion excretion that leads to systemic metabolic 
acidosis. Another common side effect of many drugs is loss of appetite or anorexia 
resulting in caloric restriction. Understanding adverse drug effects is important for 
assessing mechanisms of drug-induced toxicity and is part of the risk assessment of new 
chemical entities in pharmaceutical development. 
Changes in the concentration of many urinary metabolites including TCA cycle 
intermediates citrate, 2-oxoglutarate, succinate and fumarate have been observed with 
many types of organ toxicity as shown in Table 4.1. The observed metabolite changes 
can be related to widespread organ toxicity or to specific organ toxicity. However, 
inducing high-dose toxicity also results in reduced food intake due to poor feeding 
behaviour, which is not normally reported in toxicology studies. In metabolic profiling 
studies, the changes attributed to toxicity of a particular compound may be cofounded 
by such side effects and it is necessary to understand this additional variation prior to 
identifying candidate biomarkers of toxicity. 
Elimination of toxic metabolites as well as other waste products from the body is vital 
in order to maintain the body acid-base homeostasis. The most common route of 
excretion for low molecular weight toxic compounds is through the kidneys into the 
urine. Therefore, changes in urinary metabolite excretion reflect normal variation as 
well as pathological impact of toxicity or disease on single organ or multiple systems 
(Ghauri et al., 1993a, Nicholson et al., 1995, Nicholson et al., 1984). As previously 
mentioned, NMR spectroscopy offers a non-invasive, reproducible approach to the 
metabolic profiling of biofluids such as urine, serum, and plasma (Beckonert et al., 2007, 
Foxall et al., 1998, Keun et al., 2002b) and has been used extensively to characterise 
toxic responses (Table 4.1). 
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Table 4.1: Examples of urinary metabolites referenced as markers in toxicology studies 
Urinary levels of metabolites M- decrease, M- increase, M- no change, RP Reproductive organ, NMNA - N-methyl 
nicotinamide. NMNA - N-methvinicotinic acid and *- hnth liver ýind L-irln, -x/ tnv; - ** k-th 1,; A-, -I I--, - 
Urinary bi omarkers References 
Toxic compound 0 
Z Z 
Hydrazine (Hz) (Crockford et al., 2006, Holmes et al., 2000, Holmes (120 mg/Kg) et al., 1998b, Nicholls et al., 2001, Wu et al., 2005) 
Galactosantine (GaIN) 
(500,600 mg/Kg) (Beckwith-Hall et al., 1998, Ishihara et al., 2006) 
Butylated hydroxytoluene 
(BHT) (1000 mg/Kg) (Beckwith-Hall et al., 1998) 
cc-Napthylisothiocynate 
(ANIT) (200 mg/Kg) 
(Beckwith-Hall et al., /998, Robertson et al., 2000) 
Carbon tetrachloride (CC14) 
(0.5mUl(g) - (Robertson et al., 2000, Wu et al., 2005) 
Ethionine 
(800mg/Kg) - (Skordi et al., 2007) 
Allyl formate 
(75 mg/Kg) - 
(Clayton et al., 2003, Yap et al., 2006) 
2. 
Thioacetaniide 
- (Clayton et al., 2004, Waters et al., 2005) (150,200 mg/Kg) 
Lipopolysaccharide (LPS) 
(4.44 X 106 EU/Kg) t al., 2006) 
Pravastatin 
(500 mg/Kg) 
(Lenz et al., 2007a) 
Bromobenzene 
(1500 mg/Kg) 
(Waters et al., 2006) 
Methylene dianaline 
(Ishihara et al., 2006) (250 mg/Kg) 
1-Nitronaphthalene (NN) 
(A, -mi et al. 2005) (75 mg/Kg) , 
Clof ibrate 
(500 mg/Kg) 
(Ishihara et al., 2006) 
Methapyrilene 
raig et al., 2006b) 0 50 mg/Kg) 
2-Brornoethylaniine (BEA) (Holmes et al., /992, Holmes et al., 1998a, 
(15,150 mg/ Kg) Robertson et al., 2000) 
4-Aniinophenol (PAP) (Robertson et al., 2000) (15 & 150 mK) 
Propylenein-tine (PI) (Holmes et al., 1997a) (20,30 gUl(g) 
Mercury chloride (HgCl, ) (Holmes et al., / 992, Holmes et al., 2006, Holmes et 
(0.75 mg/Kg) al., 2000, Holmes et al., 1998a) 
Ochratoxin A (OTA) (Mally et al., 2005) (2 mg/Kg) 
,u 
D-serine (Williams et al., 2003) C 
1 
(500 m g/Kg) 0 Aristolochic acid (AA) (Zhang et al., 2006) 
(I 0m g/Kg) 
_ Ifosfamide (Foxall et al., 1996) (5 5 mg/Kg) 
Uranyl nitrate (UN) (Gartland et al., 1990a) 
(5,10,20 mg/K 
Cisplatin (Gartland et al., 1989, Portilla et al., 2006) 
(5,20 mg/Kg) 
Puromycin aminonucleoside (Cutler et al., 1999) 
(PAN) (100 mg/Kg) 
Imipenem (Harrison et al., 1991) (180 mg/Kg) 
Ethylene glycol monomethyl (Yamamoto et al., 2007) 
ether (EGME) (2000 mg/K Fýadnuum Chloride** ý4 (Nicholson et al., / 989a) 0 (r7 ), 1 C. 68 - 2.7 img/Kg) 
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In this study, the temporal changes in the metabolite composition of urine samples in 
response to metabolic alkalosis, metabolic acidosis as well as caloric restriction were 
investigated in detail using 1H NMR spectroscopy. The ultimate aim would be able to 
distinguish effects of drug toxicity from possible non-toxic or cofounding effects caused 
by metabolic acidosis and alkalosis or loss of appetite, modelled here using caloric 
restriction. 
4.2.1 Acid-base balance 
The blood pH is normally closely regulated at between 7.35 and 7.45. Maintaining the 
pH within these limits is achieved by intercellular and extracellular buffer agents such 
as phosphate, bicarbonate, and ammonia, and the primary organs the lungs and the 
kidneys. A short term method of compensating for acid-base imbalance involves 
regulating ventilation rate, which results in alteration of the concentration of carbon 
dioxide in the blood and consequently the pH. In the long term, the kidneys maintain 
acid-base homeostasis by altering the excretion of excess acids or bases. The plasma 
hydrogen ion concentration, referred to as pH, is determined by the partial pressure of 
carbon dioxide (PaC02) in arterial plasma and the bicarbonate system, which is the 
main buffer in the extracellular fluids. This can be simply described by the following 
equation: 
a 
PaC02 
HCO- 3 
Both acidosis and alkalosis describe the acid-base disturbances which lead to changes in 
the plasma hydrogen ion concentration. There are two different modes of disturbance of 
acid-base balances: respiratory and metabolic. Respiratory disorders are due to the 
changes in the PaC02 and metabolic disturbances are initiated by the changes in the 
plasma bicarbonate. 
Respiratory alkalosis and acidosis 
Respiratory alkalosis increases the over breathing/hyperventilation leading to decreased 
plasma carbon dioxide concentration. The causes of hyperventilation include anxiety, 
stress and caffeine overdose. 
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On the other hand, respiratory acidosis results from the accumulation of carbon dioxide 
in the blood. This is often caused by pulmonary problems such as chronic bronchitis, 
asthma, severe pneumonia and aspiration, head injuries and brain turnours. 
Metabolic alkalosis and acidosis 
Metabolic alkalosis is a primary pathophysiological condition caused by the abnormal 
rise of blood bicarbonate concentration or the loss of non-volatile acids from 
extracellular fluid (Khanna et al., 2006). This is the second most common acid-base 
disorder in hospitalised adults (Hodgkin et al., 1980, Mazzara et al., 1974), generated 
by either the loss of acid through the gastrointestinal tract (GI) tract or kidney from 
vomiting and diarrhoea or the gain of alkali by either oral or parenteral bicarbonate 
administration, or by lactate, acetate or citrate administration (Khanna et al., 2006) 
The kidney maintains the acid-base balance by two mechanisms involving bicarbonate. 
Reclarnation/reabsorption of bicarbonate is mainly by the proximal tubule and 
bicarbonate regeneration occurs predominantly in the distal tubule (Khanna et al., 2006). 
Metabolic alkalosis is normally caused by severe vomiting, mineralocorticoid excess, 
liquorice ingestion, diuretic administration and Banter's and Gitelma's syndromes 
(Khanna et al., 2006). Therapy involves reversing the contributory factors promoting 
alkalosis and in severe conditions, administration of carbonic anhydrase inhibitors, acid 
infusion and bicarbonate dialysis (Khanna et al., 2006). 
In contrast, metabolic acidosis leads to changes of substrate levels in the opposite 
direction to those seen in metabolic alkalosis. In response to metabolic acidosis, the 
kidney undergoes several adaptive changes in its function and increases the acid 
excretion in the urine (Faroqui et al., 2006). The main adaptive change takes place in 
the proximal tubule, which exhibits an increase in H' secretion and bicarbonate (HC03-) 
absorption, stimulation of ammoniagenesis and bicarbonate production and reduction in 
the reabsorption of inorganic potassium and sulphate, which contribute to the increase 
of acid secretion in the collecting duct (Faroqui et al., 2006). 
Systemic metabolic acidosis can be caused by the ingestion of acids (H') or the 
excessive production of H+ or the loss of HC03- frOM the body. There are various 
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disease states and conditions related to metabolic acidosis including renal tubular 
acidosis, chronic renal failure and total parenteral nutrition (Faroqui et al., 2006). 
Sometimes, there could be more than one acid-base disorders occurring in the patient at 
the same time, as shown in Table 4.2: 
Table 4.2: The primary acid-base disorders 
Condition pH Compensation 
Respiratory acidosis Down (pH <7.35) Respiratory 
Metabolic acidosis Down (pH <7.35) Renal 
Respiratory alkalosis Up (pH >7.45) Respiratory 
Metabolic alkalosis UP (pH >7.45) Renal 
In this study, metabolic alkalosis was induced in rats by the administration of the 
diuretic compound sodium bicarbonate (NaHC03)which increases the flow of sodium 
ions into the distal and collecting tubes. This results in rapid reabsorption of sodium 
ions from the tubules, leaving the excess of bicarbonate (HC03-) anions behind in the 
tubules. The HC03- anions combine with H' ions, resulting in the loss of H' from the 
extracellular fluid, leading to metabolic alkalosis. Metabolic acidosis was induced in 
rats by the administration of ammonium chloride (NH4CI). Treatment with NH4Cl 
increases the plasma NH4' concentration which combines with HC03- tOform urea in 
the liver (Boon et al., 1996). Administration of excessive amount of NH4Cl causes an 
excess of ammonium ions which deplete HC03-, causing a fall in blood HC03- 
concentration, characteristic of metabolic acidosis. 
4.2.2 Kidney anatomy and functions 
The kidney is the primary organ for the maintenance of acid-base homeostasis and 
regulates the excretion of waste products generated during the metabolism of dietary 
protein and other metabolic processes (Lote, 2000) . Kidneys are paired organs situated 
behind the peritoneum on either side of the vertebral column. The kidneys process about 
20% to 25% of total cardiac output blood supply. 
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There are four main homeostatic functions of the kidneys: 
1. To excrete a variety of metabolic wastes including urea from protein catabolism, 
uric acid from nucleic acids, creatinine from muscle activity and water. 
2. To maintain body acid-base homeostasis by regulating the excretion of renal 
hydrogen ions generated during the metabolism of dietary protein and other 
metabolic processes. 
3. To regulate blood pressure by maintaining normal sodium ion balance, extracellular 
fluid volume and blood volume via the renin-angiotensin-aldosterone system 
(RAAS). 
4. To secrete a variety of hormones including erythropoietin for the regulation of red 
blood cell production, rennin for the reduction of glomerular filtration and vitamin 
D for the re-absorption of calcium ions. 
The structure of the kidney facilitates the elimination of waste products from the body. 
The basic morphological unit of kidney is the nephron as shown in Figure 4.1. Each 
kidney contains about 1-1.5 million nephrons. The nephron functions to filter and 
regulate the concentration of small ions and molecules such as water, sodium ions, 
glucose, and amino acids. Larger molecules such as proteins are not absorbed. The 
anatomy of a nephron consists of a close-ended tube, forming a capsule (Bowman's 
capsule) around a knot of blood capillaries called the glomerulus. The Bowman's 
capsule leads into the proximal convoluted tubule (PCT), loop of Henle, distal. 
convoluted tubule (DCT) and finally the collecting duct (Lote, 2000). 
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Figure 4.1: The structure of a mammalian nephron 
Adapted from http: //"ýý, w. ivy-rose. co. Lik/Topics/Uri nary System Nephron Diagram. php 
The glomerulus serves as a filter for blood. Fluids from blood are filtered from the 
glomerulus into the space made by the Bowman's capsule due to a high pressure across 
the glomerulus. The glomerular filtrate then flows through the PCT, where pH is 
regulated through exchange of bicarbonate (HC03-) and hydrogen (H') ions. Sodium 
(Na'), chlorine (Cl-), potassium (K'), calcium (Ca') and phosphate W04 3- ) ions are also 
reabsorbed here along with water, amino acids, urea and glucose. In addition the PCT 
also secretes organic acids (e. g. hippurate) and bases (e. g. choline and histamine) into 
the filtrate. The loop of Henle follows from the PCT, where a counter-current multiplier 
system concentrates solutes by regulation of the movement of water. A high 
concentration of solute is maintained in the intercellular fluid of the renal medulla, 
which surrounds the loop of Henle. As the loop of Henle descends into the medulla, 
water can freely move out of the descending limb of the loop by osmosis, but solutes are 
not actively transported out. The vasa recta is a long straight bundle of capillaries which 
help to concentrate the filtrate by extending deep into the medulla and paralleling to 
loops of Henle. The fluid in the descending limb of the loop of Henle therefore becomes 
concentrated and the osmotic pressure is increased. This causes the fluid to flow 
through towards the ascending loop. In contrast, the epithelial cells in the ascending 
limb of the loop of Henle are impermeable to water and actively transport solute ions 
such as Na', K' and Cl' ions out of the filtrate. This allows dilution of the ascending 
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limb fluid. From the ascending limb the fluid drains into the DCT where tubular 
secretion of materials such as creatinine, ammonia and H' ions occurs from the blood 
directly into the tubule by active transport. Finally the fluid then flows into the 
collecting duct where the ion and water concentrations are finally regulated. Under 
normal conditions the collecting duct is impermeable to water and only becomes 
permeable to water in the presence of antidiuretic hormone (ADH). 
4.2.3 Re-absorption of bicarbonate ions in kidney 
The kidney regulates the acid-base balance through the reabsorption of filtered HC03- 
and the excretion or replenishment of H' ions by adjusting plasma HC03- concentration. 
The HC03- is filtered freely by the glomerulus and regenerated or reabsorbed in the 
plasma and both the proximal and distal tubules of the nephron in acidification. Figure 
4.2 shows the mechanism of bicarbonate (HC03-) ion reabsorption in the proximal 
tubule. Under the influence of the enzyme sodium-potassium adenosine triphosphatase 
(Na+W -ATPase), sodium ions are pumped out of the proximal tubule cell in exchange 
for potassium ions. 
As the intracellular sodium ion concentration is decreased, passive absorption of sodium 
ions from the tubular lumen occurs. In order to maintain neutrality, one H' ion is 
secreted into the tubular lumen for each sodium ion absorbed. The secreted H' ion 
combines with filtered HC03- ions in the tubular lumen to form carbonic acid (H2CO3) 
which dissociates to C02and H20. C02diffuses into the proximal tubular cell where it 
hydrated to H2CO3in the presence of carbonic anhydrase. H2CO3 dissociates within the 
cell and produce H' and HC03- ions. H' ions are exchanged with Ne ions in the tubular 
lumen while HC03- are exchanged with Cl- in the plasma (Atherton, 2006) 
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Mechanisms of HC03- reabsorptlon 
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Figure 4.2: Mechanism of bicarbonate reabsorption in the proximal tubule, adapted from 
(Atherton, 2006) 
4.2.4 Tricarboxylic acid (TCA) cycle intermediates in acid- 
base balance 
Under normal physiologic conditions, an average rate of 50-70 mmol/day of a variety 
organic acids is produced by a healthy person (Hood et al., 1998). Any disturbance in 
the pH of extracellular fluid as the result of an excess or loss of acid or base, shifts the 
pH until it can be stabilised by appropriate changes in the renal acid excretion (Boon et 
al., 1996). An increase in acidity or alkalinity, as a result of accumulation of large 
quantities of HC03- and NH4' ions from amino acid metabolism, is prevented by the 
synthesis of urea and the excess NH4' is also incorporated into glutamine synthesis in 
the liver (Boon et al., 1996). Therefore, the metabolism of glutamine is essential for 
acid-base balance in the plasma. The carbon skeleton of glutamine is synthesised by 
gluconeogenesis which produces a chain of many energy metabolism metabolites and 
enzymes including the tricarboxylic acid (TCA) cycle metabolites. 
In eukaryotes, the TCA cycle is located in the matrix of the mitochondrion, playing a 
critical role in energy metabolism by conducting a series of chemical reactions as shown 
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in Figure 4.3. It occupies a central position in intermediary metabolism by converting 
acetyl-Co-A to CO,, and reducing the energy carrier nicotinamide adenine dinucleotide 
(NADH) and flavin adenine dinucleotide (FADH2) from the breakdown of sugars, 
amino acids and fats. 
Acetyl-CoA CoA 
Oxaloacetic acid 
J, 
kh 
Mali( 
'd k, 
7 
1 
FADH 
Fumaric acid vir 
CoA 
D 
6ý 
Succinic acta - 
ATP 
Figure 4.3: The tricarboxYlic acid (TCA) cycle 
Metabolites highlighted in green are measured in this current study; others are usually non-detectable in extracellular matrix and 
biofluids 
A number of studies reported that the urinary secretion of TCA cycle intermediates 
particularly citrate and 2-oxoglutarate, change with fluctuating acid-base balance (Evans 
et al., 1957, Gamble et al., 1961, Packer et al., 1995, Simpson et al., 1979). Previous 
investigations have revealed significant increases of citrate and 2-oxoglutarate excretion 
in response to metabolic alkalosis (Balagura-Baruch et al., 1973, Gamble et al., 1961). 
In contrast, studies have shown a significant decrease of citrate and 2-oxoglutarate in 
response to metabolic acidosis (Trivedi et al., 1986). 
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4.2.5 Caloric restriction 
The side effects of drugs can widely vary, depending on individual person's disease, age, 
weight, gender, ethnicity and general health. Some drugs cause side effects such as 
nausea, vomiting and drowsiness thereby decreasing levels of food intake, leading to 
ketosis or anorexia. Ishii et al. reported that acute induction of the orexin-1 receptor 
antagonist SB-334867 induced significant body weight loss and anorexia in male rats 
after 24 hours (Ishii et al., 2005). Low-carbohydrate diet such as Atkins diet, results in 
decreasing insulin levels and weight loss, inducing a state of ketosis which suppresses 
appetite (Adam-Perrot et al., 2006). 
Feeding behaviour or changes in diet have been known to strongly influence the body's 
acid-base homeostasis, leading to malnutrition as a result of various biological changes 
(Remer, 2001). Interpretation of any drug toxicity results can be complicated by the 
changes induced by such weight loss. 
On the other hand, mild caloric restriction (CR) has been shown to have benefits in 
terms of health. There has been great interest in investigating the relationship between 
CR and anti-ageing. The exact mechanism for the relationship between CR and anti- 
ageing is not known. Many studies of CR indicate that this nutritional manipulation 
retards the ageing processes, as shown by increased longevity. A restriction of 30-60% 
in food intake increased average and maximal life span by amounts proportional to the 
level of restriction (Weindruch et al., 1986). Several studies have shown prolonged life 
span via continuous moderate food restriction throughout the life of mice (Weindruch et 
al., 1986), dogs (Lawler et al., 2007, Wang et al., 2007), rodents (Tatsumi et al., 2007), 
primates (Roth et al., 1999) and man (Holloszy et al., 2007) and lower animals 
including microbes (Smith et al., 2007), nematodes (Crawford et al., 2007) and insects 
(Bass et al., 2007). Hagopian et al. reported that cellular energy metabolism under CR 
plays an important role in the anti-ageing process. The energy metabolism metabolites 
including TCA cycle inten-nediates citrate and 2-oxoglutarate decreased during 
moderate CR (Hagopian et al., 2004). The alterations in the TCA cycle metabolites can 
cause mutations in the longevity gene NDY which extends life in a variety of species 
(Knauf et al., 2006, Knauf et al., 2002). 
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The aim of the present study is to examine the effect of food restriction on energy 
metabolism metabolites including TCA cycle intermediates. Male rats were subjected to 
the moderate dietary food restriction of 25% or 50% for 7 days and were compared to 
either ad libitum fed (controls) or rats with food restricted completely for 24 hours 
which were then returned to the same ad libitum regime as that of controls. 
4.2.6 Use of 1H NMR spectroscopy in metabolic studies 
1H NMR spectroscopy has been used to study temporal changes in the metabolite 
profiles of biofluids as a response to toxic insult (Nicholson et al., 1999). It has been 
successfully applied to provide valuable information on drug-induced biochemical 
composition perturbations of biofluids such as urine, serum and plasma (Bollard et al., 
2005a, Coen et al., 2003, Yap et al., 2006) and has identified a number of novel 
biomarkers in chemically induced toxicology studies (Holmes et al., 1995, Nicholls et 
al., 2001, Sanins et al., 1992). 
The application of 'H NMR spectroscopy in toxicology has been evaluated and 
validated as a screening tool of pre-clinical toxicology by the COMET (the Consortium 
on Metabonomic Toxicology) project (Ebbels et al., 2007, Lindon et al., 2003b), which 
generated databases and a predictive expert system of different model toxins for liver 
and kidney from the analysis of rat and mice urine and serum in 147 different studies. 
This study also highlighted the ability of 1H NMR spectroscopy to analyse the toxicity 
by following the each animal non-invasively throughout the experiment. Additionally 
successful and reliable metabonomic screening tools were developed to predict 
liver/kidney toxicity with relatively minimal error. This approach, based on the 
construction of the CLOUD model using 80 minimal toxic interventions from COMET 
databases, has enhanced preclinical toxicity assessment (Ebbels et al., 2007). 
Physiological induced changes can also be monitored using metabolic profiling 
strategies. Wang et al. showed the usage of 
IH NMR spectroscopy in monitoring 
urinary metabolic profiles of moderate dietary restricted dogs throughout their lifetimes 
(Wang, 2007). The energy metabolism metabolites such as creatine, N-methyl 
nicotinamide (NMND), lactate, acetate, and succinate were reduced in dietary restricted 
dogs (Wang, 2007). 
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Unpublished work from the lab (Stanley, 2002) investigated the biochemical 
composition and clinical chemistry of rat urine and plasma models under different 
physiological and acid-base homeostatic conditions using pattern recognition methods 
such as principal component analysis (PCA) and projections to latent structures- 
discriminant analysis (PLS-DA). The chemometric analysis showed a clear separation 
between controls and treatment groups due to the attribution of the concentration of 
TCA cycle intermediates citrate, 2-oxoglutarate, succinate and fumarate in both 
metabolic acidosis and alkalosis studies. In the current study, 1H NMR spectroscopy 
was used to investigate the temporal relationships between TCA cycle intermediates and 
other energy metabolism metabolites often observed in many toxicology studies (Table 
4.1) such as hippurate, NMNA, NMND and trans-aconitate and rat urine models from 
three studies metabolic acidosis, alkalosis and caloric restriction undertaken as part of 
the COMET project, designed to provide a background on non-toxic or co-founding 
physiological effects which are often superimposed on the toxic effects of drugs. 
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4.3 Methodology 
4.3.1 Dose groups and sample collection 
Table 4.2 shows the dose regime/ diet restriction and pre- and post-dose urine collection 
time points for metabolic alkalosis, acidosis and caloric restriction studies. 
Metabolic alkalosis and acidosis studies 
30 Sprague Dawley male rats (6-8 weeks old) were separated into 3 groups (n=10) 
control, low dose and high dose for both the chemically induced metabolic alkalosis and 
metabolic acidosis studies. 
Metabolic alkalosis was induced by oral administration of sodium bicarbonate 
(NaHC03). The control animals were fed with water, whereas the low dose and high 
dose treatment groups were administered with 0.1 M and 0.35 M NaHC03 in the 
drinking water respectively for 5 days. Metabolic acidosis was induced by oral 
administration of ammonium chloride (NH4CI). The control animals were administered 
saline, where as the dose groups were administered NH4Cl in the drinking water, 
equivalent to 0.07 M (low dose) and 0.28 M (high dose) of body weight of each animal 
for 5 days. 
Urine samples were collected over the following periods (Table 4.2): -24-8 hrs, -8-0 hrs, 
0-8 hrs, 8-24 hrs, 24-32 hrs, 32-48 hrs, 48-56 hrs, 56-72 hrs, 72-80 hrs, 80-96 hrs, 96- 
120 hrs and afterwards every 24 hrs in both acid-base studies, ending at 288 hrs post 
treatment for metabolic acidosis; 312 hrs for metabolic alkalosis. 
Caloric restriction study 
A total of 36 Sprague Dawley male rats (6-8 weeks old) were separated into 4 groups 
(n=9). The control group was fed ad libitum with Purina Certified Rodent Chow 5002 
meal and dechlorinated tap drinking water and other groups were dietary restricted by 
25% (7 days), 50% (7 days) or 100% (1 day). The mean food consumption of controls 
was calculated daily and the individuals in groups 25% (7 days) and 
50% (7 days) were 
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fed by 75 and 50%, of the control group the previous day respectively. The 100% group 
was dietary restricted for 24 hours and then returned to the same diet as the control 
group. 
Urine samples were collected over -24-8 hrs, -8-0 hrs, 0-8 hrs, 8-24 hrs and afterwards 
every 24 hrs till 168 hrs as shown in Table 4.3. Urine volumes were recorded and 
samples were stored at -40 'C for NMR analysis. 
Table 4.3: Dose regime/ diet restriction and pre and post dose urine collection time points 
for metabolic alkalosis, acidosis and caloric restriction studies 
Dose regime / diet 
restriction 
Urine collection of pre and post dose tirne points (hr-s) 
Study 
IV9ý10 
4b Nj, 
/44 
Metabolic Control, I ow (0.1 NI) and 
alkalosis 
high dose (0.35 NI) for 5 
days 
Metabolic Control, low (0.07 NI) and 
acidosis 
high dose (0.28 NI) for 5 
-4 -4 4 4 -4 4 -4 4 4 4 -4 -4 4 -4 -4 4 4 4 days 
Control, diet restriction of 
C-Woric 75% (7days), 50% (7days) 
restriction and 100% (1 day only then -4 4 -4 
I return to control diet) LI I 
4.3.2 Urinary pH measurements 
Urinary pH values for all individual animals in metabolic alkalosis, metabolic acidosis 
and caloric restriction studies were measured at all time points. The mean pH values for 
each group were calculated for each time point. 
4.3.3 Sample preparation 
Urine samples were prepared by mixing 200 [il of 0.2M sodium phosphate buffer 
solution (pH 7.4) containing I mM trimethylsilyl-2,2,3,3-tetradeuteropropionic acid 
(TSP), 3m. M sodium azide and 10% 
D20( see Appendix 2) with 400 [tl undiluted urine. 
The samples were centrifuged at 1500 g for 5 minutes, to separate any precipitate. 
Aliquots of 500 [tl of the resulting solution were transferred into 96-well plates using an 
NMR flow injection Gilson robot for analysis. 
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4.3.4 111 NMR analysis of urine samples 
Urine samples were analysed at 300K using 1H NMR spectroscopy at 600.44 MHz 
using a flow-injection system (Bruker Biospin, Karlsruhe, Germany). For each sample, 
64 free induction decays (FIDs) were collected into 32k computer data points using a 
spectral width of 12019.23 Hz, giving an acquisition time 1.36 s with an additional 
relaxation delay (RD) of 2 s. 1H NMR spectra were acquired with suppression of the 
water resonance using a standard presaturation pulse sequence comprising (RD-90'41- 
90'-tm-90'-acquire FID (Bruker Biospin Germany) (Nicholson et al., 1995) where tl is 
a short delay of typically 2, us and tm is a mixing time (100 ms). Irradiation of the water 
signal was achieved during tm and RD. The summed FIDs were multiplied by an 
exponential weighting function corresponding to a line broadening of 1.0 Hz prior to 
Fourier transformation. Baseline correction and phasing of the spectra was achieved 
with in-house software (courtesy Dr. T. M. D. Ebbels and Dr. H. Keun, Imperial College, 
London) and internally referenced to trimethylsilyl-2,2,3,3-tetradeuteropropionic acid 
(TSP, 5HO. 00) using XWWWR software (Bruker, Germany). 
4.3.5 Data pre-processing 
The 1H NMR spectra measured at 600.44 MHz were reduced to 20001 intensity 
variables, calculated by integrating regions of equal width (0.00055 ppm) corresponding 
to the chemical shift range 0.5 - 9.5 using software written in house (courtesy Dr. 0. 
Cloarec, Imperial College, London) in Matlab R2007b from MathWorks, USA. The 
reduced data were then normalised using the probabilistic quotient nonnalisation 
method (Dieterle et al., 2006) to minimise the effects of variation in urine 
concentrations across the samples, as described in Chapter 2, section 2.2.1. 
4.3.6 Rationalisation for choice of metabolites 
A number of literature reports including unpublished work from this laboratory (Stanley, 
2002) describe the metabolic changes of TCA cycle intermediates citrate, 2- 
oxoglutarate, fumarate and succinate during acidosis and alkalosis. Hippurate is the 
product of benzoic acid metabolism, formed via the conjugation of benzoate with 
saturated glycine in mitochondria and is the major gut microbial mammalian co- 
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metabolite (Gavaghan et al., 2000, Phipps et al., 1998). The variations in the gut 
microbial population an influence on drug metabolism and toxicity in man and animals 
(Nicholson et al., 2005). Previous toxicological studies have reported about the 
metabolic variation of N-methylnicotinic acid (NMNA) (Nicholls et al., 2001) and N- 
methyl nicotinamide (NMND) (Connor et al., 2004). The metabolic changes in trans- 
aconitate concentration were of some interest because it is an isomer of the TCA cycle 
intermediate cis-aconitate which is not observed in the excretion profiles. The mean 
excretion rates for each time period of metabolites were calculated from the urinary 1H 
NMR spectra. 
Additionally, principal component analysis (PCA) was performed on caloric restriction 
data using pareto scaling in order to confirm that changes in the concentration of those 
eight metabolites were still significant as observed in metabolic acidosis and alkalosis. 
The acquired caloric restriction data was reduced to 9001 intensity variables, calculated 
by integrating regions of equal width (0.001) corresponding to the chemical shift range 
0.5-9.5 in Matlab R2007b from Math Works, USA. The region 8H 4.5-6.1 was 
eliminated to remove spurious effects due to variability of the water suppression. The 
regions of 6H3.035-3.06 and 6H4.04-4.08 were also excluded from the analysis to avoid 
classifying data based upon changes of creatinine which is closely correlated with 
muscle mass and nutritional status. The reduced data were then normalised using the 
probabilistic quotient normalisation method (Dieterle et al., 2006). 
A clear separation between controls and the 50% food restricted group was achieved 
using principal components analysis (PCA) (Figure 4.4 (A)). The loadings plot (Figure 
4.4 (B)) demonstrated that the separation was attributed due to the changes in the 
concentration of citrate, 2-oxoglutarate, taurine and trans-aconitate. Figure 4.4 
(C) 
shows the loading plot after removing highly dominating metabolites citrate, 
2- 
oxoglutarate and taurine in Figure 4.4 (B). The separation was attributed 
due to other 
lower concentration metabolites such as succinate, hippurate, NMNA, 
NMND and 
trans-aconitate. 
The chemometric analysis confirmed that these metabolites citrate, 
2-oxoglutarate, 
succinate, hippurate, NMNA, NMND and trans-aconitate were 
key metabolites for the 
caloric restriction study. Although taurine was also a 
key metabolite for the separation 
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of 50% food restricted group from controls, the temporal relationship of taurine was not 
investigated in this study due to the overlap of its all spectral regions with other 
metabolites. However, furnarate was not strongly discriminatory because of its lower 
intensity compared to other TCA cycle intermediates. 
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Figure 4.4: PCA analysis of rat urine samples from caloric restriction study (A) scores 
plots of principal component 1 (PC 1) (X axis) and PC 2 (Y axis) of controls and 50% food 
restricted group, (B) loadings plot, (C) loadings plot after removing spectral regions of 
citrate, 2-oxoglutarate and taurine 
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4.3.7 Urinary mean excretion plots 
In order to investigate the temporal relationships, eight metabolites which showed 
obvious changes in the chemometric analysis of 'N NMR data and commonly observed 
to be perturbed in a variety of toxicology studies including those relating to energy 
metabolism such as TCA cycle intermediates as shown in Table 4.4 were selected to 
construct urinary excretion profiles. 
Table 4.4: 'H NMR resonances integrated for quantification of urinary metabolites 
Metabolite 81H of integrated signal No of 1H 
Citrate 2.50-2.60 2 
2-Oxoglutarate 2.99-3.04 2 
Fumarate 6.52-6.54 2 
Succinate 2.40-2.42 4 
Hippurate 7.80-7.86 2 
Trans-aconitate 6.58-6.63 1 
N-methylnicotinic acid (NMNA) 9.11-9.14 1 
N-methyl nicotinamide (NMND) 9.26-9.29 1 
TSP ( reference standard) 0.00 9 
Quantification of peaks was achieved via integration of 1H NMR resonances relative to 
that of the internal standard. The mean excretion rates of each metabolite were 
calculated in mole/hr using the following equations (eq). 
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NMR spectroscopy quantification using internal reference TSP signal 
The stock solution concentration of TSP =I mM 
The dilution ratio of TSP to urine sample = 200 gl: 400 gl = 1: 2 
The concentration of TSP when diluted into urine = 
Imm 
= 0.33 mM 3 
Calculating area of TSP =9 protons (H) 
Peak area of TSP = fTSP =a units 
Peak area of 
TSP f TS P or eq H //9 
ý/9 ......... 
this area corresponds to 0.33 mM of TSP 
Metabolite quantification using proton in metabolite signal 
Area of metabolite =f metabolite =b units 
Number of H in the metabolite =n 
Peak area of metabolite = 
metabolite 
or %** *** " eq n 
In order to calculate concentration of metabolite: Equation 2 divided by I 
[metabolite] =9xf 
metabolite 
x 0.33 
nx fTSP 
Number of moles of metabolite excreted per hou. - 
[metabolite] x volume of urine 
Number of hours for collection 
The mean urinary excretion profiles over time for these urinary metabolites were 
generated by calculating the mean value of intensities per group for each metabolite. In 
order to remove diurnal variation, urine samples were not combined but the calculated 
data values for each metabolite at each time point were combined between time points - 
8-0 hrs (values at time points -8 hrs +0 hrs), 8-24 hrs (values at time points 8 hrs + 24 
hrs), 32-48 hrs (values at time points 32 hrs + 48 hrs), 56-72 hrs (values at time points 
56 hrs + 72 hrs), 80-96 hrs (values at time points -8 hrs +0 hrs) for both metabolic 
alkalosis and acidosis studies and the data from 80-96 hrs) and 8-24 hrs (values at time 
points 8 hrs + 24 hrs) of the caloric restriction study. 
The urinary excretion profile of each metabolite shows the overview of excretion 
patterns of controls and treatment groups or diet restricted groups with time course. 
Additionally, two-way ANOVA (analysis of variance) statistical analysis was carried 
out on all groups to identify differences in the excretion profiles between groups. Two- 
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way ANOVA was chosen over one-way ANOVA analysis because there were at least 
two factors systematically affecting the excretion profiles; dose related changes and 
time course. For each metabolite, the urinary excretion values of 5 samples per each 
time point were selected and the two-way ANOVA was carried out. For urinary 
metabolites in which the two-way ANOVA analysis highlighted the significance in the 
excretion profiles, a student t- test was carried out for pair-wise comparisons of 
excretion profiles between groups. The same two-way ANOVA and student t-test 
statistical analysis procedure was carried out to investigate urinary pH between groups 
for all three studies. 
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4.4 Results 
4.4.1 Metabolic alkalosis 
Visual analysis of NMR spectra 
Figure 4.5 shows representative urinary 1H NMR spectra of low (0.1 M) and high (0.35 
M) dose of NaHC03 treatment at two selected time points, 48 hours and 144 hours post 
dose, and a control. Treatment with NaHC03caused a variation in the chemical shift of 
citrate from8H2.5 5 and 8H 2.7 in controls to 8H2.54 and 8H 2.69 in treated samples 
collected at 48 hours due to pH changes of urine samples during the experiment (See 
Chapter 2, section 2.1.1). 
48 hours post dose: Visual comparison of 111 NMR spectra from control and treatment 
groups at 48 hours post dose (Figure 4.5: A, B, D) showed that treatment with NaHC03 
caused an increase in the concentration of the TCA cycle intermediates citrate, 2- 
oxoglutarate, succinate and fumarate. The concentration of trans-aconitate, hippurate, 
N-methylnicotinic acid (NMNA) and N-methyl nicotinamide (NMND) increased in low 
dose group but decreased in high dose group. No discernible visual differences between 
low and high groups for the concentration of TCA cycle intermediates. 
144 hours post dose: The concentration of the all TCA cycle intermediates were 
increased in both treatment groups but no visual difference was observed between low 
and high dose groups (Figure 4.5: C, E). The concentration of hippurate and trans- 
aconitate increased in the low dose group but decreased in the high dose group as 
compared to controls. Differences in the concentrations of NMNA and NMND between 
control and treatment groups were difficult to determine by eye. 
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Figure 4.5: Series of 600 MHz 1H NMR spectra of urine samples collected at 48 and 144 
hours post-dose from (A) control rat at 48 hours (B) treated with OAM NaHC03 at 48 
hours (C) treated with O. IM NaHC03at 144 hours (D) treated with 0.35M NaHC03 at 48 
hours (E) treated with 0.35M NaHC03 at 144 hours after treatment. 
89 
Chapter 4 
Urinary pH 
Figure 4.6 shows the mean urinary pH values of controls and both low and high dose 
NaHC03 treatment groups over the study. All three groups follow the same general 
pattern with pronounced diurnal variation from pre -16 hours to post 96 hours, due 
mainly to collection point time intervals. The urinary pH increased in both treatment 
groups compared to controls between post 8-192 hours. Both treatment groups follow 
the same profiles along with the urinal variation from post 8-192 hours. Comparison of 
the high and low dose group manifested only a slight difference in the pH between post 
8-192 hours. The urinary pH for both treatment groups recovered to control level post 
192 hours. The high dose group showed a maximum pH of 9.1 at post 80 hours whereas 
the low dose group showed a maximum pH of 8.9 at post 56 hours. 
0 control --M- Low dose High dose 
CL 
Figure 4.6: Mean urinary pH values of samples collected from control rats and rats 
treated with low and high doses of NaHC03 
Table 4.5 shows the two-way ANOVA statistical analysis of urinary pH between 
controls and both low dose and high dose treatment groups for time period 0- 312 
hours and the pair-wise student t-test comparison of pH between both treatment groups 
and between controls and both treatment groups. The statistical analysis reveals that 
there was a significant difference in the pH between controls and both treatment groups. 
However, the pH was not significantly different between low dose and high dose groups. 
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Table 4.5: two-way ANOVA statistical analysis and pair-wise student West between both low and high treatment groups and between controls and treatment groups for time 
period 0-312 hours for urinary pH during metabolic alkalosis Key: ns - not significant 
Significance of two-way Significance of student West 
ANOVA between control, 
low and high dose groups 
Control and low Control and Low and high 
dose high dose dose 
p<0.001 (1.84E-21) P<0.001 P<0.001 ns (0.17) (1.54E-8) i (5.85E-11) i 
Urinary excretion profiles of metabolites during metabolic alkalosis 
Figure 4.7 shows the urinary excretion profiles of TCA cycle intennediates, hippurate, 
trans- aconitate, NMNA and NMND for low and high dose NaHC03 treated rats and 
controls. TCA cycle inten-nediates citrate, 2-oxoglutarate, succinate and furnarate 
illustrate similar excretion profiles to each other as compared to other urinary 
metabolites. The excretion of citrate, 2-oxoglutarate and succinate were increased in the 
treatment groups compared to the controls from 24 - 144 hours post treatment. However, 
urinary furnarate was not increased in the high dose group compared with the low dose 
group until 96 hours post treatment. All TCA intermediates show the highest excretion 
level at 144 hours post treatment in both treatment groups. Both treatment groups 
recovered to control levels at post 168 hours although the high dose group only revealed 
a recovery to control levels for succinate and citrate. The excretion profiles for TCA 
cycle intermediates for both high and low dose treatment groups showed a similar 
excretion rate for citrate and a slight overall increase for 2-oxoglutarate, succinate and 
furnarate with the highest excretion level at post 144 hours in high dose group. 
Other metabolites hippurate, trans-aconitate, NMNA and NMND demonstrated similar 
excretion profiles (Figure 4.7) to each other and opposite effects to that of TCA cycle 
intermediates, although only the high dose group showed a decrease in the excretion 
levels as compared to controls. All these four metabolites show the lowest excretion 
level at 72 hours post treatment in the higher dose group. Both NMNA and NMND 
showed a recovery at 192 hours post treatment where as the hippurate and trans- 
aconitate did not demonstrate any recovery until 312 hours post treatment. The 
concentration of hippurate increased significantly for all three groups from post 120 - 
312 hours as compared to post 0-96 hours. 
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Figure 4.7: Mean urinary excretion rates of (A) citrate, (B) 2-oxoglutarate, (C) succinate, 
(D) fumarate, (E) trans-aconitate, (F) hippurate, (G) N-methyl nicotinamide (NMND) and 
(H) N-methylnicotinic acid (NMNA) for samples collected from control rats and rats 
treated with low and high doses of NaHC03 
Each time point represents the time merged excretion from the previous measurement starting at -24 hrs pre-dose, C: 
control, LID: Low dose, HID: High dose, each error bar represents the standard error 
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Table 4.6 shows the maximum excretion change (%) for each metabolite as calculated 
by the ratio of maximum excretion of high dose to control during metabolic alkalosis, 
the two-way ANOVA statistical analysis for time period 0- 312 hours and the pair- 
wise student t-test comparison between both low dose and high dose treatment groups 
and between controls and both treatment groups. The 144 hours post dose period 
showed that treatment with high dose of NaHC03 caused the maximum increase in the 
excretion rate of TCA cycle intermediates. Hippurate, trans-aconitate, NMNA and 
NMND illustrated the lowest excretion level at post 72 hours in higher dose group. The 
two-way ANOVA analysis also demonstrated a significant difference in the excretion 
profiles of controls and both treatment groups existed for all TCA cycle intermediates 
compared to other metabolites, confin-ning the findings observed in the urinary 
excretion profiles. 
The pair-wise student mest analysis also showed that the excretion levels of all TCA 
cycle metabolites between both treatment groups and controls were significantly 
different. Comparison of high dose with low dose shows significance for 2-oxoglutarate, 
furnarate and succinate, but not citrate. The excretion profile of citrate is similar in both 
low and high dose groups, as shown in Figure 4.7. 
Table 4.6: Maximum % change of metabolites of high dose compared to controls and two- 
way ANOVA statistical analysis for time period 0-312 hours for metabolites during 
metabolic alkalosis 
Key: ns - not significant 
Maximum % Significance of Significance of student West 
change from 
two-way 
control 
ANOVA 
Control Control Metabolites between Low and and low and high Time control, low dose dose high dose 
point % and high dose 
(hrs) groups 
Citrate 144 153 P<0.001 p<0.05 P<0.001 ns 
2-oxoglutarate 144 282 P<0.001 P<0.001 P<0.00 I P<0.01 
Succinate 144 205 P<0.001 P<0.00 I P<0.00 I p<0.05 
Fumarate 144 165 p<0.05 p<0.05 P<0.00 I P<0.01 
Trans-aconitate 72 64 ns - - - 
Hippurate 72 68 ns - - - 
N- 
methylnicotinic 72 68 ns - - - 
acid (NMNA) 
N-methyl 
nicotinamide 72 80 ns - - - 
(NMND) 
.1 
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4.4.2 Metabolic acidosis 
Visual analysis of 111 NMR spectra 
Figure 4.8 shows the urinary 1H NMR spectra of both low dose and high dose of NH4Cl 
treatment at two selected time points, 48 hours and 144 hours post dose, and a control. 
The changes of metabolites are more apparent compared to metabolic alkalosis. 
48 hours post dose: Visual comparison of 1H NMR spectra from the control and 
treatment groups at 48 hours post dose (Figure 4.8: A, B, D) showed that the 
concentration of the TCA cycle intermediates citrate, 2-oxoglutarate, succinate and 
fumarate were decreased in both groups after treatment with NI-LCI as compared to the 
control group. In addition, the concentrations of hippurate and trans-aconitate were 
decreased in the treatment groups compared to the control. Differences in the 
concentrations of NMNA and NMND between control and treatment groups were 
difficult to determine by eye. 
144 hours post dose: The low dose treatment rats appeared to recover faster from 
metabolic acidosis than the high dose group as seen by higher levels of TCA cycle 
intermediates, hippurate and trans-aconitate in the low dose compared to the high dose 
at 144 hours post dose. (Figure 4.8: C, E). The levels of TCA cycle metabolites and 
other metabolites in the high dose group were lower compared to the controls. 
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Figure 4.8: Series of 600 MHz 1H NMR spectra of urine samples collected at 48 and 144 
hours post-dose from (A) control rat at 48 hours (B) treated with 0.07 M NH4CI at 48 
hours (Low dose) (C) treated with 0.07 M NH4CI at 144 hours (Low dose) (D) treated with 
0.28 M NH4Cl at 48 hours (high dose) (E) treated with 0.28 M NH4CI at 144 hours (high 
dose). 
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Urinary pH 
Figure 4.9 shows the mean urinary pH values of controls and both low and high dose 
NH4Cl treatment groups. Controls and both low and high dose treatment groups of 
NH4Cl revealed a significant difference in the urinary pH between 24 - 176 hours post 
treatment. All three groups demonstrated diurnal variation between 8-120 hours post 
treatment, due mainly to collection point time intervals. The urinary pH decreased in 
both treatment groups compared to controls from 24 hours post treatment and recovered 
at 144 or 168 hours post treatment for the low dose and high dose respectively. The 
average minimum pH was 5.5 at 48 and 72 hours post treatment in the high dose group 
and pH 6.3 at 48 hours post treatment in the low dose group. This decrease in urinary 
pH for treatment groups was due to a rise in H' secretion in the extracellular fluid. 
0 control --IIF- Low dose High dose 
8.30 
7.90 
00 
CL T 
6.70 
6.30 
T 
5.90 
-16 8 32 56 80 104 128 152 176 
200 224 248 272 296 
Time(hrs) 
Figure 4.9: Mean urinary pH values of samples collected from control rats and rats 
treated with low and high doses of NH4Cl 
Table 4.7 shows the two-way ANOVA statistical analysis of urinary pH between 
controls and both low dose and high dose treatment groups for time period 0- 288 
hours and the pair-wise student t-test comparison of pH between both treatment groups 
and between controls and both treatment groups. The statistical analysis also confirmed 
that there was a significant change in the pH between controls and both treatment 
groups and between the low and high dose treatment groups. 
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Table 4.7: two-way ANOVA statistical analysis between controls and both low and high 
treatment groups and pair-wise student West between both low and high treatment 
groups and between controls and treatment groups for time period 0-312 hours for 
urinary pH during metabolic acidosis 
Key: ns - not significant 
Significance of two-way Significance of student West 
ANOVA between control, low Control and Control and Low and 
and high dose groups low dose high dose high dose 
P<0.001 P<0.001 P<0.001 
p<0.001 (6.68E-44) 
(2.85E-10) (2.38E-15) (2.28E-05) 
Urinary excretion profiles of metabolites during metabolic acidosis 
Figure 4.10 shows the urinary excretion profiles of citrate, 2-oxoglutarate, succinate, 
furnarate, hippurate, trans-aconitate, NMNA and NMND for low and high dose NH4Cl 
treated animals and controls. As with metabolic alkalosis, the TCA cycle intermediates 
also illustrated similar excretion profiles to each other. Compared to the controls, both 
treatment groups showed that TCA cycle intermediates decreased until 48 hours, 
plateaued until 120 hours and then recovered between 120 hours to 168 hours with a 
rather steeper increase in levels for 2-oxoglutarate. Fumarate returned to control levels 
at 144 hours. Comparison of the high dose with the low dose treatment group 
demonstrated a significant difference in the concentration for citrate, 2-oxoglutarate and 
succinate compared to furnarate. 
excretion level at post 48 hours. 
All TCA cycle intermediates revealed the lowest 
The urinary metabolites both hippurate and NMNA were not affected by the treatment 
of NH4Cl since a similar excretion profile was observed in both dose groups and 
controls. As with metabolic alkalosis, the concentration of 
hippurate increased 
significantly for all three groups from post 120 -288 hours as compared to post 
0-96 
hours. Trans-aconitate was only affected in the high dose group with a sharp fall at post 
120 hours and an immediate recovery by post 144 hours. 
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Figure 4.10: Mean urinary excretion rates of (A) citrate, (B) 2-oxoglutarate, (C) succinate, 
(D) fumarate, (E) trans-aconitate, (F) hippurate, (G) N-methyl nicotinamide (NMND) and 
(H) N-methylnicotinic acid (NMNA) for samples collected from control rats and rats 
treated with low and high doses of NH4Cl 
Each time point represents the time merged excretion from the previous measurement starting at -24 
hrs pre-dose, C: control, LD: 
Low dose, HD: High dose, each error bar represents the standard error 
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Table 4.8 shows the maximum concentration decrease (%) for each metabolite as 
calculated by the ratio of maximum concentration of high dose to control during 
metabolic acidosis, the two-way ANOVA statistical analysis for time period 0- 288 
hours and the pair-wise student t-test comparison between both low dose and high dose 
treatment groups and between controls and both treatment groups. The 48 hours post 
dose period showed that treatment with high dose of NaHC03 caused the maximum 
decrease in the excretion rate of TCA cycle intermediates, hippurate and NMNA and 
120 and 192 hours post dose for trans-aconitate and NMND respectively. The two-way 
ANOVA statistical analysis confirmed that the treatment groups and controls were 
significantly different for all TCA cycle metabolites, trans-aconitate and NMND. It also 
confirmed that both hippurate and NMNA levels were not significantly different 
between treatment groups and controls. 
From the pair-wise t-test analysis of TCA cycle intermediates only citrate was 
significantly different between low and high dose groups and between controls and both 
treatment groups. The difference in excretion levels of fumarate and succinate were 
only significant between controls and high dose and between low and high dose and the 
excretion level of 2-oxoglutarate only illustrated significant difference between controls 
and high dose. Trans-aconitate did not reveal any significant differences in the excretion 
level between groups, although two-way ANOVA analysis demonstrated there was a 
difference in the excretion profiles between groups. In the excretion profile of trans- 
aconitate (Figure 4.10), the sharp fall at 120 hours post dose of high dose could be an 
anomalous result, due to outliers in the high dose group. NMND showed considerable 
variation between controls and both low and high dose groups. 
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Table 4.8: Maximum % change of metabolites of high dose compared to controls and two- 
way ANOVA statistical analysis for time period 0-288 hours for metabolites during 
metabolic acidosis 
Key: ns - not significant 
Maximum % Significance Significance of student West 
change from of two-way 
control ANOVA Metabolites between Control Control L nd Time control, low and low and high 
ow a 
high dose 
point % and high dose dose 
(hrs) dose groups 
Citrate 48 86 P<0.001 p<0.05 P<0.001 P<0.01 
2-Oxoglutarate 48 81 P<0.001 ns P<0.01 ns 
Succinate 48 15 P<0.001 ns P<0.01 p<0.05 
Fumarate 48 50 P<0.001 ns P<0.001 p<0.05 
Trans-aconitate 120 48 P<0.01 ns ns ns 
Hippurate 48 15 ns 
N- 
methylnicotinic 48 15 ns 
acid (NMNA) 
N-methyl 
nicotinamide 192 4 P<0.001 P<0.01 P<0.01 ns 
(NMND) 
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4.4.3 Caloric restriction study 
Visual analysis of 1H NMR spectra 
Figure 4.11 shows the urinary 1H NMR spectra of restricted diet of 25%, 50% and 
100% (24 hours only then returned to ad libitum diet) at selected time points, 48 hours 
and 144 hours post dose and a control (ad libitum). Urine samples were collected pre- 
dietary restriction (- 16hrs) and post treatment at 0,8,24 hrs and then every 24 hours till 
168 hours after administration of food either ad libitum (control) or restricted by 25%, 
50% or 100% (24 hours only then returned to ad libitum diet). 
48 hours post dietary restriction: Visual comparison of 1H NMR spectra from control 
and dietary restricted groups (Figure 4.11: A, B, C, D) showed that the concentration of 
the TCA cycle intermediates citrate, 2-oxoglutarate, succinate, trans-aconitate, NMNA 
and hippurate were decreased in the 25% and 50% dietary restricted rats. NMND was 
increased in both 25% and 50% dietary restricted rats compared to controls. Differences 
in the concentrations of TCA cycle intermediates and NMND between controls and the 
100% (24 hrs) dietary restricted group were difficult to determine by eye. However, 
hippurate was clearly decreased and trans-aconitate was clearly increased as compared 
to controls. 
144 hours post dietary restriction: The concentration of TCA cycle intermediates, 
hippurate, trans-aconitate, NMNA and NMND were decreased as compared to control 
in the 25% and 50% dietary restricted rats (Figure 4.11: E, F, G). The 100% restricted 
group showed an increase in the TCA cycle intermediates citrate and 2-oxoglutarate 
compared to the controls. 
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Figure 4.11: Series of 600 MHz 1H NMR spectra of urine samples collected at 48 and 144 
hours post-dose after (A) administration of ad libitum (control), and animals dietary 
restricted by (B) 25% at post 48 hours (C) 50% at post 48 hours (D) 100% (1 day only) at 
post 48 hours (E) 25% at post 144hours (F) 50% at post 144 hours (G) at 100% (1 day) 
post 144 hours. 
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Urinary pH 
Figure 4.12 shows the mean urinary pH values of controls and dietary restricted animals 
by 25% (7 days), 50% (7 days) or 100% (1 day only then returned to ad libitum diet). 
The urinary pH values as compared to the controls were not significantly changed for 
the 25% and 50% dietary restricted groups. In the 100% dietary restricted group the 
urinary pH remained at a similar level as the 25% and 50% restricted animals between 
pre 16 hours and 48 hours and then showed a significant increase in the pH between 
posts 48-168 hours after which they returned to that of controls. 
9% 4%0% 
H 
p 
1 
-6-AL ---9-25% 50% --9-100%(1 da] 
Figure 4.12: Mean urinary pH of samples collected from control rats (C) and animals of 
dietary restricted by 25 %, 50 % or 100 % (24 hours only then returned to ad libitum diet). 
Table 4.9 shows the two-way ANOVA of urinary pH between controls and caloric 
restriction groups of 25% and 50% and between controls and 100% caloric restricted 
group for I day only. This statistical analysis also confirms that there was no significant 
change in urinary pH between controls, 25% and 50% caloric restricted groups 
However, there was a significant change in the pH between controls and 100% (1 day) 
caloric restricted group. 
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Table 4.9: two-way ANOVA statistical analysis between controls and caloric restriction 
groups of 25% and 50% and between controls and 100% restricted group for I day only Key: ns - not significant 
Significance of two-way ANOVA 
Between control and caloric restriction 
of 25% and 50% groups 
Between control and 100% (only 1 day) 
Caloric restriction 
ns (0.47) p<0.001 (0.0002) 
Urinary excretion profiles of metabolites during caloric restriction 
Figure 4.13 shows the mean excretion profiles of organic acids for ad libitum fed rats 
(controls) and 25%, 50% 100% (24 hours only then returned to ad libitum diet) dietary 
restricted rats. Overall each group showed similar urinary excretion profiles for the 
TCA cycle inten-nediates citrate, 2-oxoglutarate, succinate and furnarate. The excretion 
level of citrate, 2-oxoglutarate and furnarate were reduced in all dietary restricted 
groups as compared to the controls for the first 48 hours. Succinate was not reduced in 
the 25% and 50 % dietary restricted groups as compared to control rats until post 48 
hours. From post 48 hours to post 168 hours of the food restriction, the concentration of 
TCA intermediates remained lower in the dietary restricted rats as compared to the 
controls, with the exception of the 100% dietary restricted group, which recovered faster 
and followed similar mean excretion profiles to the controls from 72 hours onwards, for 
succinate from 96 hours onwards. However, the pH of 100% dietary restricted group 
was different as compared to controls between post 48 hours to post 168 hours, although 
the metabolite profiles returned to control levels. 
The excretion level of hippurate was not changed significantly for any of the dietary 
restricted groups during the first post 48 hours after which it started to deplete in the 
25% and 50% restricted groups from post 48 hours. Compared to controls, the 100% 
food restricted group showed a higher level of urinary hippurate between 72 to 168 
hours, but with large variation as exhibited by the high standard error which could be 
due to inter individual variation. NMNA and trans-aconitate followed similar mean 
excretion profiles. The 100% dietary restricted group recovered to control levels from 
post 24 hours for both metabolites. NMND only decreased for the 50% diet restricted 
group as compared to other groups. As with metabolic acidosis and alkalosis, the 
concentration of hippurate increased for all groups from post 48 -168 hours as compared 
to 0 hours. 
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Figure 4.13: Mean urinary excretion rates of (A) citrate, (B) 2-oxoglutarate, (C) succinate, 
(D) fumarate, (E) trans-aconitate, (F) hippurate, (G) N-methyl nicotinamide (NMND) and 
(H) N-methyinicotinic acid (NMNA) for samples collected from ad libitum food intake rats 
and rats restricted with 50%, 25% food intake and 100% restricted for a day then 
returned to the diet of controls. Each time point represents the time emerged excretion 
from the previous measurement starting at -24 hrs pre-dose 
AL: control, 25%: rats restficted with 25%, 50%: rats restricted with 50%, 100%: rats restricted with 100% for one day then 
returned to the diet of controls, each error bar represents the standard error. 
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The two-way ANOVA statistical two-way (Table 4.10) illustrated significant changes 
for all TCA cycle intermediates, trans-aconitate and NMNA between controls and 
dietary restricted groups. From the pair-wise t-test analysis (Table 4.10), comparison 
between controls and 100% dietary restricted group (I day only) revealed no 
significance since the restricted group returned to the diet of controls after a day. Citrate, 
2-oxoglutarate, fumarate, NMNA and trans-aconitate showed significant changes 
between controls and 25% restricted, between 25% and 50% dietary restricted and 25% 
and 100% (1 day) dietary restricted groups. However, succinate only illustrated 
significant changes between controls and the 25% dietary restricted groups. 
Table 4.10: Two-way ANOVA statistical analysis for time period 0-168 hours for 
metabolites during caloric restriction samples collected from ad libitum food intake rats 
and rats restricted with 50%, 25% food intake and 100% restricted for a day then 
returned to the diet of controls. 
Key: ns - not significant 
Significance of Significance of student t-test 
two-way Control 25% diet 
ANOVA between Control and 25 % and restricted 
Metabolites control, 25 %, and 25 % 100% 50% and 100% 
50% and 100% restricted restricted restricted restricted 
(only 1 day) diet diet only diet diet only for 
restricted diet for 1 day 1 day 
Citrate P<0.001 P<0.001 ns P<0.001 P<0.001 
2-oxoglutarate P<0.001 P<0.001 ns P<0.001 P<0.01 
Succinate P<0.001 P<0.0 I ns ns ns 
Fumarate P<0.001 P<0.001 ns P<0.001 P<0.0 I 
Trans- 
P<0.001 P<0.001 ns P<0.001 P<0.0 I aconitate 
hippurate ns 
N- 
methyinicotinic P<0.001 P<0.001 ns P<0.001 P<0.001 
acid (NMNA) 
N-methyl 
nicotinamide ns 
(NMND) 
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4.5 Discussion 
1H NMR spectroscopy was used to investigate the temporal relationship between 
urinary metabolites citrate, 2-oxoglutarate, succinate and fumarate and other urinary 
metabolites such as hippurate, N-methylnicotinic acid (NMNA), N-methyl nicotinamide 
(NMND) and trans-aconitate in the urine from rat models of chemically induced 
metabolic alkalosis, metabolic acidosis as well as caloric restriction. This was in order 
to determine the temporal changes in metabolism which were due to the non-toxic or 
confounding physiological effects often observed in toxicological studies. This 
background knowledge can subsequently be subtracted from toxicology study profiles 
in order to refine descriptors of toxic effects as opposed to physiological or non specific 
effects. 
Metabolic alkalosis was induced by the administration of sodium bicarbonate (NaHC03) 
whereas metabolic acidosis was induced by the administration of ammonium chloride 
(NH4CI). Metabolic acidosis induced a stronger response as compared to metabolic 
alkalosis. An acute rise was observed in the levels of the TCA cycle intermediates in the 
treatment groups after NaHC03 administration. Administration of NaHC03 increases 
the flow of sodium ions into the distal and collecting tubes, resulting in rapid absorption 
of Na' ions from the tubules and leaving the bicarbonate (HC03-) ions behind in the 
tubules. The urinary pH increased in both low and high dose treatment groups compared 
to controls between post 8-192 hours. The increase in urinary pH of the treatment 
groups was due to the accumulation of HC03- ions in the extracellular fluid. In contrast, 
metabolic acidosis as expected showed the opposite effect of decreased urinary pH and 
TCA cycle intermediates to those seen in the metabolic alkalosis. The TCA cycle 
intermediates also decreased in the caloric restriction study. 
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4.5.2 Effect of acid-base balance on excretion of metabolites 
Metabolic alkalosis and acidosis 
The metabolic alkalosis study indicated that treatment with NaHC03caused a rise in the 
concentration of the TCA cycle intermediates citrate, 2-oxoglutarate, and succinate. 
Both treatment groups showed similar excretion profiles for citrate, 2-oxoglutarate, and 
succinate compared to fumarate, which was not increased in the high dose group 
compared to the low dose group until 72 hrs post treatment. Measurement of fumarate 
will be less precise and sensitive because of its lower intensity compared to other TCA 
cycle metabolites. The two-way ANOVA statistical analysis and pair-wise t-test 
revealed that the excretion profiles of TCA cycle inten-nediates changed with dose 
response. Hippurate, trans-aconitate, NMND and NMNA did not demonstrate a 
significant difference between controls and dose groups in the excretion profiles. 
In the metabolic acidosis study, the urinary excretion profiles of the TCA cycle 
inten-nediates citrate, 2-oxoglutarate, succinate and fumarate illustrated an opposite 
effect to that seen with metabolic alkalosis study, but with a stronger metabolic 
response. All four TCA cycle intermediates decreased in both treatment groups 
compared to controls. Both treatment groups and controls revealed similar dose 
response excretion profiles for all TCA cycle intermediates. The two-way ANOVA 
statistical analysis and t-test demonstrated that all observed TCA cycle intermediates 
and NMND showed significantly different excretion levels between controls and 
treatment groups. 
In the kidney, the proximal tubules reabsorb TCA cycle inten-nediates citrate, succinate, 
2-oxoglutarate and fumarate through Na'-coupled transporters at the brush border 
membranes (Law et al., 1992, Simpson, 1983, Ullrich et al., 1984, Wright, 1985, Wright 
et al., 1982a, Wright et al., 1983, Wright et al., 1982b). Most of these intermediates can 
be transported directly into the mitochondria where they are used as respiratory fuel for 
the TCA cycle. There has been great interest in the metabolism of TCA cycle 
intermediates, the excretion of which in the urine, is highly dependent on the acid-base 
balance. The results from the current study are consistent with the literature and have 
shown that the excretion of urinary TCA cycle intermediates, particularly citrate and 
2- 
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oxoglutarate, decrease during acidosis and increase during alkalosis (Balagura-Baruch 
et al., 1973, Gamble et al., 1961, Trivedi et al., 1986). 
TCA cycle intermediates can be taken up from blood via transporters. These 
transporters belong to SLC13 gene family, which are found in many different organs 
including kidney, intestine, liver and brain (Markovich et al., 2004, Pajor, 2006). The 
SLC13 gene family consists of five members in vertebrate species and exhibits both 
sodium-dependent and sodium- independent transport mechanisms. NaDC I, NaDC3 and 
NaCT are three main Na' dependent tricarboxylate and dicarboxylate carriers for TCA 
cycle intermediates including citrate, 2-oxoglutarate and succinate (Ho, 2007, 
Markovich et al., 2004, Pajor, 2006). NaDCI is a low affinity Na/dicarboxylate 
transporter where as NaDC3 is a high affinity Na/dicarboxylate transporter. Although 
NaDC3 has a broader tissue distribution than NaDCI, both transporters are found in 
different parts of the renal proximal tubule (Pajor, 2006). NaDCI is found on apical 
membranes of cell and NaDC3 is found on the basolateral membranes. NaCT is a citrate 
specific transporter, found in brain, liver and testis (Pajor, 2006). The current study may 
imply that the systematic changes of TCA cycle intermediates in three observed 
different conditions studies could be due to the same transporter mechanism. Rat 
organic anion transporterl. (rOAT 1) and rOAT3 play major role in the renal uptake of 
hippurate on the basolateral membrane of the proximal tubules (Deguchi et al., 2004). 
The disturbance of acid-base balance affects the intercellular processes, particularly the 
uptake of substrates by the mitochondria (Simpson, 1983). Under normal physiological 
conditions, the mitochondrial matrix is more alkaline compared to the surrounding 
cytoplasm. During acidosis, the increasing mitochondrial pH gradient stimulates TCA 
cycle Na' dependent tricarboxylate and dicarboxylate transporters, which are located on 
the inner membrane. The flux of citrate is increased into the mitochondrial matrix by the 
tricarboxylate carrier transporters, whereas the flux of furnarate and succinate is 
increased by the dicarboxylate transporters. 2-Oxoglutarate is transported by specific 
oxoglutarate transporters. Therefore, stimulation of these carriers caused by increasing 
pH gradient results in decreased cytosolic concentration of TCA cycle inten-nediates in 
the mitochondria. Reabsorption of the intermediates in the proximal tubule is increased 
to restore the intracellular concentrations, thus causing the observed decrease in urinary 
excretion of TCA intermediates (Simpson, 1983). Metabolic alkalosis shows the 
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opposite effect to that seen in metabolic acidosis, where reabsorption of the TCA cycle 
intermediates in the proximal tubule is decreased, thus causing the increase in urinary 
excretion TCA cycle intermediates. 
Caloric restriction 
The urinary pH between controls and both the 25% and 50% caloric restriction groups 
remained unchanged. However, the 100% restricted group showed an increase in the pH 
as compared to controls. This could be due to increased ammonium ion efflux, which 
has been shown to be stimulated in the peritubular capillaries during starvation (Elhamri 
et al., 1993, Graczykowska-Koczorowska et al., 1972). The urinary excretion profiles 
showed that the excretion level of citrate, 2-oxoglutarate and fumarate were reduced in 
all three dietary restricted groups as compared to controls for the first post 48 hours of 
food restriction. Succinate was only reduced in the 100% (24 hrs only) dietary restricted 
group. The excretion levels of TCA intermediates remained lower in both the 25% (5 
days) and 50% (5 days) dietary restricted groups from post 48 hours till the end of the 
experiment. The 100% dietary restricted group recovered faster and followed similar 
mean excretion profiles of controls from 72 hours or from 96 hours for succinate. The 
statistical analysis also showed that there was a change in the excretion levels of the 
TCA cycle inten-nediates between controls and 25% dietary restricted, between 25% and 
50% dietary restricted and between 25% and 100% (1 day) restricted groups. 
The excretion level of hippurate was not changed significantly for any dietary restricted 
groups during first post 48 hours but started to deplete in the 25% and 50% restricted 
groups from post 48 hours. Compared to controls, the 100% food restricted group 
showed a higher level of urinary hippurate between 72 to 168 hours but with large 
values of standard errors, which could be due to inter individual variations in the data 
set. Hippurate is a major gut microbial co-metabolite, produced from microbial 
benzoate and thus depends on starch and protein breakdown in the gut. Higher excretion 
levels of hippurate in 100% (1 day) restriction group compared to controls could be due 
to the disturbances of gut microbes during the starvation process (Simpson et al., 2002). 
Each group followed similar excretion profiles for NMNA and trans-aconitate. The 
100% dietary restricted group recovered to control levels from post 24 hours for both of 
these metabolites. The excretion level of NMND showed a change for only the 50% 
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restricted group. Two-way ANOVA analysis confirmed that there was no significant 
difference between groups for both hippurate and NMND. 
The Na/dicarboxylate transporter NaDC I which is responsible for the transportation of 
intermediates of the TCA cycle in mitochondria has also been implicated in extending 
the life span of the fly Drosophila melanogaster (Knauf et al., 2006, Wang et al., 2003). 
This gene sequence is most closely related to mammalian sodium dicarboxylate 
transporters (Rogina et al., 2000). Rogina et al. reported that mutation of the Indy 
("I'm not dead yet") gene in drosophila shares 50% homology with sodium-dependent 
dicarboxylate transporter (Rogina et al., 2000). The indy gene functions as an exchange 
of dicarboxylate and tricarboxylate TCA cycle intermediates and the effect of 
decreasing Indy activity alters energy metabolism in a manner that favours lifespan 
extension (Knauf et al., 2002). 
Hagopian et al. showed that the TCA cycle metabolites citrate and 2-oxoglutarate were 
decreased during caloric restriction, indicating that the long term caloric restriction 
induces alterations in TCA cycle intermediates and thus may play an important role in 
the anti-ageing process (Hagopian et al., 2004), although the exact mechanism is not 
known. This current caloric restriction study also agreed with the literature in showing 
that the concentrations of citrate, 2-oxoglutarate and furnarate were reduced in the 25% 
and 50% dietary restricted groups. Therefore, this study also raises the possibility that 
TCA cycle intermediates may play a role in the anti-ageing process. 
In the current caloric restriction study, the TCA cycle intermediates showed a similar 
response to that seen in metabolic acidosis, although the urinary pH did not confirm the 
onset of metabolic acidosis. This indicates that changes in excretion of TCA cycle 
intermediates observed here were independent of the metabolic acidosis. Changes in the 
concentration of hippurate, trans-aconitate and NMNA were only observed in caloric 
restriction, since the treatment groups showed no responses during metabolic acidosis 
and metabolic alkalosis. Therefore this indicates that changes in the urinary 
concentration of hippurate, trans-aconitate and NMNA often discussed in toxicology 
studies could be due to change in the dietary intake. Literature studies suggest that the 
normal physiological excretion levels of hippurate (Kirly et al., 
2005, Phipps et al., 
1998) and NMNA (Rezzi et al., 2007) are associated with change in diet. Connor et al. 
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suggested that the levels of TCA cycle intermediates and NMND were altered in the 
urines of rats due to reduced food intake induced by toxin exposure (Connor et al., 
2004). The levels of changes of TCA cycle metabolites in metabolic acidosis are similar 
to the hydrazine toxicity study (Crockford et al., 2006, Holmes et al., 1998b, Nicholls et 
al., 2001), indicating the changes of those TCA metabolites in the toxicity study is 
likely to be due to the non-toxic or physiological effect of metabolic acidosis. 
All three physiological studies illustrated an increase in the concentration of hippurate 
with the time. This could be due to subsequent re-distribution of gut microbes from the 
changes in diet and the environmental conditions (Gavaghan et al., 2001, Nicholls et al., 
2003, Phipps et al., 1998, Williams et al., 2005). 
The application of 1H NMR spectroscopy along with the calculation of urinary 
excretion profiles of specific TCA cycle and other energy metabolism metabolites 
revealed clear metabolic perturbation of TCA cycle metabolites citrate, 2-oxoglutarate, 
succinate and furnarate during metabolic alkalosis, metabolic acidosis as well as caloric 
restriction. This is the first study to compare the temporal relationship between TCA 
cycle inten-nediates and metabolic alkalosis, metabolic acidosis as well as caloric 
restriction studies by using 1HNMR spectroscopy, which is a non-destructive and 
reproducible method with minimal sample preparation. The urinary excretion profiles 
show the distinct temporal changes of metabolites between the controls and treatment 
groups or dietary restricted groups can be used to investigate the interaction between 
dose effects and time course in future toxicology studies. 
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4.6 Conclusion 
The use of 1H NMR spectroscopic urinalysis has clearly demonstrated the time related 
effects on urinary excreted metabolites including TCA cycle intermediates, in 
chemically induced rat models of metabolic alkalosis, metabolic acidosis as well as in 
caloric restriction. Treatment with NaHC03 caused metabolic alkalosis and the 
concentration of TCA cycle intermediates citrate, 2-oxoglutarate, furnarate and 
succinate were increased. An opposite effect was observed for treatment with NH4Cl, 
which caused metabolic acidosis. The caloric restriction study showed a similar effect 
of metabolic acidosis on TCA cycle intermediates although unlike with acidosis, there 
was no associated change in urinary pH with caloric restriction. 
Overall TCA cycle intermediates changed systematically in all three studies whereas 
hippurate, trans-aconitate and NMNA changed only in the caloric restriction studies. 
Therefore, these metabolites are independent of the effects of metabolic acidosis and 
alkalosis and dependent on the dietary intake. Since the concentration of NMND was 
not systematically changed in any of the conditions studies, any changes observed in the 
urinary levels of this metabolite are more likely to relate directly to a toxic effect. These 
urinary excretion profiles showing the temporal changes of urinary metabolites 
including TCA cycle intermediates of all three studies serve as useful models for 
investigations in future toxicology studies. 
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Chapter 5: Assessment of the Relative Efficiencies 
of 111 NMR Spectroscopy and UPLC-MS for the 
Diagnosis of Inborn Error Organic Acidurias 
5.1 Summary 
Urine samples from patients with unknown inborn errors of metabolism (IEM) and age- 
matched controls were analysed by both 1H NMR spectroscopy and UPLC-MS 
analytical platforms in order to identify and characterise metabolic profiles of these I]EM. 
Initially the investigation was carried out using 400 MHz 1H NMR spectroscopy 
without any prior knowledge of the diagnosis. Subsequently the urine samples were 
analysed by both 800 MHz 1H NMR spectroscopy and UPLC-MS. 
5.1.1 Aims and objectives 
1) To characterise the urinary metabolic profiles of selected IEM patients using 1H 
NMR spectroscopy. 
2) To compare the metabolic profiles obtained from 400 MHz and 800 MHz 1H 
NMR spectroscopy. 
3) To assess the feasibility of applying an ultra-performance liquid chromatography- 
mass spectrometry (UPLC-MS) based metabonomics approach to the detection of 
abnormal levels of urinary organic acids in clinical samples of patients with inborn 
er-rors of metabolism. 
4) To use principal component analysis (PCA) to differentiate disease samples from 
controls and to identify the metabolites associated with different inborn errors of 
metabolism. 
5) To identify biornarkers for each organic aciduria using UPLC-MS and MS/MS. 
6) To evaluate UPLC-MS and NMR methodologies used in combination to identify 
and classify IIEM. 
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5.2 Introduction 
5.2.1 Inborn Errors of Metabolism (IEM) 
Inborn errors of metabolism (EEM) are subgroups of genetic diseases characterised by 
impaired activity of enzymes or transporters involved in cellular metabolism. This 
impaired activity results in malfunctioning proteins that lead to abnormal catabolism of 
certain carbohydrates, amino acids, fatty acids and/or organic acid derivatives (Harris, 
1982, Jones et al., 2002). 
In the early 1900s, Garrod discovered the first classified IIEM, known as alkaptonuria 
(Garrod, 1899). He described the presence of alkaptonuria as urine obtained from 
infants that darkened on exposure to air. This disorder is characterised by the urinary 
excretion of homogentisic acid which is not normally found in urine. At this time the 
inheritance of alkaptonuria and other metabolic conditions was not understood and the 
diagnosis of inborn errors of metabolism were generally made from observations about 
the abnormalities of metabolites present. The disorder was deduced to be inherited by 
observation of reoccurrence in family members (Garrod, 1899). Knowledge of the 
process causing this inherited metabolic disorder evolved with subsequent identification 
of metabolic pathways and specific enzymes. 
Many inborn errors of metabolism show no apparent clinical abnormalities at birth, but 
in early childhood they can lead to severe clinical manifestations, such as mental and 
growth retardation, neurological defects and multiple organ failure, and are often life- 
threatening. Many of these clinical manifestations can be prevented if the disorder is 
diagnosed and treated with the right diet or medication at an early age. 
5.2.2 Methods for diagnosing IEM 
Recent advances in the diagnosis and treatment of inborn errors of metabolism (IIEM) 
have improved significantly the prognosis for many of these conditions. Guthrie 
developed the first bacterial inhibition assay to screen for phenylketonuria (PKU), an 
autosomal recessive condition resulting in high concentrations of phenylalanine 
in the 
blood due to reduced activity of phenylalanine hydroxylase (PAH) (Guthrie, 1992, 
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Guthrie et al., 1963). The high concentration of phenylalanine is associated with 
reduction in IQ and severe mental handicap. The early detection of PKU and 
introduction of a low phenylalanine diet in infants identified with PKU resulted in a 
significant decrease in morbidity as well as considerable savings in medical costs. 
Screening is a health service strategy in which members of a defined population are 
offered a test, to identify individuals who are affected by the disease or at risk with a 
view to reducing the risk or its complications by offering further tests or treatment. In 
order to carry out a screening programme, the condition should be an important health 
problem and adequately understood all stages of the disease with a detectable risk 
factor. The criteria for screening (Wilson and Jungner criteria), which was adapted from 
world health organisation (WHO) in 1968, is that it must be simple, ethical, cost- 
effective, reliable, sensible robust and minimise false positives. The purpose of 
screening is to identify a disease early in a population and to reduce the mortality and 
suffering from a disease. There are many different types of screening programs which 
have been initiated in the UK, including breast, cervical, bowel and prostate cancer, 
antenatal and new born and diseases in childhood. 
The national newborn screening programme for IEM commenced throughout the UK in 
1969 with screening for PKU (Guthrie, 1992), the most common IIEM, with an 
incidence of I in every 12 000 births, performed on neonatal blood spots at the age of 4- 
16 days. Subsequently, other screening programmes for the diagnosis of number of 
inborn errors of metabolism mainly including congenital hypothyroidism, sickle cell 
and cystic fibrosis in infants have been developed using conventional analytical 
techniques such as specific enzyme assays (Fuller et al., 2004, Sundaram et al., 1986), 
fluorometery (Civallero et al., 2006, Jiang et al., 2003), thin layer chromatography 
(Neto et al., 1999, Reich et al., 2002), high performance liquid chromatography 
(HPLQ 
(Streetly et al., 2008), iso-electric focusing (IIEF) (Streetly et al., 
2008) and tandem mass 
spectrometry (MS/MS) methods (Cipriano et al., 2007, 
Pandor et al., 2006, Rinaldo et 
al., 2006, Tran et al., 2007, Van Calcar et al., 
2007). However, a number of rare inborn 
errors of metabolism remain difficult to detect and understand without 
the use of 
laborious and complex analytical methodologies (Cipriano et al., 
2007). 
116 
Chapter 5 
One class of IEM, known as organic acidurias, and here analysis of organic acids can 
provide a powerful means of diagnosing these inborn errors, since they are characterised 
by the excretion of excessive amounts of urinary organic acids that are normally present 
in much lower or negligible concentrations. This chapter is focused on using NMR 
spectroscopy and mass spectrometry (MS) based analyses for characterising the 
metabolic profiles for such diseases. 
5.2.3 Established methods for the identification of IEM 
Gas Chromatography-Mass Spectrometry (GC-MS): laboratories specialised in 
diagnosing IIEM use GC-NIS for metabolic disease screening due to its simplicity, ease 
of operation and low cost per sample (Deng et al., 2004). For analysis by GC-MS, 
organic acids are firstly extracted from biofluids such as urine, plasma and serum and 
then derivatised to increase their volatility through the addition of organic functional 
groups, such as the trimethylsilyl adducts at hydroxyl groups in carbohydrates. Sample 
preparation for the derivatisation method and longer assay times are the main 
disadvantages, making GC-MS less suitable for high through-put screening. 
'H NMR spectroscopy: High resolution 1H NMR spectroscopy has been shown to be a 
powerful tool for monitoring perturbed metabolic profiles in biofluids such as urine, 
plasma and serum and can provide diagnostic information on the biochemistry of 
disease processes (Lindon JC et al., 2000). The ability conferred by NMR spectroscopy 
to profile multiple metabolites simultaneously offers a more specific diagnostic 
technique for many ]EM than assays measuring single analytes and thus a wide range of 
chemical classes can be screened concurrently without prior knowledge of the nature of 
the IEM. Since NMR spectroscopy is a non-destructive technique the sample can be 
preserved for further chemical analysis. Examples of selected IEM and the methods by 
which they have been diagnosed are summarised in Table 5.1. 
Additionally, NMR spectroscopy is in principle quantitative and so can be used to 
establish the concentrations of selected metabolites present in the biological matrix of 
interest. For example, different N-acetylated metabolites in biofluids of patients with 
various inborn errors of metabolism were identified and quantified by Engelke et al. 
(Engelke et al., 2007a). Several diseases are known to be associated with the 
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accumulation of N-acetylated metabolites such as N-acetylneuraminic acid, N- 
acetylaspartic acid and N-acetyltryptophan, which are products of many metabolic 
pathways. Many of these compounds have been analysed by one and two dimensional 
NMR spectroscopic methods and this is a very promising technique for monitoring IEM. 
However, this technique is relatively insensitive in cases where abnormal metabolites 
are found in low concentrations when compared to other advanced chromatographic 
techniques and the cost of the instrumentation is also high. 
Liquid Chromatography-Mass Spectrometry (LC-MS): Tandem mass spectrometry 
(MS/MS) is a powerful and effective diagnostic technique that has been applied to 
inborn errors of metabolism (Cipriano et al., 2007, Pandor et al., 2006, Rinaldo et al., 
2006, Tran et al., 2007, Van Calcar et al., 2007). However, direct infusion analysis of 
complex liquid samples into a mass spectrometer often causes problems such as ion 
signal suppression due the simultaneous presence of compounds. Liquid 
chromatography (LQ is a technique which separates out different compounds, 
including non-volatile molecules, in a sample mixture. The combination of LC with MS 
and MS/MS is currently the most widespread separation technique utilised as this does 
not require derivatisation of the sample as required in GC-MS. 
Over the last decade, MS/MS has also been incorporated into an escalating number of 
neonatal screening and selective screening laboratories. The application of soft 
ionisation techniques such as electrospray ionisation (ESI) combined with tandem mass 
analysers, allow for the detection of many classes of molecules. This technique is 
amenable for continuous flow analysis and automation for high-throughput newborn 
screening. LC-MS/MS is used to diagnose more than thirty inborn errors of amino acid, 
organic acid and fatty acid metabolism including phenylketonuria (PKU) and medium 
chain acyl-coA dehydrogenase deficiency (MCAD). A simple flow-injection analysis 
gives results in a few minutes with minimal sample preparation. Recent analytical 
improvements in neonatal screening by the use of LC-MS/MS has reduced the false- 
positive result rate as compared to other conventional techniques (la Marca et al., 2007, 
Lacey et al., 2004). 
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More recently the application of ultra performance liquid chromatography coupled to 
mass spectrometry (UPLC-MS) to generate metabonomic profiles in toxicity or 
phenotyping has begun to be explored (Granger et al., 2007, Plumb et al., 2005b, 
Plumb et al., 2006b). This technique has been applied to the investigation of toxicity in 
rats, to the discrimination of strain, gender and diurnal variation in mice and to disease 
models in rats (Granger et al., 2007, Plumb et al., 2005b, Plumb et al., 2006b). This 
advanced analytical system also provides an alternative platform to detect and quantify 
proteins in human serum in a multiplexed fashion without the need for antibodies (Kay 
et al., 2007). UPLC uses columns packed with 1.7 micron particles and enables elution 
of sample components in much narrower, more concentrated bands, resulting in better 
chromatographic resolution, very good separation and hence increased sensitivity. 
Quadrupole-time of flight (Q-Tof) mass spectrometers bring together the selectivity of 
MS/MS and the power of accurate mass measurements. This combination has been 
applied to the identification and structural elucidation of metabolites in complex 
biofluids (Hakala et al., 2006). UPLC-MS-based techniques, particularly when 
combined with exact mass measurements offer potential advantages in terms of 
sensitivity compared to NMR spectroscopy, and also enable the detection of different 
and complementary biomarkers. 
Preliminary investigations of this emerging technology have been very promising and 
have indicated that UPLC-MS might provide useful complementary information to that 
provided by 1H NMR based approaches (Lenz et al., 2007a). This chapter illustrates the 
value of this combined approach applied to a blind study of urine samples from five 
patients with unknown organic acid inborn errors of metabolism (IIEM) and five age- 
matched healthy controls where sample identity was initially blinded. 
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Table 5.1: A selection of inborn errors of metabolism that have been detected using IH NMR spectroscopy and/or hyphenated mass spectrometry Biotluid - technique: colour coded 
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5.3 Methodology 
Twelve clinical urine samples, of which five were from patients with unknown EEM and 
the remaining seven were aged-matched controls, with two controls having repeated 
samples on two consecutive days to test for biological reproducibility. These were 
analysed in a blind fashion using both 1H NMR spectroscopy and UPLC-MS. The 
samples were kindly provided by Prof. Ron Wevers, Radboud University Nijmegen 
Medical Centre, Nijmegen, The Netherlands. 
5.3.1 NMR analysis of clinical samples and controls 
Urine sample preparation 
Urine samples were prepared by mixing 240 [tl of a phosphate buffer solution 
(Appendix 2) with 460 [tl undiluted urine. The solution was left to stand for 10 minutes 
before centrifuging at 16089 g for 10 minutes, to separate any precipitate. Aliquots of 
600 [tl of the resulting solution were added to 5 mm NMR tubes. 
One-dimensional 1H NMR spectroscopy 
Initially urine samples were analysed using 400 MHz 1H NMR spectroscopy. This is 
because 400 MHz 1H frequency NMR spectroscopies are standard and widely available 
instruments. Subsequently the results were compared with data from a 'state of the art' 
800 MHz NMR spectroscopy in order to identify additional biomarkers for the EEM and 
to assess the effect of the NMR magnetic field strength on recovery of information 
contained in metabolic profiles. 
400 MHz 1H NMR spectroscopy 
Urine samples were analysed at 300K using 
1H NMR spectroscopy at 400.13 MHz 
employing a Bruker DRX-400 spectrometer. For each sample, 128 free induction 
decays (FIDs) were collected into 64k computer data points using a spectral width of 
8278.15 Hz, giving an acquisition time 3.96 s with an additional relaxation delay (RD) 
of 2 s. lH NMR spectra were acquired with suppression of the water resonance using a 
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standard presaturation pulse sequence comprising (RD-90'-M-90'-tin-90'-acquire FID 
(Bruker Biospin Germany) (Nicholson et al., 1995) where tl is a short delay of typically 
3 ps and tm is a mixing time (100ms). Irradiation of the water signal was achieved 
during trn and RD. The summed FIDs were multiplied by an exponential weighting 
function corresponding to a line broadening of 0.3 Hz prior to Fourier transformation 
(FT). Spectra were phase-coffected, manually baseline-corrected and internally 
referenced to trimethylsilyl-2,2,3,3-tetradeuteropropionic acid (TSP, 8H 0-00 PPM) using 
TOPSPIN software (Bruker, Germany). 
800 MHz 1H NMR spectroscopy 
Urine samples were analysed at 300K by 1H NMR spectroscopy at 800.32 MHz using a 
Bruker Avance-800 spectrometer. A total of 128 free induction decays (FIDs) were 
collected into 64k computer data points using a spectral width of 16025.641 Hz, giving 
an acquisition time 2s with an additional relaxation delay of 2 s. 1H NMR spectra were 
acquired with suppression of the water resonance using a standard presaturation pulse 
sequence comprising (RD-90'-tl-90'-tm-90'-acquire FID (Bruker Biospin Germany) 
(Nicholson et al., 1995) where tI is a short delay of 3, us and tm is 100ms. The summed 
FIDs were multiplied by an exponential weighting function corresponding to a line 
broadening of 0.3 Hz prior to FT. Spectra were phase-corrected, manually baseline- 
corrected and internally referenced to TSP (8H 0-00 PPM)- 
Two-dimensional 1H NNIR spectroscopy 
2D NMR spectra were acquired using 800 MHz 1H NMR spectroscopy in order to aid 
assignment of the 1H resonances of metabolites in ]HEM urine samples 
'H-'H Correlated Spectroscopy (COSY)(Aue et al., 1976a) 
The COSY experiment aids the assignment of 
1H NMR signals by providing 
connectivity between peaks that are J-coupled, generally acting over no more than three 
bonds. 'H-'H COSY NMR spectra of urine were acquired with water suppression using 
512 transients collected in to 4k data points per increment for 16 increments, with FI 
and F2 spectral widths of 9615 Hz and 9604 Hz respectively. 
The relaxation delay 
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between successive scans was 2 seconds. The data were apodised by means of a sine- 
bell function in both dimensions prior to FT. 
'H- IH Total Correlation Spectroscopy (TOCSY) (Braun, 1998) 
The TOCSY experiment allows identification of all the protons belonging to a common 
coupled spin system. 1H-1H TOCSY NMR spectra of urine samples were acquired using 
512 transients collected into 4k data points per increment for 16 increments, with FI 
and F2 spectral widths of 9603.9 Hz and 9615.4 respectively. The relaxation delay 
between successive scans was 2 seconds. The data were apodised by means of a shifted 
squared sine-bell function and zero-filled by a factor of 2 in both dimensions prior to FT. 
J-resolved (JRES) 'H NMR Spectroscopy (Aue et al., 1976b) 
J-resolved spectroscopy allows separation of chemical shifts and homonuclear J- 
couplings into different frequency domains with the chemical shifts in F2 and splittings 
due to J-couplings in Fl. 800 MHz JRES 1H NMR spectra of urine samples were 
acquired with presaturation of the water resonance using 16 FIDs collected into 32 
increments for a spectral width 9615.385 Hz in the F2 domain and 50 Hz in the F1 Q- 
coupling) domain. Prior to FT, a sine function was applied to the FI dimension and an 
exponential function equivalent to a line broadening of 0.3 Hz was applied to the F2 
dimension. 
IH-13 C Heteronuclear Single Quantum Coherence (HSQC) Spectroscopy 
(Bodenhausen et al., 1980) 
The HSQC experiment allows observation of coupling between protons and directly 
bonded heteroatoms, such as 1H and 13C . An 
'H- 13 C HSQC spectrum was acquired for 
selected urine samples using 4k data points in F2 with 100 scans for 256 increments and 
refocusing delay of 3.45 ms. The F2 and F1 spectral widths were 10000 Hz and 44277 
Hz respectively and prior to FT, a qsine weighting function was applied in F2. 
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5.3.2 NMR analysis of standards 
1H NMR spectra of standard solutions were acquired in order to confirm the spectra of 
authentic metabolites postulated as biomarkers for each IEM analysis. The five IEM 
were correctly identified using 1H NMR spectroscopy in a blind analysis. 
Standard solution preparation 
I mg/ml solutions of methylmalonic acid, 3-hydroxybutyric acid, orotic acid, uridine, 
uracil, 3-hydroxyisovaleric acid, isovaleric acid, tryptophan, lysine, mevalonolactone, 
and homogentisic acid were prepared by dissolving authentic compounds in the 
phosphate buffer solution (Appendix 2). The pH of the samples was finally adjusted to 
7.4 using 0.1 M HCL Samples were prepared for NMR spectroscopic analysis by 
addition of 600 [tl of the appropriate solutions to 5 mm NMR tubes. 
1D 1H NMR analysis of standard solutions 
Although IH NMR spectra of standard solutions were acquired on a Bruker DRX 600 
spectrometer (60OMHz 1H frequency) at 298K using a standard presaturation pulse 
program for water suppression (Nicholson et al., 1995), they are very simple spectra, are 
largely first order and thus the multiplet peak structure is essentially independent of the 
observation frequency. Following 8 dummy scans, 64 FIDs were acquired and each of 
the spectra was collected into 64k data points with a total spectral width of 20 ppm. 
Prior to FT, the FIDs were multiplied by an exponential function corresponding to a line 
broadening 0.3 Hz. 
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5.3.3 Data pre-processing and chemometric analysis 
The 1H NMR spectra measured at both 400 and 800 MHz were reduced into 9001 
variables, calculated by integrating regions of equal width (0.001 ppm) corresponding to 
the chemical shift range 0.5 - 9.5 using software written in house (courtesy Dr. T. M. D. 
Ebbels, Imperial College, London) in Matlab R2007b from MathWorks, USA. The 
regions 8 4.4-6.1 were eliminated to remove spurious effects of variability of water 
suppression. The reduced data were then non-nalised to a total area constant sum in 
order to minimise the effects of variation in urine concentrations across the samples 
using the method described in Chapter 2, section 2.2.1. 
Principal component analysis (PCA) was performed using SIMCA-P (version 11.5; 
Umetrics, Sweden) and employed mean centring and unit variance scaling. Initially, 
PCA was performed on mean centred data to assess the distribution of clinical urine 
samples and controls. Unit variance scaling was then applied to the same mean centred 
data matrix to maximise the separation between samples of IIEM and controls. 
125 
Chapter 5 
5.3.4 UPLC-MS analysis 
Sample Preparation 
A 150gl aliquot of each urine sample was added to 150 ýtl of H20 tOmake the total 
volume 300 gl. The samples were centrifuged at 16089 g for 10 minutes to remove 
particulates. 250 gl of diluted urine was transferred into 96 well plates for analysis. 
Chromatographic conditions 
Chromatographic separations were performed on a Waters 2.1 mm x 100 mm 
ACQUITYTM 1.7 ýtnl C 18 BEH column maintained at 40 T. The samples were 
maintained at 4T prior to injection of 5 [tl on to the column. Reversed phase 
chromatography conditions were employed using a 12 min gradient with mobile phase 
A 0.1 % formic acid (FA) in water and mobile phase B being 0.1 % FA in acetonitrile 
(ACN) as developed in Chapter 3, section 3.3. The gradient conditions are shown in 
Table 5.2. 
Table 5.2: UPLC gradient conditions for 0.1 % formic acid in water (mobile phase A) and 
acetonitrile (mobile phase B) for 12 min run 
Time (min) 
Mobile phase A (%) 
(H20 + 0.1 % FA) 
Mobile phase B (%) 
(ACN + 0.1 % FA) 
0.0 100 0 
1.0 85 15 
3.0 50 50 
6.0 5 95 
9.9 5 95 
10.1 100 0 
Mass spectrometry conditions 
Electrospray (ESI) mass spectrometry experiments were performed on a Micromass Q- 
tofrm Premier (Waters, USA) operated in both positive and negative ionisation modes. 
The micromass Q-tof TM was operated in W optics mode with 12 000 resolution using 
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dynamic range extension (DRE). The mass spectrometer was calibrated across the mass 
100-1000 Da using a solution of sodium formate. All analyses were acquired using the 
lock spray to ensure accuracy and reproducibility; 200 pg/gL leucine-enkephalin in 
H-, O: ACN (50: 50) was used as the lock mass with a flow rate 30 gUmin. Data were 
collected in centroid mode, the lockspray frequency was set at 5 s, and data were 
averaged over 10 scans. In order to identify and confirm the biomarkers for each EEM, 
tandem mass spectrometry (MS/MS) experiments were performed on the same 
Micromass Q-Toflm Premier operated in both positive and negative modes. The MS and 
MS/MS conditions for analysing samples of standards and urines in both modes are 
shown in Table 5.3. The collision energy for MS/MS experiments ranged from 15 V to 
30 V depending on the metabolite being analysed. The collision energy was initially 
optimised on standards and then applied to the urine samples 
Table 5.3: NIS and MS/MS conditions for analysing samples of standards and urines in 
both negative and positive modes 
Parameters Negative mode Positive mode 
Capillary voltage (kV) 2.4 3.2 
Cone voltage (V) 35 35 
Desolvation gas (L/hr) 900 900 
Desolvation gas temperature C) 350 350 
Cone gas (L/hr) 0 0 
Cone gas temperature (OC) 120 120 
Data acquisition rate (s) I I 
Interscan delay (s) 0.1 0.1 
Data pre-processing and chemometric analysis 
The acquired data were pre-processed using Markerlynx software (Waters) (See Chapter 
2). The data were normalised to the summed total peak height. The resulting two- 
dimensional data (intensity, mass to charge ratio/retention time couples (ni/z. RT pairs)) 
were exported into SIN4CA-P (version 11.5; Umetrics, Sweden) software as a "markers 
table" for further chemometric analysis. PCA was performed on the intensities of the 
nVz-RT pairs using both unit variance scaling and mean centring without 
further scaling. 
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5.4 Results 
5.4.1 Metabonomic investigation of inborn errors of 
metabolism using 400 MHz 1H NMR spectroscopy 
Visual analysis of urine NMR spectra of IEM and controls 
Initially, twelve urine samples of which five were from patients with unknown IIEM and 
five were age-matched controls, where two controls have repeated samples for two 
consecutive days, were analysed using ID 1H NMR spectroscopy with no prior 
knowledge about the samples. Visual inspection of the 1H NMR spectra of urine 
samples showed several peaks that were potentially of interest. Figures 5.1 and 5.3 
show the aliphatic region (8H4.5-0.5) and Figures 5.2 and 5.4 show the aromatic region 
(5H8.5-5.0) obtained for each of the urine samples numbered 1-12. Consultation with 
literature data and 1H NMR spectra of standard solutions identified several of these 
resonances and identified all five samples from the undiagnosed IIEM participants. 
Sample 1: Visual analysis of the 1H NMR spectrum demonstrated elevated peaks at 8H 
1.24 and8H3.17 as shown in Figure 5.1. Consultation with literature data (Iles et al., 
1985) and comparison with 1H NMR spectra of standard solutions confirmed that the 
elevated peaks at 8H 1.2 and 8H 3.2 were the resonances of methylmalonic acid 
indicating that sample I was a type of inborn error with elevated excretion of urinary 
methylmalonic acid. Additionally, this spectrum shows a depleted amount of hippurate 
(Figure 5.2), which is a typical metabolite of human urine, in comparison with the other 
samples. 
Sample 2: The 1H NMR spectrum showed elevated peaks at 6HI. 26,8Hl. 39,8HI. 84,6H 
2.3 8 and 8H 3.75 (Figure 5.1). A literature search and comparison with spectra of 
standard solutions indicated that those peaks were the resonances of mevalonolactone 
and mevalonic acid. The presence of mevalonolactone and mevalonic acid indicates that 
sample 2 was from a patient of mevalonoaciduria. 
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Sample 3: The 114 NMR spectrum showed elevated doublet peaks at6HO. 94,8H2.02,5H 
3.77, a multiplet at 8H2.20 and a singlet at 8H7.97 as shown in Figures 5.1 and 5.2. 
Consultation with literature data (Iles et al., 1985) and comparison with 11-1 NMR 
spectra of standard solutions confirmed that they were the resonances of 
isovalerylglycine, indicating that sample 3 was a type of inborn error with elevated 
excretion of urinary isovalerylglycine. This spectrum also possessed relatively low 
amounts of hippurate. 
Sample 4: The 1H NMR spectrum showed (Figure 5.1 and 5.2) elevated peaks at8H3.50 
and 8H 6.72. Literature search and comparison with spectra of standard solutions 
confirmed that those peaks were the resonances of homogentisic acid. The presence of 
homogentisic acid indicates that sample 4 came from a patient with alkaptonuria. 
Sample 5: Comparison with 1H NMR spectra of other IIEM and non IDEM urine samples, 
spectrum of sample 5 showed a disappearance of the urea peak at 8H 5.6-5.9 and an 
elevated singlet at 6H6.20 (Figure 5.2). Using a literature search and comparison with 
spectra of standard solution confin-ned that the resonance at 8H6.20 was orotic acid. 
This indicates that sample 5 was a type of inborn error with elevated excretion of orotic 
acid. In order to detect the correct type of orotic acid linked inborn error of metabolism 
such as orotic aciduria and ornithine transcarbamylase deftency (OTC), the other urea 
cycle metabolites such as uracil and uridine were run as standards and compared with 
the 1H NMR spectra. Uridine and uracil were found to be present together with orotic 
acid, confirming that sample 5 was obtained from a patient with OTC. 
129 
Chapter 5 
Sample 1 
Mevalonic acid H 
g zy 
Sample 2H09 OH 
Hippurate CH2(c) h 
0 
CH2 (e) 
Methylmalonic acid 
00 
HO 'I a OH 
Hippurate CH2(c) h CH2 (d) 
tý 
14 
If Lo 
0 
Sample 3 
- Creabnine CH2 M Chol 
CHA) 
Mevalono lactone ,0H 
CH2 (9) CH3 Mdb 
c 
CH3 (a) 00 
11f 
CH2 (b) 
Isovaleryl glycine 
H0 
, ýf e N 
0 Hl 
CH2 (d) 
Citrate 
Cý (b) 
Sample 4 
Sample 5 
0 
Orofic acid 
aI NH 
HO 
H 
0 
0 
HO 
1 
6llb 
d loi:, 
OH 
Lactate 
Alanine 
4.0 3.0 2.0 1.0 81H 
Figure 5.1: 400 MHz 1H NMR spectra (SH4.5-0.5) of urine samples from unknown inborn 
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Sample 6 (CI): The 1H NMR spectrum showed (Figure 5.3and 5.4) that the sample has 
a higher amount of betaine, TMAO, glycine and formate as compared to other controls. 
The present of higher amounts of betaine and glycine indicate that this urine sample was 
obtained from an infant control (Davies et al., 1988). Additionally, the 1H NMR 
spectrum shows unknown peaks from unidentified metabolites at 8HI. 15 and8H 1.25. 
Sample 7 (C2): The 1H NMR spectrum showed (Figures 5.3 and 5.4) typical urinary 
metabolites present in normal concentrations. However, the 1H NMR spectrum showed 
a set of complex peaks in the glucose region between 8H3.00 and8H4.00 as compared 
to other controls (Figure 5.3) and a doublet peak assigned to a- glucose at 8H5.23 
(Figure 5.4). This indicates that the sample 7 was obtained from a diabetic control. 
Sample 8 (C3): The 1H NMR spectrum showed (Figure 5.3 and 5.4) typical urinary 
metabolites present in normal concentrations. No unusual peaks of metabolites were 
found and this confirms that the sample 8 was obtained from a healthy control. 
Sample 9 (C4): The 1H NMR spectrum showed (Figure 5.3 and 5.4) typical urinary 
metabolites present in normal concentrations, confirming that the sample 9 was 
obtained from a healthy control. However, this sample shows a higher amount of 
TMAO compared to other controls. This could be due to higher fish diet intake. 
Sample 10 (C5): The 1H NMR spectrum showed (Figure 5.3 and 5.4) typical urinary 
metabolites presence in normal concentrations. No unusual peaks of metabolites were 
found, this confirms that the sample 10 was obtained from a healthy control. 
Sample 11 (C6): The 1H NMR spectrum showed (Figures 5.3 and 5.4) a urine sample of 
a healthy control with typical urinary metabolites present 
in normal concentrations with 
the exception of the presence of a higher amount of lactate. 
Sample 12 (C7): The 1H NMR spectrum showed (Figure 5.3 and 5.4) typical urinary 
metabolites presence in normal concentrations, confirming that the sample 
12 was 
obtained from a healthy control. 
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Figure 5.3: 400 MHz 1H NMR spectra (SH4.5-0.5) of urine samples from age-matched 
controls 
All spectra are plotted to the same scale. Abbreviations: DMA, dimethylamine; TIVIAO, trimethylamine-N-oxide; DMG, 
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From the visual inspection of the 400 MHz 1H NMR spectra of urine samples, samples 
with IEM were distinguished from controls. All five IEM were identified by elevated 
peaks of organic acids and other metabolites. Visual inspection of the 1H NMR spectra 
of control urine samples (Figures 5.3 and 5.4) indicated that the overall biochemical 
profiles were similar. IH NMR spectra for each control showed the expected 
metabolites in human urine such as creatinine, citrate, hippurate, urea, glycine, alanine, 
lactate, dimethylamine (DMA), and trimethylamine-N-oxide (TMAO). However, a 
small number of variations in the biochemical profiles of the 1H NMR urine spectra 
were noted due to difference in dietary intake and age. 1H NMR spectra showed that 
sample 6 (control 1) has a higher amount of betaine, TMAO, glycine and formate as 
compared to other controls, indicating that the sample was obtained from a infant 
control (Figure 5.3). Sample 7 (control 2) shows higher amount glucose, indicating that 
the urine was obtained from a diabetic control. Sample 9 (control 4) showed a higher 
amount of TMAO and sample II (control 6) showed a higher amount of lactate as 
compared to other controls (Figure 5.3) and this could be due to intake of various 
dietary components or to different genetic/environmental backgrounds. 
Visual analysis of repeated samples of controls (samples 8 and 9 and samples 10 and 11) 
showed overall similar profiles, although 1H NMR urine sample II demonstrated a 
higher amount of lactate as compared to the urine sample (sample 10) obtained on the 
consecutive day. 
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Principal component analysis (PCA) of IEM and controls 
To assess the distribution of samples of IEM and controls without further scaling, a 
PCA model was initially constructed on all twelve samples using mean-centring since 
this highlights the effects of the major variables. The PCA scores maps for the first two 
principal components (PCI/PC2) (Figure 5.5 (A)) showed that urine samples of methyl 
malonic aciduria (MMA) and isovaleryl aciduria (IVG) were well separated out as 
outliers. The PCI/PC2 loading plot of the PCA model (Figure 5.6A) showed that the 
separation of MMA and IVG were attributed to variation of methyl malonic acid (8HI-2) 
and isovalerylglycine(8HO. 94) respectively. 
Another PCA calculation was performed after removing those outliers and the scores 
plot in Figure 5.5 (B) highlights that the remaining three IIEM were separated out. In 
particular the urine sample of mevalonic aciduria (MEV) was well separated from the 
controls. The PCI/PC2 loadings plot (Figure 5.6B) showed that the separation of MEV 
was attributed to variation of mevalonic acid and mevalonic lactone (8111.26). However, 
in the scores plot (Figure 5.5 B) the controls were scattered, particularly the infant 
control (C1, sample6) also separated out from rest of the controls. Inspection on 1H 
NMR spectra (Figures 5.3 and 5.4) for all controls as well as the PCl/PC2 loading plot 
of the PCA model (Figure 5.6B) illustrated that the separation of infant control (sample 
6) was attributed to variation of the betaine and glycine resonances. 
Unit variance scaling, giving equal emphasis to all variables, was applied to the same 
mean-centred data and another PCA model was constructed. Unlike mean centring 
without further scaling, unit variance confers equal weights to all variables and 
therefore all metabolites are treated with equal emphasis irrespective of whether they 
are present in low or high concentrations. The PCA scores maps for the first two 
principal components (Figure 5.5 (Q) reveals that IEM samples of ALK and IVG were 
separated as outliers. The PCI/PC2 score plot using unit variance scale after removing 
ALK and IVG is given in Figure 5.5 (D) and shows that the control samples, except 
control I (sample 6), were clustered together at the centre of the scores plot whereas the 
IIEM of MMA was well separated out. The rest of the IEM samples such as OTC and 
MEV showed a small separation from the controls. 
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Figure 5.5: Score plots of principal component (PC) I (X axis) versus PC2 (Y axis) for 
NMR data of urine samples obtained from inborn errors and control samples acquired by 
400 MHz 'H NMR spectroscopy using (A) mean centred data (B) mean centred data after 
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5.4.2 Metabonomic investigation of inborn errors of 
metabolism using 800 MHz 1H NMR spectroscopy 
Urine samples of the same five IEM and age-matched controls were analysed using ID 
and two dimensional (2D) 800 MHz 1H NMR spectroscopy. Consultation with IH NMR 
spectra obtained by 400 MHz 1H NMR spectroscopy and 1H NMR spectra of standard 
solutions along with two-dimensional NMR spectroscopy experiments such as COSY, 
TOCSY, J-resolved and HSQC identified and confirmed several of the important 
resonances in spectra of IEM samples. 
Visual analysis of NNIR spectra of IEM 
Urine samples of five IIEM have been analysed using 800 MHz 1H NMR spectroscopy. 
Figure 5.7 shows the aliphatic region (8H4.5-0.5) and Figures 5.8 shows the aromatic 
region (8H8.5-5.0) obtained for each of the urine samples numbered 1-5. 
Visual analysis of 1H NMR spectrum of sample I showed elevated peaks at 8HI. 24 and 
6H3.17 as shown in Figure 5.7.2D experiments and 1H NMR spectra at 400 MHz 
confirmed that the elevated peaks at 6H 1.2 and 8H 4.2 were the resonances of 
methylmalonic acid indicating that sample I was a type of inborn error with elevated 
excretion of urinary methylmalonic acid. The 1H NMR spectrum of sample 2 (Figure 
5.7) showed elevated peaks at 5H 1.26,8H 1.39,8H 1.84,8H2.3 8 and8H3.75. The 1H 
NMR spectrum obtained at 400 MHz and spectra of standard solutions along with the 
2D experiments confirmed that these peaks were the resonances of mevalonolactone 
and mevalonic acid. The presence of mevalonolactone and mevalonic acid confirms that 
sample 2 was from a patient of mevalonoaciduria. 
For sample 3, the 1H NMR spectrum showed elevated doublet peaks at 8HO. 94,2.02, 
3.77, a multiplet at 8H2.20 and a singlet at8H7.97 as shown in Figures 5.7 and 5.8.2D 
experiments and in the 1H NMR spectrum obtained in 400 MHz, and this confirmed that 
they were the resonances of isovalerylglycine, indicating that sample 3 was a type of 
inborn error of isovaleric aciduria. 
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The visual analysis of the 1H NMR spectrum of sample 4 (Figure 5.7 and 5-8) showed 
elevated peaks at 8H 3.50 and 8H 6.72. The 1H NMR spectrum obtained at 400 MHz and 
spectra of standard solutions along with the 2D experiments confirmed that these peaks 
were the resonances of homogentisic acid. The presence of homogentisic acid confirms 
that sample 4 came from a patient with alkaptonuria. The 1H NMR spectrum of sample 
5 showed a disappearance of the urea peak at 8H 5.6-5.9 and an elevated singlet due to 
orotic acid at 8H 6.20 (Figure 5.8). The resonances of uridine and uracil were also found 
to be present, again confirming that sample 5 was obtained from a patient with ornithine 
transcarbamylase defiency (OTC). 
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Figure 5.7: 800 MHz 'H NMR spectra (8H4.5-0.5) of urine samples with inborn errors of 
metabolism 
All spectra are plotted to the same scale. 
Abbreviations: TMAO, tfimethylamine-N-oxide; TMA, tr1methyl amme; DNIG, dimethyl 
glycine; 
DMG DMA Succinate 
\ILI. 11 1 
CH2 
Mevalono lactone , OH 
(g) 
CH3 (a) CH3 Mdb II-c 
, 
K"r o0 
TMAO 
141 
Chapter 5 
Sample I 
Methylmalonic acid 
00 
HO 
)a 
OH Urea 
Sample 2 
Mevalonic acid HO Mevalono lactone . OH H0,. 
ý g 
OH 
db 
Phenylaoetylglycine 0c 
100 
p-cresol sulphate 
Iý 
Sample 3 
NH 
Sample 4 
Hippurate 
CH (b, c, d) 
I-L-l 
Homogentisic acid 
H 
a0 
HO 
d 
OH 
Sample 5 
Uridine 
Isovaleryl glycine 0 
HO e ýr fN 
0 Hl 
Orotic acid 
aI NH 
0N "'ýO 
H 
0 
Uracil CH (a) 
Uridine 
jlý4 
I- 
-" 
I) 
ý!, 
I. 
8.0 7.0 6.0 61H 
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Visual analysis of NMR spectra of controls 
Urine samples of seven controls have been analysed using 800 MHz IH NMR 
spectroscopy. Figure 5.9 shows the aliphatic region(8H4.5 -0.5) and Figures 5.10 shows 
the aromatic region (8H8.5-5.0) obtained for each of the urine samples numbered 6-10. 
Visual inspection of spectra for all urine samples using 800 MHz 1H NMR spectroscopy 
showed similar metabolic profiles as shown in the spectra obtained using 400 MHz 1H 
NMR spectroscopy. IH NMR spectra obtained at 800 MHz showed that sample 6 
(control 1) is a infant control with a higher amount of betaine (8H3.27 and 60-9), 
TMAO (8H3.27), glycine (8H3.57) and formate (8H8.4), sample 7 (control 2) with a 
higher amount of glucose (80.00-8114.00 and8H5.23), sample 9 (control 4) with a 
higher amount of TMAO (8H3.27) and sample 11 (control 6) with a higher amount 
lactate(80.33 and8H4.1 1) as compared to other controls. 
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PCA analysis of IEM and controls 
A PCA scores plot of the first two components (PC I and PC2), from the data acquired 
on 800 MHz 1H NMR spectroscopy using mean centring (Figure 5.11 (A)) shows that all 
five IIEM separated from the controls. As for the PCA plot obtained using 400 MHz 1H 
NMR spectroscopy (Figure 5.5 (A)), the urine sample of MMA was well separated as 
an outlier and the infant control (CI) also separated from the rest of controls. The 
PCI/PC2 loading plot of the PCA model (Figure 5.12A) showed that the separation of 
MMA was attributed to variation of methyl malonic acid(80.2) and the separation of 
controls 5 and 6 from the rest were attributed to variation of creatinine and creatine 
levels (8H3.05,8H4.05). 
Figure 5.11 B highlights the first two components after removing the outlier MMA and 
using mean-centring without further scaling. The other four DEM separated out from the 
controls; particularly the urine samples of mevalonic aciduria (MEV) and isovaleryl 
aciduria JVG) separated well from the rest. The PCI/PC2 loadings plot of the PCA 
model (Figure 5.12 B) showed that the separations of MEV and IVG were attributed to 
variation of mevalonic acid (8HI. 26) and isovalerylglycine respectively (8HO. 94) 
Unit variance scaling was applied to the same mean-centred data for all twelve samples 
and another PCA model was constructed. The PCA scores maps for first two principal 
components (Figure 5.11 (Q) revealed a clear separation between controls and IEM and 
this is different to the PCA plot obtained from the data acquired in 400 MHz IH NMR 
spectroscopy. Additionally, it indicates that the controls clustered together except 
control I (infant control) and control 4. Visual inspection of 1H NMR spectra shows the 
separation of infant control (C I) was attributed to variation of the betaine, TMAO and 
glycine resonances and the separation of C4 was also attributed to variation of TMAO. 
In comparison with the PCA plots obtained from the data acquired using 400 MHz 
1H 
NMR spectroscopy, the PCA plots obtained from 800 MHz 
1H NMR spectroscopy 
generally demonstrated better separation between controls and IIEM. 
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5.4.3 Comparison of IEM and controls using 400 MHz and 
800 MHz 1H NMR spectroscopies 
Visual analysis of urine NNIR spectra of IEM and controls 
Visual inspection of spectra for all urine samples using 800 MHz 1H NMR spectroscopy 
revealed similar peaks to those from the spectra using 400 MHz 1H NMR spectroscopy. 
However, the appearances of peaks (the splitting patterns) are slightly different as 
compared to the peaks acquired using 400 MHz 1H NMR spectroscopy. At 800 MHz, 
the chemical shifts as measured in Hz will be twice those at 400 MHz. However they 
will be the same by definition in ppm and the natural peak line width is expected to be 
essentially the same at both observation frequencies. Thus for a constant plot width in 
ppm, the peaks appear narrower. In addition, some chemical shifts are linearly 
dependent on the observation frequency, but the J-couplings are independent, better 
dispersion of the spin-coupled multiplets is expected at the higher observation 
frequency. Therefore, the peaks acquired at 800 MHz appear slightly narrower in peak 
width and are more clearly separated, hence more easily analysable as compared to data 
at 400 MHz. Figure 5.13 shows a comparison of important resonances in spectra 
obtained at both 400 MHz and 800 MHz observation frequencies 
Urine sample of MMA: The peaks of methylmalonic acid OH 1.24 and8H3.17) in the 
800 MHz lH NMR spectrum (Figure 5.13A) and the quartet peak at 8H3.17 were more 
resolved as compared to the 1H NMR spectrum obtained at 400 MHz. 
Urine sample of MEV. Figure 5.13B shows the doublet and triplet peaks of rnevalonic 
acid and mevalonolactone at 8H2.3 8 and8H3.75 in the lH NMR spectrum obtained at 
800 MHz appeared narrower in peak width as expected as compared to 400 MHz. 
Urine sample of IVG: The doublet peaks of isovalerylglycine OH 0.94,2.02) and a 
multiplet at 6H 2.20 in the 800 MHz 
1H NMR spectrum (Figure 5.13C) appeared 
narrower in peak width as expected and more resolved particularly the multiplet peak at 
8H2.20, which is very weak in the 400 MHz spectrum. 
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Urine sample of ALK: Figure 5.13D shows that the peaks of homogentisic acid in the 
800 MHz 1H NMR spectrum are more resolved, particularly the doublet peak at8H6.80, 
which is very weak and almost undetectable in the 400 MHz spectrum. 
Urine sample of OTC: The doublet peak of uracil (8H5.8) and the triplet peak of 
uridine(8H5.91) in the 800 MHz lH NMR spectrum (Figure 5.13E) appeared more 
resolved as compared to the 1H NMR spectrum obtained at 400 MHz. 
Urine sample of control: Figure 5.13F shows the comparison of citrate, dimethylamine 
(DMA) and hippurate resonances in spectra obtained for a typical control at 400 MHz 
and 800 MHz observation frequencies. The 800 MHz IH NMR spectrum showed that 
these peaks appeared narrower in peak width and more resolved, particularly the peaks 
of citrate and DMA are separated clearly as compared to the 1H NMR obtained by 400 
MHz. 
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Principal component analysis of IEM and controls 
Principal component analysis was then carried out on urine samples of I]EM and control 
urine samples to assess the quality of the spectra acquired using both 400 and 800 MHz 
NMR spectroscopy. The PC I /PC2 scores map containing data for 24 samples (Figure 
5.14A) using mean centring shows that most pairs of control urine samples cluster 
adjacent to each other except for three outliers, one of which is the pair of methyl 
malonic aciduria (MMA) sample. The loadings plot shows (data not shown) that the 
separation of pair of MMA was attributed to variation of the same metabolite 
methylmalonic acid, which is the highest intensity peak of MMA among other EEM 
samples at both 400 MHz and 800 MHz. Another PCA was constructed using mean 
centring after removing those outliers and the urine sample pairs of the second highest 
intensity peak of isovaleric aciduria (IVG) were separated out as shown in Figure 5.14B. 
The loadings plot shows (data not shown) that the separation of pair of IVG was also 
attributed to variation of the same metabolite isovalerylglycine, which is the second 
highest intensity peak of IVG among other IEM samples at both 400 and 800 MHz. 
Unit variance scaling, was applied to the same data of all twelve pairs and another PCA 
model was constructed. The PCA scores maps for the first two principal components 
(Figure 5.14 (Q) shows that the 400 and 800 MHz spectral pairs of IVG and 
alkaptonuria (ALK) spectra were far apart from each other as compared to other pairs 
which clustered adjacent to each other. 
Magnetic field strength clearly plays an important role in the separation of pairs of EEM 
which measured at 400 MHz and 800 MHz observation frequencies. Increasing the field 
strength increases the spectral resolution of peaks as shown in Figure 5.13, and leads to 
better characterisation of the elevated peaks of organic acid for each IEM in the 800 
MHz 1H NMR spectra as compared to 400 MHz for the same samples. 
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5.4.4 UPLC-MS analysis of inborn errors of metabolism 
Visual analysis of chromatograms of IEM samples 
Urine samples from five IEM patients and five age-matched controls, where two 
controls have repeated samples for two consecutive days, were analysed in duplicate 
using the UPLC-MS methodology developed and described earlier (See Chapter 3, 
section 3.3). Standards of relevant organic acids were also run in both negative and 
positive modes to aid the identification of organic acids from MS and MS/MS spectra 
(Table 5.4). 
Table 5.4: Retention time and m1z ratio in negative mode for standards of organic acids 
measured using UPLC-MS, listed in increasing molecular weight order 
Organic acids Calculated m1z ratio 
(monois topic) 
Retention time (niin) 
Negative mode Positive mode Negative mode Positive mode 
Isovaleric acid 101.0603 103.0759 4.21 not detected 
3-hydroxybutyric acid 103.0395 105.0552 1.45 not detected 
Uracil 111.0194 113.0351 0.74 0.75 
Betaine 116.0712 118.0868 0.52 0.52 
Methy1malonic acid 117.0188 119.0344 1.49 not detected 
3-hydroxyisovaleric acid 117.0541 119.0708 2.65 not detected 
Mesaconic acid 129.0188 131.0344 2.22 not detected 
Mevalonolactone 129.0552 131.0708 not detected 2.35 
Homocystine 134.0276 136.04322 0.65 0.67 
Lysine 145.0977 147.1134 0.45 0.46 
Orotic acid 155.0092 157.0249 0.66 0.66 
Isovalerylglycine 158.0817 160.0974 3.26 3.27 
Pimelic acid 159.0657 161.0814 3.62 not detected 
Methyladipic acid 159.0657 161.0814 3.61 not detected 
Homogentisic acid 167.0344 169.05 2.57 2.53 
Hippuric acid 178.0504 180.0661 3.6 3.61 
Azelaic acid 187.097 189.1127 4.73 not detected 
Tryptophan 203.082 205.0977 3.04 3.05 
Suberylglycine 230.1028 232.1185 3.58 3.6 
Uridine 243.0617 245.0773 1.48 1.48 
Isovalery1carnitine 244.1549 246.1705 3.5 3.5 
Biological samples such as urine, plasma, serum contain a wide range of molecular 
species including non-ionic, acidic, basic and amphoteric compounds and such samples 
:0 
i1 
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require analysis using both positive and negative ionisation modes to ensure the best 
possible chance of detecting the maximum number of metabolites. From the blind NMR 
analysis, the five IEM were correctly identified and later confirmed as methyl malonic 
aciduria (MMA), isovaleric aciduria (IVG), mevalonic aciduria (MEV), omithine 
transcarbamylase deficiency (OTC) and alkaptonuria (ALK) (See section 5.4.1). 
Therefore, standards of elevated organic acids for each IEM were selected for analysis 
by UPLC-MS (Table 5.4). In addition to these standards of organic acids, selected 
amino acids and other known urinary metabolites such as uracil and uridine, which were 
known to be elevated in OTC, were also selected from a literature search of other 
separation techniques such as HPLC (van Kuilenburg et al., 2004) and gas 
chromatography (GQ (Hori et al., 2005). 
Many standards analysed in this study, particularly amino acids, have both amino and 
carboxylic acids as functional groups. The amino group readily accepts a proton so will 
be charged in positive mode ESI, whereas the carboxylic acid readily loses a proton so 
will be charged in negative mode ESI. Therefore all amino acids were detected in both 
negative and positive modes (Table 5.4). However, most organic acids were detected in 
negative mode only due to having a carboxylic acid as the functional group, which is 
easily ionisable in negative mode. Mevalonolactone, which contains a cyclic lactone for 
potential protonation, was detected in positive mode as both a standard and in the 
relevant urine sample. Figure 5.15 shows the negative mode base peak intensity (BPI) 
chromatograms for IEM urine samples and controls whilst Figure 5.16 shows the 
positive mode BPI chromatograms. BPI chromatograms plot the greatest intensity at 
each scan and exhibit a greater apparent resolution and signal-to-noise than total ion 
chromatograms (TIC). As all standards of organic acids and amino acids have retention 
times of less than 5 min (Table 5.4), Figures 5.15 and 5.16 show the BPI 
chromatograms acquired between 0.4 to 7 min with peaks of interest labelled. Visual 
examination of the BPI chromatograms using one minute interval overlaid 
chromatograms for IEM urine samples acquired in a blind fashion showed differences 
between BPI chromatograms in both positive and negative modes. Positive and negative 
chromatograms showed complementary metabolic profile information from urine 
samples. The biochemical profile of each sample of IEM will be discussed individually 
in the next section. 
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Visual analysis of chromatograms of controls 
Seven control urine samples (from healthy individuals) including repeat urine samples 
from two controls were analysed using UPLC-MS. Figure 5.17 shows the negative 
mode BPI chromatograms from 0.4 -7 min (numbered 6-12) whilst Figure 5.18 shows 
the positive mode BPI chromatograms obtained from 0.4 -7 min for these same seven 
control urine samples (numbered 6-12). 
As with 1H NMR spectra analysis, visual inspection of the BPI chromatograms of 
control urine samples indicated that the overall metabolite profiles were similar. 
However, for sample 6, an infant control, there was a significant variation in the 
metabolite profile compared to other controls. In particular, there were more later 
eluting peaks observed in negative mode whereas in positive mode there were lower 
abundance of peaks overall throughout the chromatograms. Specifically, the negative 
BPI chromatograms of the remaining controls (Figure 5.17) show prominent peaks at 
3.40,3.57,3.65,4.08 and 5.82 minutes, which were not present or were significantly 
lower in the infant control urine. The average mass spectra of these peaks showed 
prominent ions at nilz 212.02, nVz 178.07, m/z 263.13 nilz 187.03 and nVz 331.20 
respectively. Comparison of these retention times to standards indicated that the peak at 
3.57 minutes in controls was hippuric acid (nz/z 178.07). The peak at 4.08 minutes was 
considered likely to be p-cresol sulphate (n-Llz 187.03) through comparison with a 
previously run standard from an in-house database. 
The positive BPI chromatograms of controls (Figure 5.18) show prominent peaks at 
0.54,3.60,3.67,4.83 and 5.47 minutes, which were not present or were significantly 
lower in the infant control urine. The average scan range of these peaks showed n7lz 
114.08, Wz180.09, nilz 265.14, nilz 286.22 and n-b1z 302.23 respectively. Comparison of 
these retention times to standards indicated that the peak at 3.60 minutes in controls was 
hippuric acid (nilz 180-09). 
Visual analysis of both positive and negative BPI chromatograms of repeated urine 
samples of controls (Samples 8 and 9 and sample 10 and 11) showed similar 
biochemical profiles. 
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Identification and characterisation of metabolites in samples of IEM 
Sample I 
Negative mode: Using relevant standards and visual analysis of all five negative mode 
chromatograms, sample I showed a broad peak at 1.49 minutes (Figure 5.15), which 
was absent or low in all other samples. The average mass spectrum of this peak showed 
prominent ions at n-Vz 117.0 and nilz 73.0. Comparison with nilz and retention time (RT) 
of relevant organic acid standards indicated that this was methylmalonic acid with in- 
source fragmentation producing the ion at nilz 73.0 (Figure 5.19). This was also seen 
with a standard of methylmalonic acid and corresponded to the neutral loss of carbon 
dioxide (COA 44 Da. Analysis of the MS/MS data for nzlz 117.0 for both sample 1 and 
the methylmalonic acid standard revealed identical fragmentation patterns, again with a 
loss of 44 Da (Figure 5.19). Carboxylic acids tend to fragment in this way. This 
confirmed that the nzlz 117.0 corresponded to methylmalonic acid, indicating that 
sample I was that of the patient with the inborn error methylmalonic aciduria. However, 
there might be interference of the isomer succinic acid (Carvalho et al., 2008). From 
Table 3.3, it can be seen that both isomers methylmalonic acid and succinic acid eluted 
separately (0.22 mins apart). However, the extracted ion chromatogram for "Vz 117 
shows only one peak at 1.49 mins. Therefore the possibility of co-elution must be 
considered. Both compounds have similar MS/MS fragmentation patterns and so cannot 
be distinguished in this way(http: //Www. massbank. jplSearchPage. html). BPI 
chromatograms of other IEM were checked for the presence of methylmalonic acid with 
m1z 117.0 and it was absent in other samples. 
Positive mode: Additionally, sample I showed a prominent peak at 2.15 minutes in 
positive mode (Figure 5.16) which was absent in all other samples. The average scans 
of these peaks showed an ion at m1z 218.14, which after consulting the human 
metabolome database was considered likely to be propionyl camitine. Wikoff et al. 
reported that the serum level of propionylcamitine increased in MMA patients (Wikoff 
et al., 2007). Increased levels of propiony1carnitine have also been reported in urine of 
MMA patients (Roe et al., 1983). However, MS/MS for the propionyl camitine could 
not be carried out since the authentic compound was not available (see Appendix 3 for 
MS/MS spectra of the urine sample). 
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Figure 5.19: Extracted ion chromatograms, NIS and MS/MS spectra for authentic 
methylmalonic acid and IEM urine sample I with retention time 1.49 min and M/z 117.0 in 
negative mode. m1z 117.0 corresponds to the [M-H-1 ion of methylmalonic acid and the 
fragment ion at m1z 73.0 corresponds to the ions Of C02 (44 Da) from the parent ion. 
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Sample 2 
Negative mode: The BPI of sample 2 (Figure 5.15) showed a peak at 1.65 min which 
was absent in all other chromatograms. The average mass spectrum of this peak 
revealed an ion at nilz 147.08. This nilz indicates that the compound could be mevalonic 
acid. However, this compound could not be confirmed since the standard of mevalonic 
acid was not available. Figure 5.15 also illustrates a prominent peak at 4.08 minutes, 
which is also seen in the controls (Figure 5.17) and the average mass spectrum 
generated nilz 187.03. Analysis of MS/MS for m/z 187.03 shows a daughter ion at M/Z 
107.0 due to a loss of sulphate (80 Da). Comparison with a previously run standard 
from an in-house database confirmed that this is likely to be p-cresol sulphate. However, 
MS/MS for this compound could not be carried out since the standard was not available. 
Positive mode: Visual analysis of EEM samples in the positive mode showed a peak at 
2.35 min in sample 2 (Figure 5.16). There was also a peak at this RT in sample 5. 
However, the average mass spectrum of this peak showed prominent ions at nilz 131.08 
and nz/z 113.09 for sample 2 but n7lz 152.07 for sample 5. Therefore, they were different 
compounds that eluted at the same RT. Comparison with the RT and nVz of relevant 
organic acid standards indicated that this peak in sample 2 was mevalonolactone with 
in-source fragmentation producing an ion at m1z 113.09 (Figure 5.20) corresponding to 
the loss of water from the parent ion. Analysis of the MS/MS spectra for "Vz 131.08 
from sample 2 and the standard of inevalonolactone showed virtually identical 
fragmentation patterns of daughter ions at mlz 113.07 and also at nzlz 71.06, a loss of 42 
Da from 113.07 (Figure 5.20). This confirmed that the m1z 131.08 was mevalonolactone, 
indicating that sample 2 that the IEM of mevalonic aciduria. Additionally, sample 2 
showed a prominent peak at 4.25 minutes in positive mode (Figure 5.16) which was 
absent in all other samples. The average mass spectrum of this peak showed nilz 331.1, 
which has not been identified (See Appendix 3 for MS/MS spectra and for possible 
biomarker identification). 
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Figure 5.20: Extracted ion chromatograms, NIS and MS/MS spectra for authentic 
mevalonolactone and IEM urine sample 2 with retention time 2.35 min and M/z 131.1 in 
positive mode. The ion at m1z 131.1 corresponds to the [M+H]' ion of the mevalonolactone 
while m1z 113.0 is due to a loss of water from the parent ion. 
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Sample 3 
Negative mode: Visual analysis of sample 3 in negative mode showed peaks at 2.83, 
3.11, and 3.26 min which were absent or very low in all other samples (Figure 5.15). 
The average mass spectra of these peaks showed prominent ions at nilz 208.08, m1z 
229.14 nVz and 158.09 respectively. Comparison of these retention times to standards 
indicated that the peak at 3.26 minutes (n-Vz 158.09) was isovalerylglycine (Figure 5.21). 
Analysis of the MS/MS data obtained for both sample 3 and the standard of 
isovalerylglycine showed a fragment ion of glycine (nVz 74.0) and another fragment ion 
at nilz 114.1 from a loss of theC02 (44 Da) from the parent ion (Figure 5.21). This 
confirmed that the nzlz 158.09 peak was isovalerylglycine, indicating that sample 3 was 
that of the inborn error metabolism isovaleric aciduria. MS/MS experiments were 
carried out on ion at nzlz 208.08 nVz and 229.14, but these have not been yet identified. 
The MS/MS spectra and possible biomarkers for those peaks are shown in Appendix 3. 
Additionally the sample contained a prominent peak at 5.82 mins with a nilz of 331.0, 
which also present in the controls. 
Positive mode: The BPI chromatograrn showed a dominant peak at 3.50 min (Figure 
5.16) that was absent in all other samples. The average mass spectrum of this peak 
showed n-Vz 246.17. Comparison of this retention time to standards indicated that this 
peak was isovalery1carnitine (Figure 5.22). MS/MS spectra of both the standard of 
isovalery1carnitine and urine sample 3 generated identical fragmentation patterns with 
daughter ions at nz/z 144.13 and nVz 187.12. This metabolite was not seen by 
114 NMR 
spectroscopy. 
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Figure 5.21: Extracted ion chromatograms, NIS and MS/MS spectra for authentic 
isovalerylglycine and IEM urine sample 3 with retention time 3.26 min and M/z 158.0 in 
negative mode. m1z 158.0 corresponds to the [M-Hl' ion of isovalerylglycine while the ion 
m1z 74.0 corresponds to glycine. 
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Sample 4 
Negative mode: Visual analysis identified a peak at 2.54 min in sample 4. There was 
also a peak at this RT in samples I and 2 (Figure 5.15). However, the average mass 
spectrum of this peak showed prominent ions at m1z 167.05 and n? lz 123.05 for sample 4 
but mlz 181.05 for both samples I and 2. Therefore, they were different compounds 
eluting at the same RT. Comparison of this retention time to a standard indicated that 
this peak in sample 4 was homogentisic acid with an in-source fragmentation ion at Wz 
123.05 (Figure 5.23) again due to neutral loss Of C02 (44 Da) from the parent ion. 
Analysis of the MS/MS data obtained for both sample 4 and the standard of 
homogentisic acid demonstrated identical fragmentation patterns with the neutral loss of 
C02 (Figure 5.23). This confirmed that the nz/z 167.05 was homogentisic acid, 
indicating that sample 4 was that of inborn error of metabolism of alkaptonuria. 
Positive mode: The BPI chromatogram highlighted dominant peaks at 0.61 min, 3.63 
min and 4.87 min (Figure 5.16). The average mass spectrum of peak 3.63 min revealed 
prominent ions m1z 180.1 and nilz 105.0. Comparison of this retention time to standard 
indicated that this peak in sample 4 was hippuric acid with an in-source fragmentation 
ion at mlz 105.0. Although hippuric acid was observed in all other samples with varied 
concentrations, it was a dominant peak in sample 4. The average mass spectra of peaks 
at 0.61 min and 4.87 min showed nVz 286.2 and 144.1 respectively. Both ions were also 
present in other 11EM samples in lower concentrations, but were not identified. 
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Sample 5 
Negative mode: Visual analysis of the BPI chromatogram of sample 5 contained a peak 
at 0.66 min (Figure 5.15) that was absent or very small in other samples. The average 
mass spectra of this peak of sample 5 highlighted prominent ions at nz/z 155.0 and nilz 
111.04. Comparison of this retention time to standards indicated that this peak was 
orotic acid with an in-source fragmentation ion at nVz 111.04 (Figure 5.24) 
corresponding to lossOf C02. Analysis of the negative mode MS/MS data obtained for 
both sample 5 and the standard of orotic acid demonstrated identical fragmentation 
patterns (Figure 5.24). This confirmed that the nz/z 155.0 was orotic acid, indicating that 
sample 5 was that of inborn error metabolism of with elevated amount of orotic acid. 
Positive mode: The BPI chromatograrn also revealed a peak at 0.66 min (Figure 5.16) 
that was absent or very small in other samples. The average mass spectrum of this peak 
generated nilz 157.0. Comparison with standards illustrated that orotic acid was also 
detected in positive mode, although it ionised better in negative mode (Figure 5.25). 
MS/MS spectra of both the standard of orotic acid and urine sample 5 showed identical 
fragmentation patterns with a loss of 46 Da (Figure 5.25). 
From NMR studies, other urea cycle metabolites such as uracil and uridine were also 
detected in the urine sample 5 and confirmed by through comparison with standards. 
The confirmation of the presence of uracil was difficult since it has a similar RT to 
orotic acid in this system and nilz of [M-H]- is also the same as a fragmentation ion of 
orotic acid (nz/z I 11.0). Figure 5.26 shows the MS and nVz 243.0 in positive mode 
MS/MS spectra for uridine. This confirmed that the sample 5 was that of inborn error 
metabolism of OTC. 
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Figure 5.24: Extracted ion chromatograms, MS and MS/MS spectra for authentic orotic 
acid and IEM urine sample 5 with retention time 0.66 min and mlz 155.0 
in negative mode. 
m1z 155.0 corresponds to the [M-H-1 ion of orotic acid and the 
ion at m1z 111.0 is due to a 
neutral lossC02 (44 Da) from the parent ion 
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The elevated organic acids detected for all five IIEM were methylmalonic acid for 
methyl malonic aciduria, isovalerylglycine and isovalery1carnitine for isovaleryl 
aciduria, homogentisic acid for alkaptonuria, mevalonolactone for mevalonic aciduria 
and orotic acid for orotic aciduria. These were checked on each of the negative and 
positive mode BPI chromatograms of all seven controls and it was confirmed that none 
of the above organic acids were detected in controls. 
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PCA analysis of UPLC-MS data from IEM samples and controls 
Negative mode 
To assess the distribution of samples of EEM and controls, a PCA model was initially 
constructed on all twelve samples using mean-centring, a technique which highlights 
the important discriminating variables. The PCA scores maps of the first two principal 
components (PC I/PC2) for the negative mode data (Figure 5.27 (A)) shows three out of 
five IEM separated from the control samples. These were isovaleryl aciduria JVG), 
ornithine transcarbarnylase defiency (OTC) and methylmalonic aciduria (MMA), 
particularly the urine sample of IVG, which was well separated out as an outlier. 
However, the urine sample of infant control (C 1, sample 6) also separated out from rest 
of the controls and clustered close to the sample OTC, which also from an infant. The 
PCI/PC2 loadings plot of this PCA model (Figure 5.28) showed that the separation of 
IVG was attributed to variation of isovalerylglycine (RT-nvz: 3.25 
- 
158) and both OTC 
and control I had lower hippurate. Removal of IVG and reprocessing of the data did not 
enhance the separation of any of the other IEM samples from the controls. 
Unit variance scaling was applied to the same data and another PCA model was 
constructed. The PCA scores maps for PCI/PC2 (Figure 5.27 (B)) shows that the 
control samples except the infant control I (sample 6) were clustered together whereas 
the IIEM samples with elevated concentrations of organic acids OTC, MMA, fVG and 
ALK were separated from the controls. However, the urine sample of MEV was not 
separated from the controls. Unlike mean centring, unit variance treats all variables with 
equal weights and therefore all metabolites were treated with equal emphasis, 
disregarding whether they were present in low or high concentrations. The PCI/PC2 
loading plot of the PCA model (data not shown) demonstrated that the separation of 
MMA and OTC was attributed to variation of biomarkers including methylmalonic acid 
(1.45_1 16.9) and orotic acid (0.63_155.0) respectively. No distinguishing variables 
could be observed for IVG and ALK. Figure 5.27(C) illustrated the PCI/PC2 scores 
map of negative mode unit variance data after removing the outlier MMA. This 
increased the separation of urine samples of OTC, IVG and ALK from the controls. 
However, the urine sample of MEV was not still well separated from the controls, and 
the infant control (C 1) was still well separated and closer to the OTC sample. 
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Figure 5.28: Loading plot of PC1 (X axis) versus PC2 (Y axis) negative mode UPLC-MS 
data (corresponding to Figure 5.27 (A)) of urine samples obtained from IEM patients and 
controls using mean centring. Separation is due to isovalerylglycine (3.25_158.0). 
Positive mode 
The PCA scores maps of first two principal components (PCI/PC2) using mean 
centring (Figure 5.29(A) showed that only the urine samples of IVG and OTC were well 
separated out from the controls. The PC I/PC2 loadings plot of the PCA model (Figure 
5.30) allowed that the separation of IVG and OTC, attributed to variation of 
isovalery1carnitine (3.50_246.1) and an unknown metabolite with nilz 555.0 (RT 3.65 
min) respectively. Removal of IVG and OTC and reprocessing the data did not further 
separate the IEM samples from controls. 
Another PCA model was built for the same data set using unit variance scaling and in 
Figure 5.29(B), four out of five DEM (OTC, IVG, ALK and MMA) were separated from 
the controls. However, the urine sample of mevalonic aciduria was still not separated 
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from the controls in the positive mode and the infant control (C I) was still an outlier 
from the remainder of the control group. 
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Figure 5.29: Score plots of principal component 1 (PC 1) (X axis) versus PC 2 (Y axis) for 
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5.5 Discussion 
Urine samples from five patients with IEM and age-matched controls were analysed in a 
blind fashion using both NMR spectroscopy and UPLC-MS analytical platforms. From 
the blind examination of urine samples from the patients with unknown IEM and 
controls using both 400 MHz and 800 MHz IH NMR spectroscopies and UPLC-MS, all 
five IEM were correctly identified as methylmalonic aciduria (MMA), alkaptonuria 
(ALK), isovaleric aciduria (IVG), mevalonic aciduria (MEV), and ornithine 
transcarbarnylase deficiency (OTC). 
5.5.1 Identification 
Methylmalonic aciduria (MMA) 
Methylmalonic aciduria is caused by a defect in the mitochondrial enzyme 
methylmalonyl-CoA-mutase which is involved in the metabolism of amino acids valine 
and isoleucine (Figure 5.3 1). This results in the accumulation of methylmalonic acid, 
elevated levels of which were easily observed by both 1H NMR spectroscopy and 
UPLC-MS. 
Isoleucine Valine 
Propionyl-CoA 
I 
y 
Methylmalonyl-CoA 
Methylmalonic acid 0ý < 
Succinyl-CoA 
Figure 5.31: Metabolic pathway of valine and isoleucine metabolism (Engelke et al., 2007a) 
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Mevalonic acidutia (MEV) 
Mevalonic aciduria is a defect in the biosynthesis of peroxisomal cholesterol, caused by 
a defiency of the enzyme mevalonate kinase, resulting in an accumulation of 
mevalonolactone and mevalonic acid in body fluids (Figure 5.32). Both IH NMR 
spectroscopy and UPLC-MS detected mevalonolactone in the urine sample obtained 
from the patient with mevalonic aciduria. The presence of mevalonic acid could not be 
confirmed due to lack of a standard. 
Mevalonate Mevalonolactone 
Mevalonate 
kinase 
> 
Mevalonate-5-phosp hate 
y 
Cholesterol 
Figure 5.32: Metabolic pathway of peroxisomal cholesterol metabolism (Engelke et al., 
2007a) 
Isovalefic aciduria (IVG) 
This is an autosomal recessive disorder, caused by a deficiency of isovaleryl coenzyme 
A dehydrogenase in the metabolism of the amino acid leucine, resulting in an elevated 
amount of isovalerylglycine (Figure 5.33), which was detected by both 1H NMR 
spectroscopy and UPLC-MS. Additionally a significant concentration of 
isovalery1carnitine was detected by UPLC-MS, which was not seen using NMR 
spectroscopy. This provides additional information or extra biomarker. 
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Figure 5.33: Metabolic pathway of leucine metabolism, adapted from (Engelke et al., 2007a) 
Alkaptonuria (ALK) 
Alkaptonuria is a defect in the catabolism of tyrosine, leading to accumulation of 
homogentisic acid in blood, resulting from the deficiency of the enzyme homogentisic 
acid oxidase (Figure 5.34). Both IH NMR spectroscopy and UPLC-MS detected 
homogentisic acid in the urine sample obtained from the patient with alkaptonuria. 
Tyrosine 
y 
4-OH-Phenylpyruvic acid 
4-OH-Phenylacetic acid 
4-OH-Phenyl lactic acid 
Homogentisic acid 
Homogentisic acid oxid-as--e, 
Maleylacetoacetic acid 
Figure 5.34: Metabolic pathway of tyrosine metabolism, adapted from (Engelke et al., 
2007a) 
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Ornithine transcarbamylase deficiency (OTC) 
Ornithine transcarbamylase deficiency (OTC) is a dominant X-linked inherited urea 
cycle disorder, caused by a deficiency of one of the enzymes in the urea cycle. OTC is 
one of six enzymes that play a role in the catabolism and removal of nitrogen from the 
body. The lack of the OTC enzyme results in excessive accumulation of nitrogen, in the 
form of ammonia (hyperammonemia), in the blood (Figure 5.35). Urea cycle 
metabolites such as orotic acid, uracil and uridine were detected by both 1H NMR and 
UPLC- MS. Ammonia is invisible in 1H NMR spectroscopy and was not detected in the 
MS mass range scanned nz/z 50- 1000. 
Orotic acid; Orotidine; Uracil; Uridine 
Jý 
Carbamoyl ýphosphate 
-, v-ýýOrnýithine 
ýtransýcarbaýmylasýe 
L-Omithine 
Urea 
L-Citrulline L-Aspartic acid 
L-Arginine Argininosuccinic acid 
ob 
Fumaric acid 
Figure 5.35: Metabolic pathway for urea formation, adapted from (Engelke et al., 2007a) 
5.5.2 Use of lH NMR spectroscopy for identification of IEM 
Reproducibility and robustness have allowed 1H NMR spectroscopy to become 
established as a principal analytical technique for metabonomics studies (Keun et al., 
2002c). Many complicated and rare inborn errors of metabolism in babies such as 2- 
hydroxyglutaric aciduria, dihydropyrimidine dehydrogenase deficiency and 
dihydropyrimidinase deficiency have been studied by 1H NMR spectroscopy (Holmes et 
al., 1997b, Wevers et al., 1997). Most of the studies involving the use of using human 
urine, the collection of which is non-invasive and thus samples are easily obtained. 
NMR instruments with magnetic field strength of 400 MHz are widely available for 
diagnosing IEM, although they might not be present in most hospitals and clinical 
laboratories. This was used for the initial blind study and all five IEM were correctly 
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identified through elevated concentrations of particular organic acids. Consultation with 
literature and comparison with 1H NMR of standards aided the identification of all these 
organic acids. PCA plots constructed from data acquired using 400 MHz IH NMR 
spectroscopy using both mean centring and unit variance scaling showed that IIEM 
samples of IIVG and MMA were separated from the controls. Additionally, the PCA plot 
using unit variance scaling also shows the urine sample of ALK to be well separated 
from rest of the samples. 
Visual inspection of spectra generated using 800 MHz 1H NMR spectroscopy showed 
similar peaks to the spectra obtained using conventional 400 MHz 1H NMR 
spectroscopy. Consultation with spectra obtained at 400 MHz with 1H NMR spectra of 
standard solutions along with 2D NMR spectroscopy experiments such as COSY, 
TOCSY, J-resolved and HSQC confirmed several of these resonances of IEM samples. 
However, the spectra acquired at 800 MHz showed higher spectral resolution with more 
resolved peaks as expected compared to 400 MHz. In order to extract the information 
from the PCA models for the different magnetic field strengths, scores and loadings 
were elucidated. Comparison of loadings for the different magnetic field strengths 
revealed that the higher spectral resolution with increasing magnetic field strength did 
not introduce any new metabolites in the PCA models based on the 800 MHz data. In 
contrast, the NMR variables which contributed to the loadings were independent of the 
magnetic field strengths. However, slight differences in the intensity of peaks were 
observed particularly for the elevated peaks of organic acids and other major 
metabolites. This probably explains why the PCA constructed from the data acquired on 
800 MHz showed a much clearer separation of all five IEM from the controls as 
compared to 400 MHz. The PCA plot constructed on data acquired using 800 MHz 
1H 
NMR spectroscopy for both mean centring and unit variance scaling showed that all 
five IEM and even the infant were separated out from the remainder of the controls. 
The PCA models for comparison of 400 MHz and 800 MHz frequencies for all 24 
samples showed that the urine sample pair of MMA (i. e. 400 MMA and 800 MMA) 
(Figure 5.14), which had the highest intensity of methyl malonic acid among other IEM, 
was an outlier when using mean centring and the pairs of IVG and ALK were well 
separated when using unit variance scaling. Magnetic field strength clearly plays an 
important role for the separation of pairs of EEM between 400 MHz and 800 
MHz 
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observation frequencies. Increasing field strength increases the spectral dispersion of the 
organic acid peaks for each IEM, with more resolved lines as expected in the 800 MHz 
1H NMR spectra as compared to 400 MHz for the same samples. 
5.5.3 Use of UPLC-MS for identification of IEM 
UPLC-MS has been successfully applied to the analysis of small molecules in biofluids 
(Stephanson et al., 2007). It reduces the experiment time as compared to other 
separation techniques without compromising analytical resolution and sensitivity, 
making it ideal for high throughput screening. It can offer complementary information 
to NMR spectroscopy and is rapidly becoming an important tool in metabonomics 
studies (Chan et al., 2007, Giri et al., 2007, Lu et al., 2006, Nordstrom et al., 2006, 
Plumb et al., 2005a, Plumb et al., 2006b, Wilson et al., 2005, Yin et al., 2006). Visual 
examination of the BPI chromatograms of urine sample of patients with IEM and age- 
matched controls showed differences in both positive and negative ionisation modes. 
The positive and negative chromatograms revealed complementary metabolite profile 
information for the same urine sample. One example from this study is the urine sample 
of IVG (sample 3). Negative mode MS shows the presence of isovalerylglycine which 
was also confirmed by the NMR and MS/MS spectra, whereas positive mode mass 
spectra and MS/MS spectra confirmed the presence of isovalerylcamitine in the urine 
sample. This is another marker for IVG and was not detected by NMR spectroscopy in 
this study. 
PCA models for both positive and negative modes showed that four out of five of the 
IEM were separated out from the rest of the samples. The MEV was not well separated, 
due in part to the poor ionisation of mevalonolactone. Additionally, the urine sample of 
OTC and its appropriate age-matched infant control (Cl) were clustered together in the 
PCA scores plots for both positive and negative modes due to similar UPLC-MS 
metabolite profiles. This was not seen in the PCA models constructed from both 400 
MHz and 800 MHz NMR spectroscopy indicating that a different set of metabolites 
dominated the UPLC-MS and NMR urine spectra. The separation of IEM from each of 
techniques is summarised in Table 5.5. 
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Visual analysis of both NMR spectra and positive and negative UPLC-MS 
chromatograms from the infant control showed a different biochemical profile as 
compared to the rest of controls. PCA score plots from both 1H NMR and UPLC-MS 
analysis also showed that the infant control (Cl) sample was separated from the rest of 
controls. The loading plot of NMR data showed that the separation of the infant control 
was attributed to relatively high in comparison with betaine levels. NMR spectra and 
positive mode NIS also confirmed that the urine sample of the infant control contained a 
higher amount of betaine as compared to the other controls (Davies et al., 1988). 
Additionally, the negative chromatogram showed prominent peaks, which were absent 
or low in other controls, at 3.84 min, 4.62 min and 5.51 min. The average mass spectra 
for these peaks shows, n-Llz 399.16, nilz 530.30 and Wz 510.26 respectively. There were 
likely to be bile acids, although no standards were available for confirmation (Eva et al., 
1989). 
Biomarkers identified by both 400 and 800 MHz 1H NMR spectroscopies for each IEM 
were elevated concentrations of methyl malonic acid for MMA, mevalonic acid and 
mevalonolactone for MEV, isovalerylglycine for IVG, homogentisic acid for ALK and 
orotic acid, uracil and uridine for OTC. Other typical urinary metabolites in both IEM 
and controls were hippurate, creatinine, creatine, p-cresol sulphate, TMA, TMAO, 
alanine, lactate, formate and DMG also identified by 1H NMR spectroscopy. 
Biomarkers identified by negative mode MS were methyl malonic acid for MMA, 
isovalerylglycine for IVG, homogentisic acid for ALK and orotic acid and uridine for 
OTC. In positive mode mevalonolactone for MEV and isovalery1carnitine for IVG were 
identified. Orotic acid and hippurate were detected in both modes. Additionally, 
negative mode MS showed a prominent peak at 4.08 min with m1z 187.03. This is likely 
to be p-cresol sulphate, which is a host-bacterial co-metabolite originating from 
clostridium difficile and other unidentified bugs (Dawson et al., 2008, Selmer et al., 
2001). 
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Table 5.5: Separation of IEM urine samples from controls using PCA analysis from both 
NMR and UPLC-MS techniques 
NMR UPLGMS 
PCA scaling 400 MHz 800 MHz Negative Positive 
mode mode 
Mean centring MMA MMA IVG IVG 
IVG IVG MMA 
ALK 
NIEV 
Unit variance MMA MMA MMA MMA 
IVG IVG IVG IVG 
ALK ALK ALK ALK 
MEV (), I 
Both NMR and UPLC-MS analytical platforms can be used for metabolic profiling 
offering complementary infon-nation. Urine sample preparation for both NMR and 
UPLC-MS is very simple with dilution of urine samples with water for UPLC-MS and 
addition of buffer and the internal standard (TSP) for NMR analysis. As UPLC has a 
shorter run time (12 min) compared to other chromatographic separation techniques 
such as conventional HPLC, both ID NMR and UPLC-MS techniques have almost 
same length of experimental time. This minimal sample preparation and shorter running 
time makes both analytical platforms ideal tools for future selective metabolic screening 
as compared to conventional GC-MS methods, as they can easily be adapted to large 
scale studies. Tandem mass spectrometry (MS/MS) can give additional metabolite 
structural information. However, structural identification of an unknown molecule by 
MS/MS alone can be difficult as compared to NMR spectroscopy, for which well 
established databases and literature are readily available. It should be noted that the 
capital cost of a high field NMR spectroscopy may limit the use of this technology, 
particularly in rural areas, but lower field NMR spectroscopy can give much valuable 
information as demonstrated in this chapter. In addition, some advanced MS 
instruments are expensive and require skilled operators, but can be worth the investment 
of time and training. 
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5.6 Conclusion 
All five IEM methyl malonic aciduria, isovaleric aciduria, mevalonic aciduria, ornithine 
transcarbarnylase deficiency and alkaptonuria were detected and identified correctly by 
both NMR and UPLC-MS analytical platforms. NMR and UPLC-MS analysis revealed 
complementary biochemical information urine samples of IEM and controls. Even 
though small numbers of samples employed there were age-matched controls, and the 
study was infon-nation rich from the metabonomic analysis using two platforms. This 
could be applied to larger sample set indicating more types of IEM. 
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Chapter 6: NMR Spectroscopy and UPLGMS 
Based Metabonomic Approaches for Detection of 
Urinary Metabolic Differences in Human 
Populations 
6.1 Summary 
The global aim of this study is to assess and compare the capability of 1H NMR and 
UPLC-MS technologies in extracting latent metabolite information from a subset of 
urine samples from a large human population which form part of the INTERSALT 
study. Initially, urine samples for this study obtained from 194 participants from nine 
countries were analysed by both 1H NMR spectroscopic and UPLC-MS technologies. 
Chemometric methods such as principal component analysis (PCA) and orthogonal 
projection to latent structure discriminant analysis (0-PLS-DA) were applied to selected 
populations in order to identify those metabolites responsible for characterising the 
different countries. Iceland showed a particularly distinctive metabolic profile, therefore, 
this study was repeated with a larger number of samples to identify urinary biomarkers 
which discriminate the most differentiated subgroup, the Iceland participants, from 
other populations. 
Aims and objectives 
To obtain urinary metabolites profiles and characterise each country/population 
using IH NMR spectroscopy. 
2 To assess the feasibility of applying an ultra performance liquid chromatography- 
mass spectrometry (UPLC-MS) based metabonomics approach to investigate the 
urinary metabolite profile differences between populations. 
3 To use chemometric analysis (PCA, O-PLS-DA) to generate pair-wise comparisons 
of selected populations in order to characterise population differences and to 
identify the metabolites associated with population differences. 
4 To further characterise metabolites associated with population differences using 
MS/MS. 
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6.2 Introduction 
6.2.1 INTERSALT study 
The INTERSALT (INTERnational study of SALT and blood pressure) study is a 
standardised international epidemiology study of the relationships of blood pressure. 
This study was designed to investigate the correlation between sodium, potassium and 
alcohol intake and body mass index across a 52 population-based sample set in 32 
countries, which resulted in the collection of urine samples from 10,079 men and 
women aged 20-59 years (Elliott et al., 1989, Rose et al., 1989, Stamler, 1997, Stamler 
et al., 1996). 
The INTERSALT study followed a standardised protocol with common field methods 
such as standardised questionnaires and examination methods, extensive quality control 
in all 52 centres and centralised training and certification of the researchers; thus the 
data are acceptably valid for cross-cultural comparisons. Associations between 24-hour 
urinary sodium and potassium excretion and blood pressure were examined within and 
across populations. Body mass index (BMI) and alcohol intake and their independent 
contribution to blood pressure were also investigated. A second collection of samples 
was obtained from a random 8% of participants about three weeks later to estimate 
within-person variability of sodium, potassium and nitrogen excretion and to correct for 
a regression dilution problem during the statistical analysis (Dyer et al., 1997, Elliott et 
al., 1989, Rose et al., 1989, Stamler, 1997, Stamler et al., 1996). 
By controlling for age, sex, and each of the other major variables such as BMI, alcohol 
use and 24 hrs urinary potassium excretion, the study found a significant positive 
association between urinary sodium excretion and systolic blood pressure (SBP) within 
populations. Conversely an inverse correlation between SBP and potassium intake was 
found. The findings also showed that BMI and heavy alcohol consumption have a 
significant and independent relationship to blood pressure. In cross-population 
comparisons, sodium excretion was significantly related to 
blood pressure with 
adjustment for multiple possible cofounders (Dyer et al., 1997, Elliott et al., 
1989, Rose 
et al., 1989, Stamler, 1997, Stamler et al., 1996). 
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INTERSALT within-person comparisons also showed an inverse association between 
education and blood pressure for many samples from world-wide centres. The findings 
showed that the lower the education of individuals, the greater was their 24 hour sodium 
excretion, alcohol excretion, BMI and the lower their potassium excretion. These four 
variables accounted significantly for the inverse relation between education and blood 
pressure (Stamler et al., 1996). 
For the purpose of this study ten diverse populations were chosen from nine countries 
around the world. These can be classified as western (Iceland, UK, USA (black and 
white), Italy and Colombia); eastern (India, Japan and China); and African (Zimbabwe) 
populations. Generally western countries have a higher fat diet and coffee and alcohol 
consumption as compared to eastern countries (Suh et al., 2001). Iceland and Japan have 
the strongest preference for fish and sea foods (Zhang et al., 2000) while America 
shows the strongest preference for red meat. Among westerners, Icelanders also have a 
high caffeine and nicotine intake (Perry et al., 1982). As for many African countries, a 
majority of Zimbabweans depend on staple foods which mainly derive either from 
cereals such as wheat, maize, or rice, or starchy root vegetables such as potatoes, taro, 
and cassava (Allain et al., 1997, Namazi, 2004). Indians have a high carbohydrate and 
low fat diet compared to the western diet (Ramachandran et al., 2003). 
6.2.2 Use of metabonomics in epidemiology studies 
The association between diet/nutrients and chronic diseases such as diabetes, 
cardiovascular disease and certain types of cancer have long been explored via 
epidemiological studies (Stamler et al., 1996). The advances in the-omics technologies 
(proteomics, genomics, and transcriptomics) are now enabling researchers to discover 
more about the interaction of diet and genome at molecular, cellular and systemic 
levels 
and to identify the ways in which individuals respond differently to 
different diets 
according to their genetic make-up. Nutrigenomics is an approach to nutrition and 
human health that examines the effect of genetic differences in individual response to 
diet with the aim of extrapolating how such subtle changes can affect 
human health 
(Elliott et al., 2002, Gorduza et al., 2008, Stover, 
2006). This is a new avenue for 
personalized healthcare and can be exploited via 
high-throughput 'omics' technologies 
to address important nutritional and health 
issues. 
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Metabonomics is a powerful approach for measuring changes in metabolic 
concentrations (metabolic profiling) in biofluids such as urine and plasma using either 
1H NMR spectroscopy (Nicholson et al., 2002, Nicholson et al., 1999) or mass 
spectrometry (Jonsson et al., 2005) and interpretation of these metabolite profiles can be 
often enhanced by pattern recognition techniques. A particular advantage of using 
biofluids for metabolic profiling is that they can be obtained non-invasively (urine) or 
minimally invasively (plasma) and can be applied on a large scale for metabolic 
phenotyping. 
Recent advances in both 1H NMR spectroscopy and liquid chromatography-mass 
spectrometry (LC-MS) have allowed improved detection of hundreds of low molecular 
weight species in complex mixtures such as urine and plasma (Jonsson et al., 2005). 
With the development of automated sample acquisitions, these methods can now be 
applied to generate endogenous metabolic profiles in large-scale human epidemiological 
studies (Dumas et al., 2006, Jonsson et al., 2005). The extremely information-rich data 
generated by these techniques, that provide large baseline or control data sets, offer 
great possibilities for improving the understanding of physiological and pathological 
states of human diseases, toxic responses and genetic modification. Application of this 
technology, in combination with chernometric and mathematical modelling, has been 
used to characterise a range of pathologies such as cardiovascular disease (Brindle et al., 
2002), inborn errors of metabolism (Engelke et al., 2007a), renal disease (Neild et al., 
1997), diabetes (Nicholson et al., 1984) and neurodegenerative conditions (Ghauri et al., 
1993a). 
A number of human population based studies such as UK Biobank (Palmer, 2007, 
Senior, 2006), Molecular Phenotyping to Accelerate Genomic Epidemiology 
(MolPAGE), LOndon LIfe sciences POPulation (LOLIPOP) (Griffin et al., 2006), 
European Prospective Investigation into Cancer and Nutrition (EPIC) (Riboli et al., 
2002) and INTERnational collaborative of MAcronutrients and blood Pressure 
(INTERMAP) (Stamler et al., 2003) have or are in the process of profiling metabolic 
patterns of small molecules in biological fluids in order to assess the metabolic 
differences caused by diet, lifestyle, genetic and environmental exposure. Metabonomic 
analysis of urine samples from a large human population study explored the 
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reproducibility and accuracy of the metabonomics methodology as well as variation in 
urinary metabolite profiles across populations (Barton et al., 2008, Dumas et al., 2006). 
This chapter assess the capability of 1H NMR spectroscopy and UPLC-MS technologies 
along with chemometric and pattern recognition methods for extracting latent biological 
information from a subset of population based study. 
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6.3 Methodology 
This initial scoping study was carried out with randomly selected 194 urine samples 
from nine countries (10 populations) using 20 samples per population (10 - male and 10 
- female) as shown in Table 6.1. However, the total number of samples for Colombia 
was 15 and Italy was 19 since only 5 male samples for Columbia and 9 male samples 
for Italy were available between the age of 25-35. The samples were analysed using 
both 'H NMR spectroscopy and UPLC-MS. 
Table 6.1: Demographics of urine samples of 194 participants from part of the 
INTERSALT study for initial 'H NMR and UPLC-MS analysis 
Continent Country City Age Male Female Total 
North America 
us Jackson - Black 25 to 35 10 10 20 
us Jackson - white 25 to 35 10 10 20 
South America Colombia Tuquerres 26 to 35 5 10 15 
Iceland Reykjavik 25 to 35 10 10 20 
Europe Italy Gubbio 25 to 35 9 10 19 
UK Birmingham 25 to 35 10 10 20 
Japan Tochigi 25 to 35 10 10 20 
Asia P. R. China Nanning 25 to 35 10 10 20 
India New Delhi 25 to 35 10 10 20 
Africa Zimbabwe Harare 25 to 35 10 10 20 
Total 94 100 194 
The data obtained from the unne samples of ten populations using both 
1H NMR 
spectroscopy and UPLC -MS were analysed by both unsupervised and supervised 
chemometric methods as shown in Figure 6.1 in order to identify those metabolites 
responsible for characterising people from the different countries. 
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H NMR analysis UPLC-MS analysis 
Exploratory analysis 
Unsupervised method - PCA 
Country separations estabilish country clustering patterns 
Discfiminant analysis 
SuDervised method - O-PLS-DA analvsis on selected DODUlation mirs 
Find biornarker candidates 
1H NMR data 
STOCSY analysis 
UPLC-MS data 
MS/MS analysis 
Identification of metabolites Identification and confirmation of 
metabolites by repeating with 
larger number of samples 
Figure 6.1: A flow diagram illustrating the method used for analysis of INTERSALT 
study urine samples 
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6.3.1 1H NMR analysis of INTERSALT urine samples 
1H NMR spectra of randomly selected 194 urine samples from nine countries (10 
populations) as shown in Table 6.1 were acquired. Additionally, a 1H NMR spectrum of 
an authentic solution of N-methylnicotinic acid was acquired in order to confirm the 
spectra of authentic metabolite postulated as biomarker which discriminates Iceland 
from the rest of samples. 
Experimental 
(a) Sample preparation 
Urine: Urine samples were prepared by mixing 240 [tl of a phosphate buffer solution 
(Appendix 2) with 460 [tI undiluted urine. The samples were then stored at -800C. On 
the day of the NMR experiment, samples were thawed and centrifuged at 16089 g for 
10 minutes, to separate any precipitates. Aliquots of 600 [LI of the resulting solution 
were added to 5 mm NMR tubes for subsequent analysis. 
Authentic N-methylnicotinic acid: AI mg/ml solution of N-methylnicotinic acid 
(NMNA) was prepared by dissolving the authentic compound in the phosphate buffer 
solution (Appendix 2). The pH of the samples was then adjusted to 7.4 using 0.1 M HCL 
Samples were prepared for NMR spectroscopic analysis by addition of 600 RI of the 
appropriate solutions to 5 mm NMR tube. 
(b) One-dimensional (ID) 'H NMR spectroscopy analysis 
Urine samples 
Urine samples were analysed at 300K using 1H NMR spectroscopy operating at 600.44 
MHz using a Bruker DRX-600 spectrometer. For each sample, 64 free induction decays 
(FlDs) were collected into 32k computer data points using a spectral width of 12019.23 
Hz, giving an acquisition time 1.36 s with an additional relaxation delay (RD) of 2 s. 
IH 
NMR spectra were acquired with suppression of the water resonance using a standard 
presaturation pulse sequence comprising (RD-90'-tl-90'-tm-90'-acquire FID (Bruker 
Biospin Germany) (Nicholson et al., 1995) where tI is a short delay of typically 2, us 
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and tm is a mixing time (100 ms). Irradiation of the water signal was achieved during 
tm and RD. The summed FIDs were multiplied by an exponential weighting function 
corresponding to a line broadening of 1 .0 
Hz prior to Fourier transformation. Baseline 
correction and phasing of the spectra was achieved with in-house software (courtesy Dr. 
T. M. D. Ebbels, and Dr. H. Keun, Imperial College, London) and internally referenced 
to trimethylsilyl-2,2,3,3-tetradeuteropropionic acid (TSP, 8H 0.00) using XWINNMR 
software (Bruker, Germany). 
Authentic solution of N-methylnicotinic acid 
A 1H NMR spectrum of the standard solution was acquired on a Bruker DRX 600 
spectrometer (60OMHz 1H frequency) at 298K using a standard presaturation pulse 
program for water suppression (Nicholson et al., 1995). Following 8 dummy scans, 64 
FIDs were acquired and each of the spectra was collected into 32k data points with a 
total spectral width of 9615.385 Hz. Prior to FT, the FIDs were multiplied by an 
exponential function corresponding to a line broadening 1.0 Hz. 
Data analysis of 'H NMR spectroscopy 
(a) Data pre-processing 
The 1H NMR spectra of urine samples measured at 600 MHz were reduced to 901 
intensity variables, calculated by integrating regions of equal width (0.01 ppm) 
corresponding to the chemical shift range 0.5 - 9.5 using software written in house 
(courtesy Dr. T. M. D. Ebbels, Imperial College, London) in Matlab R2007b from 
MathWorks, USA. The regions 8H4.4-6.1 were eliminated to remove spurious effects 
due to variability of the water suppression. The reduced data were then normalised 
using the probabilistic quotient normalisation method (Dieterle et al., 2006) to 
minimise the effects of variation in urine concentrations across the samples, using the 
method described in Chapter 2, section 2.2.1. 
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(b) Data analysis 
An unsupervised chemometric method Principal Component Analysis (PCA) and a 
supervised method Orthogonal Projections to Latent Structure Discriminant Analysis 
(O-PLS-DA) were applied as shown in Figure 6.1 to selected populations in order to 
extrapolate and identify the metabolites responsible for country differences. 
Initially, the unsupervised method of principal component analysis (PCA) was used to 
construct models that allowed selection of the distinct outliers and gave an overview of 
the 'clustering' trends within the multivariate data set. PCA was performed using 
SIMCA-P (version 11.5; Umetfics, Sweden) and employed mean centring and unit 
variance scaling. Initially, PCA was performed on mean centred data without scaling to 
assess the distribution of urine samples between populations. Unit variance scaling, that 
allows equal weighting of all variables, was then applied to the same mean centred data 
matrix. 
Supervised orthogonal projection to latent structures discriminant analysis (OPLS-DA) 
(see Chapter 2, section 2.2.2) was then applied to the data matrix to reduce the 
classification-irrelevant variation from data matrix and improve the interpretability of 
the spectral variation between classes. The 1H NMR spectra data were again reduced to 
9001 intensity variables, calculated by integrating regions of equal width (0.00 1 ppm) in 
order to obtain better resolution of spectra that will directly aid identification. The 
regions 6H4.4-6.1 were eliminated to remove spurious effects due to variability of the 
water suppression. The reduced data were then normalised using the probabilistic 
quotient normalisation method (Dieterle et al., 2006) to minimise the effects of 
variation in urine concentrations across the samples, using the method described in 
Chapter 2, section 2.2.1. The loadings coefficients were unit variance scaled. All 0- 
PLS-DA models were constructed using one predictive component and two orthogonal 
components. The variance explained by the model based on the Y matrix (R 
2 Y) and the 
validation parameter Q2 was calculated using 7-fold cross validation method in order to 
prevent over fitting of spectra data. 
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6.3.2 UPLC-MS analysis of urine samples 
The randomly selected 194 urine samples from nine countries (10 populations) as 
shown in Table 6.1 were also analysed by UPLC-MS. Mass spectrometry experiments 
were performed in both positive and negative ionisation modes. 
Reproducibility: A random urine sample from Japan was injected every twenty 
injections throughout the experiment with a total of 9 repeat injections in order to examine 
the reproducibility of the UPLC-MS system. 
Experimental 
(a) Sample preparation 
A 50 gl aliquot of each urine sample was added to 150 gl of H20 tOmake the total 
volume 200 ýtl. The samples were centrifuged at 16089 g for 10 minutes to remove 
particulates. 180 gl of diluted urine was transferred into 96-well plates for analysis. 
(b) Chromatographic conditions 
Chromatographic separations were performed on a Waters 2.1 mm x 100 mm 
ACQUITYTm 1.79M C18BEH column maintained at 40 'C. The samples were placed in 
an autosampler and maintained at 4 'C prior to injection of 2 [tl on to the column. 
Reversed phase chromatography conditions were employed using a 12 min gradient 
with mobile phase A 0.1 % formic acid (FA) in water and mobile phase B being 0.1 % 
FA in acetonitrile (ACN) as described in Chapter 3, section 3.3. The gradient conditions 
are shown in Table 6.2. 
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Table 6.2: UPLC gradient conditions for 0.1 % formic acid in water (mobile phase A) and acetonitrile (mobile phase B) for 12 min run 
Time (min) Mobile phase A 
(H20 + 0.1 % FA) 
Mobile phase B 
(ACN + 0.1 % 
FA) 
0.0 100 0 
1.0 85 15 
3.0 50 50 
6.0 5 95 
9.9 5 95 
10.1 100 0 
(c) Mass spectrometry conditions 
Initially, electrospray ionisation (ESI) mass spectrometry experiments were performed 
on a LCT Premier (Waters, USA) operated in both positive and negative modes. The 
LCT was operated in W optics mode with 12 000 resolution using dynamic range 
extension (DRE). The mass spectrometer was calibrated across the mass range 100- 
1000 Da using a solution of sodium formate. All analyses were acquired using the lock 
spray to ensure accuracy and reproducibility where 250 pg/ýtL leucine-enkephalin in 
H20ACN (50: 50) was used as the lock mass with a flow rate of 30 gUmin. Data were 
collected in centroid mode, the lockspray frequency was set at 5 s, and data were 
averaged over 10 scans. The MS conditions for analysing urine samples in both modes 
are shown in Table 6.3. 
Table 6.3: NIS conditions for analysing samples of standards and urines in both negative 
and positive ESI modes using Micromass LCT Premier (Waters, USA) 
Parameters Negative mode Positive mode 
Capillary voltage (kV) 2.8 3.2 
Cone voltage (V) 35 30 
Desolvation gas (L/hr) 900 959 
Desolvation gas temperature( C) 350 350 
Cone gas (L/hr) 10 30 
Cone gas temperature (C) 100 120 
Data acquisition rate (s) I I 
Interscan delay (s) 0.1 0.1 
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Data analysis of UPLC-MS 
(a) Data pre-processing 
The acquired data were pre-processed using Markerlynx software (Waters) (See Chapter 
2, section 2.2.1). The data were normalised to the summed total peak height. The 
resulting two dimensional data (intensity, retention time/mass to charge ratio (nzlz_RT 
pairs)) were exported into SIN4CA-P (version 11.5; Umetrics, Sweden) software as a 
"markers table" for further chernometric analysis. Data acquired between retention time 
of 0.4 to 8 min were used, with the gradient employed in this study, as most urinary 
metabolites have a retention time (RT) less than 7 mins. 
(b) Data analysis 
As with 1HNMR data, the pattern recognition strategy was carried out in two steps. 
Initially, principal component analysis (PCA) was performed on the intensities of the 
retention time/mass to charge ratio pairs using mean centring and unit variance scaling. 
Subsequently, the intensity data (based on retention time/mass to charge ratio pairs) 
from SIMCA (version 11.5; Umetrics, Sweden) were then exported into Matlab R2007b 
for OPLS-DA analysis (See Chapter 2). All O-PLS-DA models were constructed using 
one predictive component and one orthogonal component. The variance explained by 
the model based on Y matrix (R 2 Y) and the validation parameter Q2 was calculated 
using 7-fold cross validation method in order to prevent over fitting of spectra data. 
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6.3.3 Validation and characterisation of urinary biomarkers 
From the UPLC-MS analysis of the scoping study of the randomly selected 194 urine 
samples, the Iceland samples showed the greatest discrimination from other populations. 
Therefore, in order to calculate the proportion of urine samples with metabolites which 
discriminated Iceland participants from the remaining populations and to identify those 
metabolites, the UPLC-MS analysis was repeated with a larger number of samples for 
each population, including participants between the age 25 -60 years as shown in Table 
6.4. This took the total of Icelandic participants to 100, while other countries had 40 
participants. 
Table 6.4: Urine samples of 420 participants from part of the INTERSALT study for 
repeated UPLC-MS analysis 
Continent Country City Samples 
A i 
us Jackson -Black 20 North mer ca us Jackson - white 20 
South America Colombia Tuquerres 40 
Iceland Reykjavik 100 
Europe Italy Gubbio 40 
UK Birmingham 40 
Japan Tochigi 40 
Asia P. R. China Nanning 40 
India New Delhi 40 
Africa Zimbawe Harare 40 
Total 420 
Experimental 
(a) Sample Preparation 
For MS and MS/MS analysis of this larger sample set, urine samples were diluted 
slightly differently to the previous analysis, resulting in more concentrated samples. 
This was to increase the amount of lower abundance metabolites. A 70gl aliquot of each 
urine sample was added to 130 gl of H20 tOmake the total volume 200 gl. 
The samples 
were centrifuged at 16089 g for 10 minutes to remove particulates. 
200 gI of diluted 
urine was transferred into 96 well plates for analysis 
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(b) Chromatographic conditions 
Chromatographic separations were performed on a Waters 2.1 mm x 100 mm 
ACQU, TyTM 1.7 9M C18 BEH column maintained at 40 'C. The samples were 
maintained at 4 *C prior to injection of 5 [tl on to the column. Reversed phase 
chromatography conditions were employed using a 12 min gradient with mobile phase 
A 0.1% formic acid (FA) in water and mobile phase B being 0.1% FA in acetonitrile 
(ACN). The gradient conditions are shown in Table 6.2. 
(c) Mass spectrometry conditions 
ESI mass spectrometry experiments were performed on a Micromass Q-toflm Premier 
(Waters, USA) operated in both positive and negative modes. The micromass Q-tof TM 
was operated in W optics mode with 12000 resolution using dynamic range extension 
(DRE). The mass spectrometer was calibrated across the mass range of 100-1000 Da 
using a solution of sodium formate. All analyses were acquired using the lock spray to 
ensure accuracy and reproducibility where 200 pg/gL leucine-enkephalin in H20: ACN 
(50: 50) was used as the lock mass with a flow rate of 30 gL/min. Data were collected in 
centroid mode, the lockspray frequency was set at 5 s, and data were averaged over 10 
scans. 
In order to identify the urinary biomarkers which discriminated Icelandic participants 
from other populations, tandem mass spectrometry (MS/MS) experiments were 
performed on the same Micromass Q-Tof"m Premier operated in negative mode. The 
MS and MS/MS conditions for analysing urine samples in both modes are shown in 
Table 6.5. 
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Table 6.5: MS and MS/MS conditions for analysing urine samples in both negative and 
positive ESI modes using Micromass Q-Tof TM Premier (Waters, USA) 
Parameters Negative mode Positive mode 
Capillary voltage (kV) 2.4 3.2 
Cone voltage (V) 35 35 
Desolvation gas (L/hr) 900 900 
Desolvation gas temperature C) 350 350 
Cone gas (L/hr) 0 0 
Cone gas temperature C) 120 120 
Data acquisition rate (s) 1 1 
Interscan delay (s) 0.1 0.1 
Collision energy for MS/MS (V) 25 - 
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6.4 Results 
6.4.1 1H NMR analysis of urine samples 
Exploratory analysis 
Principal component analysis (PCA),, was performed on mean-centred 1H NMR data 
from all nine countries (ten populations) to overview the effects of changes in 
resonances of metabolites on the separation of urine samples. Mean-centring centres the 
data so that variations due to large systematic changes can be easily assessed The mean- 
centred data set examined by PCA analysis revealed four distinct outliers as shown in 
Figure 6.2. The loadings plot, along with visual inspection of the corresponding 1H 
NMR spectra, clearly showed peaks from ethanol or its metabolites (8H 1.18,8H L 19,8H 
1.2,80.6660.67) from alcohol consumption. These four outliers were removed for 
the rest of the chemometric analysis. 
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Figure 6.2: Principal component analysis (PCA) of mean- centred 'H NMR data of 194 
urine samples from nine countries (A) scores map; data coloured according to country (B) 
loadings map. Four outliers due to ethanol metabolites were subsequently removed 
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(a) PCA analysis of mean-centred data 
PCA models were then constructed using mean centred data after removing the outliers 
to assess the separation between populations (Figure 6.3). The scores plot for the first 
two principal components (PCI/PC2) for mean-centred data, conferring the maximum 
variation between groups, shows a clear but incomplete separation of Iceland, USA and 
Chinese populations from the rest of populations (6.3 (A)). The loadings plot (Figure 
6.3 (B)) for the mean-centred data shows that the separation of participants from Iceland 
from China was attributed mainly to a variation in the level of hippurate and a 
metabolite with a resonance0f 6H4.445. The separation of USA samples was attributed 
largely to the variation in the level of creatinine. 
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Figure 6.3: Principal component analysis (PCA) of urine 
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countries after removal of four outliers samples containing ethanol (A) scores map using 
mean centring; 'H NMR data coloured according to country (B) loadings map of mean- 
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The circled resonance at 4.445 was determined to be N-methyinicotittic acid (NMNA) using STOCSY analysis 
In order to identify the metabolite that gave a 1H NMR peak at 8H 4.445 which 
discriminates Iceland from the rest of the samples, a STOCSY calculation (see Chapter 
2, section 2.2.2 for background information) was performed for the 1H NMR data from 
the Icelandic population. STOCSY analysis (see Chapter 2, section 2.2.2) takes 
advantage of the linear correlation between all peak intensities for a given molecule 
across a set of spectra and displays the correlation behaviour among the intensities of 
the various peaks of molecules. Figure 6.4 shows a one dimensional NMR loadings plot 
based on an O-PLS analysis for the resonance at 8H 4.445, indicating a strong 
correlation to the resonances at 6H 9.199 6H 8.87,6H 8.10 and the resonances of 
hippurate at 8H 3.97,6H 7.55,8H 7.64 and 8H 7.84. Consultation with the literature and a 
IH NMR spectrum of a standard solution confirmed that the unknown was N- 
methylnicotinic acid (NMNA or Trigonelline) with resonances at 8H 9.199 6H 8.87,8H 
8.10 and 81-l 4.444. 
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Figure 6A One dimensional STOCSY analysis of Iceland population for the selected 
variable at 4.445ppm. The degree of correlation across the spectrum has 
been colour 
coded and projected on the spectrum that has the maximum for this variable. 
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(b) PCA analysis of unit variance (UV) scaled data 
Unit variance scaling, was applied to the same mean-centred IH NMR data from all nine 
countries (ten populations) and another PCA model was constructed as shown in Figure 
6.5. Unlike mean centring, unit variance confers equal weights on all variables and 
therefore all metabolites are treated with equal emphasis irrespective of whether they are 
present in low or high concentrations. This is important because often low concentration 
variables can have a large biological contribution. The PCA scores map for the first two 
principal components showed clear separation of Iceland and China from other populations. 
However, the individuals of US population were scattered and showed no clear separation 
with unit variance scaling. It was difficult to identify metabolites which discriminated 
Iceland and China from the rest of populations from the loadings plot since unit variance 
(UV) scaling gives equal emphasis to all variables which makes the interpretation of 
changes in biomarkers difficult (loadings plot not shown). The supervised method, 0- 
PLS-DA, was used to identify metabolites which discriminated Iceland and China from 
the remaining countries and will be discussed in the next section 
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Figure 6.5: The scores map of PCA of urine 'H NMR urine data from nine countries after 
removal of four outliers samples containing ethanol using unit variance scaling. 
Additionally, a pair-wise PCA comparison was carried out between participants from 
Iceland and from China. Figures 6.6 (A) and 6.6 (C) of mean centred and UV scaled 
data respectively, show a clear separation between those two populations in the 
first 
component. The loadings plot of the mean centred data given in Figure 
6.6(B) shows 
ým 
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that the separation of participants from Iceland and from China was mainly attributed to 
higher urinary excretion of creatinine, hippurate and NMNA. 
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Figure 6.6: Principal component analysis of urine 1H NMR data of Iceland and China 
after removal of outliers samples containing ethanol (A) scores map using mean centring; 
1H NMR data coloured according to country (B) loadings map of mean-centred 1H NMR 
data (C) scores map using unit variance scaling. 
210 
ter 6 
Discriminant analysis of 1H NMR data 
The PCA of unit variance scaled 1H NMR data from all countries (Figure 6.5) showed 
that Iceland and China separated from the remaining overlapping seven countries. The 
metabolic phenotypes which separated the remaining seven countries could not be 
distinguished in the first two components. In order to investigate the variation of 
individuals of Iceland and China from the non-distinct populations in terms of 
metabolic phenotype, a supervised pattern recognition method, which maximises the 
separation between countries, was used. The O-PLS-DA method was applied to IH 
NMR data to remove variation in X (NMR spectra variables) which was orthogonal 
(unrelated) to Y (countries/populations). Figures 6.7 and 6.8 show the O-PLS-DA 
models of urinary IH NMR data from Iceland versus all other countries and China 
versus all other countries respectively. The O-PLS-DA model analysed for Iceland vs. 
all other countries described 74.37% of variation in the class variable Y matrix ((R 2y = 
74.37%) with a predictive value of 51.22% using the cross validation parameter (Q2y = 
51.22%), which indicates that the model is not overfitted. Figure 6.7 (a) shows the 
cross-validated score plot of urinary 1H NMR data from Iceland versus all other 
countries and a slight separation was achieved between Iceland and all other countries. 
The O-PLS-DA loadings for the discrimination of Iceland and other countries are 
presented in Figure 6.7 (b). The colour scale corresponds to the variable weights and 
allows for the identification of significant metabolites for the discrimination. As with 
the result of PCA and STOCSY analysis, the O-PLS-DA coefficients plot of hippurate 
and N-methylnicotinic acid (Figure 6.7(b)) also indicate that the highest concentrations 
of these metabolites are found in the urine samples from Iceland and these metabolites 
are highly significant for the discrimination of Iceland from other populations. 
The O-PLS-DA model calculated for China versus all other countries explained 76.68% 
of the variance within the Y matrix with a predictive value of 52.96%. The cross- 
validated scores plot for urinary 1H NMR data from China versus all other countries 
(Figure 6.8) shows a good separation between China and all other countries with only a 
slight overlap between the two groups. The O-PLS-DA loadings for the discrimination 
of China and other countries (Figure 6.8 (b)) shows the metabolites alanine, glutamine, 
taurine and unknown metabolites at 8H 2.78 (singlet), 8H 2.81 (singlet), 8H 2.83 
(singlet), many resonances between 8H 3.0 and8H 3.20,8H6.87 (doublet) and8H6.9 
211 
Chapter 6 
(doublet) are found in higher concentrations in urine samples of China and these 
metabolites are highly significant for the discrimination of China from other populations. 
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Figure 6.8: O-PLS model for the discrimination of IH NMR urine spectra of China versus 
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Comparison of geographical populations 
Pair-wise O-PLS-DA was carried out between Iceland and the UK, a similar 
geographical and environmental western country and between China and Japan, a 
similar geographical and environmental eastern country, to identify biomarkers which 
specifically discfiminated Iceland and China. 
Iceland vs. UK: The O-PLS-DA model explained 91.58% of the variance within the Y 
matrix with a predictive value of 51.42%. Figure 6.9 (a) shows the cross-validated score 
plot of urinary 1H NMR data from Iceland and the UK. Separation was still achieved 
between Iceland and UX with a slight overlap between the two groups. The O-PLS-DA 
coefficients plot shows that hippurate and N-methylnicotinic acid and unknown 
metabolites at 8H 2.04 and 8H8.52 were highly significant for the discrimination of 
Iceland and UX as shown in Figure 6.9 (b). 
China vs. Japan: The O-PLS-DA model described 93.74% of the variance within the Y 
matrix with a predictive value of 71.74%. The cross-validated scores plot of urinary 1H 
NMR data from China and Japan (a similar geographical and environmental eastern 
country) also showed a good clear separation as shown in Figure 6.10 (a). In the O-PLS- 
DA coefficients plot (Figure 6.10 (b), the upper half of the plot represents metabolites 
increased in the urine samples of China whereas the lower half represents metabolites 
decreased in intensity. On the analysis of the O-PLS-DA coefficients plot, the 
discriminatory metabolites responsible for differentiation of participants of China from 
participants of Japan were revealed to be elevated levels of dimethylamine (DMA) and 
unknown metabolites at5H2.1 ppm, 8H6.87 (doublet) and 8H6.9 (doublet), 8H 1.80 and 
8H3.2. 
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6.4.2 UPLC-MS analYsis of urine samples 
Exploratory analysis of UPLC-MS data 
UPLC-MS was used initially to analyse the population subset containing 194 randomly 
selected urine samples from nine countries (as shown in Table 6.1) in order to identify 
those metabolites responsible for characterising people from the different countries. An 
unsupervised method principal component analysis (PCA) was performed on both 
negative and positive ESI mode UPLC-MS data of these urine samples to in order to 
assess the separation between population phenotypes related to country of origin. 
Initially, PCA was performed on negative mode data using mean-centring, a scaling 
technique which is more sensitive to variables with largest variance contribution. The result 
is shown in Figure 6.11 (A) and 6.11 (B) respectively. Figure 6.11 (A) illustrates the scores 
plot of the first two components (PCI and PC2) with a few outliers and no clear separation 
between populations. The loadings plot (Figure 6.11 (B)) shows the masses that cause 
separation of outliers from the rest of the samples, these were attributed to the variation of 
variables with nz/z 263.1022(3.26 min), nz/z 345.1545(3.56 min) and nVz 331.1531(4.93 
min). 
The PCA analysis of the unit variance (UV) scaled data was performed in order to 
assess the separation between populations. As with 1H NMR spectra analysis (6.4.1), 
the PC I /PC2 scores plot (Figure 6.11 (Q) shows the urine samples of Iceland and China 
were clearly separated from the rest of populations, even though there was a slight 
overlap between China and other populations. It was very difficult to identify variables 
(mass to charge ratio/ retention time couples (mlz-RT pairs)) which discriminated 
Iceland from the rest of populations from the loadings plot since UV scaling gives equal 
emphasis to all variables which makes the interpretation of changes in biomarkers 
difficult (Loadings plot not shown). The unsupervised method PCA and the supervised 
method O-PLS-DA were used to identify metabolites which discriminated Iceland and 
China from the remaining countries. 
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PCA models of positive mode data using both mean centring and mean centring with 
unit variance scaling methods did not show any clear separations between populations 
(data not shown). 
Reproducibility: One important factor in the chromatographic analysis is the 
reproducibility of the system. The reproducibility of the chromatographic system was tested 
with nine repeat injections of the same urine sample injected every twenty injections 
throughout the experiment. The PCI/PC2 scores plot (Figure 6.11(Q) shows that these 
samples are tightly clustered, indicating good reproducibility 
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PCA analysis of Iceland vs. China 
Subsequently, a pair-wise PCA comparison was carried out between participants from 
Iceland and China in order to examine the biomarkers which discriminate these two 
populations. Figure 6.12 shows a clear separation between these two populations using 
both mean centred (Figure 6.12 (a)) and unit variance scaling data (Figure 6.12 (c)). UV 
scaling data showed better separation between these two populations compared to mean 
centred data with the separation occurring in the first component. The loadings plot 
(Figure 6.12 (B)) for mean centred data shows that the separation of Iceland from China 
was attributed to the variation of unknown variables with the biomarkers with nzlz_RT 
pairs of 495.224.46 and 263.1023.26. 
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Visual comparison of these negative mode base peak intensity (BPI) chromatograms 
showed a significant difference in the metabolite profile of Iceland and China. Figure 
6.13 shows representative negative mode BPI chromatograms for urine samples of 
Iceland and China. BPI chromatograms plot the greatest intensity at each scan and 
exhibit a greater apparent resolution and signal-to-noise. In particular, the BPI 
chromatogram of the participant from Iceland shows prominent peaks at 1.24,1.59,2.84, 
3.47,4.19 and 4.46 mins, which were not present or were significantly lower in the urine 
sample of participant from China. The average mass spectra of these peaks showed 
prominent ions at nz/z 324-0806, nz/z 181.0556, nVz 313.0625, "Vz 150.0737 and nilz 495-22 
respectively. 
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Figure 6.13: Comparison of Negative mode Base Peak Intensity (BPI) chromatograms 
between 0.4 -7 min for urine samples of participant from Iceland and china. 
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Comparison by geographical region 
Additionally, PCA was performed on urinary negative mode UPLC-MS data from the 
western countries US, UK, Italy, Colombia and Iceland only using unit variance scaling. 
Figure 6.14 shows that participants from US and UK were scattered and participants 
from Colombia and Italy overlapped with participants from US and UK. However, 
participants from Iceland were clearly separated from the rest of western countries. 
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Figure 6.14: PCA scores map of urine UPLC-MS data of western countries Colombia, 
Iceland, Italy, USA and UK using unit variance scaling; UPLC-MS data coloured 
according to country. Iceland separated out clearly from rest of the western countries 
Another PCA model was constructed on urinary negative mode UPLC-MS data from 
the eastern countries China, Japan and India only using unit variance scaling as shown 
in Figure 6.15. All three eastern countries were differentiated from each other. 
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Figure 6.15: PCA scores map of urine UPLC-MS data of eastern countries India, Japan 
and China using unit variance scaling; UPLC-MS data coloured according to country. All 
three countries clearly separated 
Discriminant analysis of UPLC-MS data 
The supervised method O-PLS-DA was also applied to negative mode UPLC-MS data 
in order to identify biomarkers which discriminate Iceland and China from other 
populations. Figure 6.16 shows the O-PLS-DA plot for Iceland versus all other 
countries whilst Figure 6.17 shows the O-PLS-DA plot for China versus all other 
countries. The constructed O-PLS-DA model for Iceland versus all other countries 
described 62.89% of the variance within the Y matrix (R 2 Y) with a predictive value 
(Q2y) of 45.86%, this indicates that the model is not over fitted. The O-PLS-DA model 
for China versus all other countries explained 58.08% variation in the Y matrix with the 
predictive value of 35.87%. The most significant biomarkers with nzlz-RT pairs that 
discriminate Iceland and China from other populations were shown in Tables 6.6 and 
6.7 respectively. 
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Figure 6.16: O-PLS model for the discrimination of UPLC-MS data of Iceland versus all 
other countries, the signal orientation indicates the higher (positive orientation) or lower 
(negative orientation) concentration of metabolites with respect to Iceland. The colour bar 
corresponds to the weight of the corresponding variable in the discrimination between 
Iceland and all other populations (R 2y: 62.89%, Q2y: 45.86%) 
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Figure 6.17: O-PLS model for the discrimination of UPLC-MS data of China versus all 
other countries, the signal orientation indicates the higher (positive orientation) or lower 
(negative orientation) concentration of metabolites with respect to China. The colour bar 
corresponds to the weight of the corresponding variable in the discrimination between 
China and all other populations (R'Y: 58.08%, Q2y: 35.87%) 
Additionally, a pair-wise O-PLS-DA was performed on Iceland vs. selected populations 
to identify biomarkers which discriminate Iceland from other populations. The O-PLS- 
DA plot for Iceland versus UK is shown in Figure 6.18. The O-PLS-DA model 
described 74.79% of the variance within the Y class matrix with a predictive value of 
40.22%. The same biomarkers, which discriminates Iceland versus all other countries, 
with n? lz_RT pairs (Table 6.6) were also the most significant for the discrimination of 
Iceland from UK, despite Iceland and UK being ethnically and geographically similar 
western populations. 
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Figure 6.18: O-PLS model for the discrimination of UPLC-MS data of Iceland and UK, 
the signal orientation indicates the higher (positive orientation) or lower (negative 
orientation) concentration of metabolites with respect to Iceland. The colour bar 
corresponds to the weight of the corresponding variable in the discrimination between 
Iceland and all other populations (R 2y: 74.79%, Q2y: 40.22%) 
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Table 6.6: Mass to charge ratio/retention time couples of positive correlation from O-PLS- DA analysis for discriminating ions for Iceland from other countries and UK (Green - common biomarkers discriminate Iceland from both other countries and UK, black - biomarkers only discriminate Iceland from other countries, blue - biomarkers only discriminate Iceland from UK) 
Monoisotopic Mass in Negative Mode Retention time 
187.1318 4.05 
281-1132 3.67 
282.1157 (isotope of 281.113-1) 3.65 
317.0317 2.76 
319.1902 4.20 
321.1931 3.86 
335.2213 4.74 
337.0949 0.36 
349.1925 3.61 
495.2219 4.19 and 4.46 
496.226 (isotope of'495.2219) 4.17 
505.2638 4.58 
511.2604 4.79 
512.2588 (isotope of 511.2604) 4.74 
Table 6.7: Retention time/mass to charge ratio couples of positive correlation from O-PLS- 
DA analysis for discriminating ions for China from remaining countries 
Monoisotopic Mass in Negative Mode 
_Retention 
time 
187.3769 3.34 
209.0795 4.14 
293.9855 0 5.68 
373.132 3.75 
405.2619 5.54 
407.2786 5.18 
428.1101 4.14 
Visual analysis for variables (the highlighted ni/z-RT pairs from Table 6.6) which 
discriminate Iceland from both all countries and UK was also carried out. Figure 6.19 
shows the extracted ion chromatograms (EICs) of participants from Iceland and China 
for ions with nz/z 495.2 and n? lz 511.2. The EIC of Iceland for nVz 495.2 shows three 
prominent peaks at 3.76,4.19 and 4.46 mins which were absent in the urine sample 
from China. The O-PLS-DA analysis for both Iceland vs. the remaining countries 
(Figure 6.16), and Iceland vs. UK (Figure 6.18) revealed two out of these three peaks 
(RT at 4.19 and 4.46) were significant for the discrimination. For nilz 511.2, the 
extracted ion chromatogram of Iceland illustrated prominent peaks at 3.27,3.63,4.74 
and 5.39 mins, all of which except the peak with RT at 5.39 mins were absent in the 
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urine sample from China. The O-PLS models for both Iceland vs. remaining countries 
(Figure 6.17) and Iceland vs. UK (Figure 6.18) also show the peak at RT 4.74 which 
was significant for the discrimination. These were investigated further by MS/MS as 
described in the next section. 
Visual analysis of biomarkers which discriminated China from all countries (Tables 6.7) 
was also carried out (chromatograms not shown). The variables which discriminated 
China from remaining countries were also present in urine samples of Iceland but at 
much lower concentrations. In this study, only the unique variables which separated 
Iceland from the rest of the populations were further investigated with the aim of 
identification of biomarkers shown in Table 6.6 (the highlighted nt, /z-RT pairs). 
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Figure 6.19: Extracted ion chromatograms of urine samples of participant from Iceland 
and china for (A) at m1z 495.2 and (B) at m1z 511.2 
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6.4.3 Validation and characterisation of urinary biomarkers 
The UPLC-MS analysis was repeated with a larger number of samples for each 
population (a total of 420 samples including 100 urine samples from Iceland and 40 
urine samples from each of remaining eight countries) as shown in Table 6.4, to identify 
urinary biomarkers which discriminated Iceland participants from other populations. 
Validation of unknown metabolites 
Figure 6.20 shows the median intensity value of ions nz/z 495.2 and mlz 511.2 for all 
countries. There were three prominent peaks for nWz 495.2 as shown in Figure 6.20. The 
retention times of these peaks were shifted by 0.6 mins for each peak since the repeated 
experiment was carried out on a differentC 18 column. The histogram showed Iceland 
samples contained higher intensities of these ions compared to other countries. 
Additionally, other western countries Colombia, Italy, UK, and US also contained these 
peaks but at lower levels. These peaks were completely absent in the eastern countries 
of China, Japan and India. Only the ion of nVz 511.2 was present in the urine samples of 
participants from Zimbabwe. Therefore these were potential biomarkers which 
discriminated Iceland from other populations 
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Figure 6.20: Bar chart of mean intensity values of m1z 495.2 and m1z 511.2 for all nine 
countries 
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Characterisation of unknown metabolites in urine samples from 
Iceland 
MS/MS experiments were also carried on these two unknown biomarkers (shown in 
bold in Table 6.6). MS/MS fragmentation data for nilz 495.2 and nilz 511.2 are shown in 
Figure 6.21. Both nilz 495.2 and n-Vz 511.2 showed similar fragmentation patterns, 
particularly the loss of nilz 176, giving 319.2 and 335.2 respectively and fragmentation 
ions at n-b1z 113.0 and nVz 175.0, which is likely due to the presence of a glucuronide 
(Little et al., 2004). Coupled with the fact that they have similar retention times, it is 
likely that these two compounds are related. 
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Figure 6.21: MS/MS spectra of a urine sample of Iceland with m1z 495.2 and m1z 511.2 
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To further characterise these metabolites, an extensive database and literature search 
was carried out for nVz 495.2 ± 0.1 (molecular weight (MW) 496.2) and nVz 511.2 ± 0.1 
(MW 512.2) and several compounds were found to be potential matches (Table 6.8). As 
the most likely possibility was that these compounds were glucuronides, the Human 
metabolome database (http: //www. hmdb. ca) was searched using "I/z 319.2 ± O. I(MW 
320.2) and nilz 335 ± 0.1 (MW 336.2). 
Glucuronidated Arachidonic acid metabolites: Glucuronidated metabolites of 
arachidonic acid were strong candidates as shown in Table 6.8. These are hydroxyl- 
eicosatetraenoic acids (HETE) (Wz 319.2), epoxy-eicosatetraenoic acids (EET) (nilz 
319.2) and dihydroxyl-eicosatetraenoic acids (diHETE) (Wz 335.20). The HETEs, 
EETs and diHETEs can be hydroxylated in one of several positions giving numerous 
potential isomeric matches (Little et al., 2004, Turgeon et al., 2003). Leukotriene B4 
(LTB4) and prostaglandin BI (PGBI) are also possible candidates for nilz 335.2. No 
standards of these glucuronides were available commercially for comparison. 
Coffee bean metabolite: Another possibility for nVz 495.2 is the glucuronide of 2-P- 
hydroxy-15-oxo-atractylan-4-carboxylic acid (Griffiths et al., 2001). This metabolite is 
an isomer of atractyligenine, which is the aglycone of atractylosides isolated from 
coffee (Cofea arabia) beans. No standard of this compound was available 
commercially for comparison. 
Steroid metabolites pregnandiol and pregnantriol: The third possibility is that these 
metabolites are the deprotonated molecules of endogenous steroid hormone metabolites; 
the glucuronides of pregnandiol (nzlz 495.2) and pregnantriol (nilz 511.2) (Griffiths et al., 
2001) are common in urine of both males and females. No standard of this compound 
was available commercially for comparison. 
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Table 6.8: Data base and literature search for possible biomarkers which discriminate Iceland from other countries 
m1z 495.2 m1z 511.2 
hydroxyleicosatetraenoic acid dihydroxyl-eicosatetraenoic 
(HETE)-glucuronide acid(diHETE)- glucuronide 
CH COCH 
"Y 0 
0 
1- 
CH OOCH 
CH 0 
CH CH 
epoxy-eicosatetraenoic acids (EET 
Leukotriene B4 (LTB4)- 
glucuronide glucuronide 
Arachidonic 
acid 
0 
COOH 
-ý4 
HD 
COOH 
0H CH 0 
metabolite 
OH CH 
glucuronides Prostaglandin B1 (PGB1)- 
glucuronide 
H0 
H3C(H2C)l, 
JH 
H 
H 
2-p-hydroxy-15-oxo-atractylan-4- 
carboxylic acid glucuronide 
Coffee bean 
metabolite COOH 
glucuronide OH 
0 0( 0 
0 C 0 
OH COOH 
Pregnandiol glucuronide Pregnantriol glucuronide 
Steroid OH 
OH 
OH 
metabolites 
glucuronides 
COOH 
7 
COOH 
17 
I 
0 
OH 
0 
OH 
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6.5 Discussion 
Urine samples from nine countries (10 populations) from around the world were 
analysed using both NMR spectroscopy and UPLC-MS analytical platforms. 
Chernometric methods such as principal component analysis (PCA) and orthogonal 
projection to latent structure discriminant analysis (0-PLS-DA) were applied to both 1H 
NMR and UPLC-MS data matrices in order to extrapolate and identify the metabolites 
responsible for country differences. 
Both the unsupervised method PCA and the supervised method O-PLS-DA of 1H NMR 
data showed that hippurate and N-methylnicotinic acid were found in higher 
concentrations in urine samples from Iceland and these metabolites were highly 
significant for the discrimination of Iceland from the rest of the populations. The 
application of STOCSY analysis aided the elucidation of the identity of the metabolite 
N-methylnicotinic acid in the urine samples of Icelanders. 
Dietary changes can influence the biochemical composition of urine (Bollard et al., 
2005b, Gavaghan et al., 2001, Griffin et al., 2000, Phipps et al., 1998). The literature 
shows that dietary changes alter the amount of hippurate and other metabolites excreted 
in urine for different natural diets (Gavaghan et al., 2001). Variation in the composition 
of diet and distribution of microfloral populations results in the attribution of the 
balance of metabolites composition in biofluids (Phipps et al., 1998). The study by 
Phipps et al. showed that the changes in the diet alter the amount of hippurate and 
chlorogenic acid metabolites such as m-hydroxyphenylpropionic acid excreted in the 
unne. 
The PCA model of 1H NMR data shows that variation in the creatinine level contributed 
to the discrimination of China from rest of populations where as the O-PLS-DA model 
shows that metabolites alanine, glutamine, taurine and unknown metabolites at 8H2.78 
(singlet), 6H2.81 (singlet), 8H2.83 (singlet), many resonances between8H 3.0 and8H 
3.20,8H 6.87 (doublet) and 8H 6.9 (doublet) were highly significant for the 
discrimination of China from rest of the populations. Excretion of urinary creatinine is 
generally considered to be quite constant. However, the other factors such as high 
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amount of protein and exercise will be contributing variables for creatinine (Hoogwerf 
et al., 1986). 
PCA score plots of negative mode UPLC-MS data for both samples of all participants 
and samples of western countries such as US, UK, Italy and Iceland showed a clear 
separation of Iceland from the rest of populations. O-PLS-DA analysis of both Iceland 
versus all other countries and a pair wise comparison of Iceland with another similar life 
style western country, the UK showed that the biomarkers with nz/z_RT pairs of 
281.11323.67,282.11573.65,317.03172.76,319.1902 
- 
4.20,321.19313.86, 
335.22134.74,495.22194.19,496.2264.17,505.2638_4.58,511.2604 
- 
4.79 and 
512.25884.74 were also the most significant for the discrimination of Iceland from the 
rest of populations. These could be arachidonic acid metabolite glucuronides (Little et 
al., 2004, Turgeon et al., 2003). Possible dietary origins for metabolites of arachidonic 
acid are meat, eggs and dairy products (Vanden Heuvel, 2004). 
The second possibility for m1z 495.2221 was 2-p-hydroxy-15-oxo-atractylan-4- 
carboxylic acid glucuronide which is the aglycone of atractylosides isolated from coffee 
(Cofea arabia) beans. The 1H NMR data analysis also shows that N-methylnicotinic 
acid was found in higher concentrations in urine samples from Iceland and this 
metabolite was highly significant for the discrimination of Iceland from rest of the 
populations. N-methylnicotinic acid is one of the constituents of coffee (Stennert et al., 
1994, Wu et al., 1997). The bar chart of mean intensity values of nzlz 495.2 and mlz 
511.2 for all nine countries (Figure 6.18) shows that urine samples of Iceland contained 
higher intensities of these ions compared to other countries. Additionally, urine samples 
of other western countries Colombia, Italy, UK, and US also contained these peaks. 
These were absent in the eastern countries China, Japan and India. The statistical 
analysis of the average weight of coffee consumed (Kg) annually by each person in each 
country, obtained from International Coffee Organisation is shown in Table 6.9. This 
survey also shows that Icelanders were the highest coffee drinkers and Chinese were the 
lowest drinkers between 1975 to 1985, when these samples were collected for 
INTERSALT study. 
The third possibility is that these metabolites are glucuronides of pregnandiol (nilz 495.2) 
and pregnantriol (nVz 511.2) (Griffiths et al., 2001). Even though these steroids are 
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higher in pregnant women, they were present in men's urine in average amounts 
equalling to 1-2 mg/24 hrs (Cox et al., 1953). 
Although the O-PLS-DA models from NMR data is more robust than the O-PLS-DA 
models of UPLC-MS based on the higher Q2y values of NMR data, the loadings plots 
of both NMR and UPLC-MS data revealed complementary biochemical information of 
urine samples of Iceland and China. 
Both NMR spectroscopy and UPLC-MS analyses of urine samples provided 
complementary nutritional/dietary metabolite information about the subsets of 
INTERSALT populations, particularly Iceland, which separated from the rest of the 
populations due to hippurate, NMNA and metabolites with nzlz 495.2 and nilz 511.2. 
These later two metabolites were potentially dietary in origin. These technologies may 
have a potential in human nutrigenomics by linking the metabolome database to 
phenotype databases and identifying association with various diet regimes, leading to 
personalised therapeutic approaches implemented by tailoring dietary metabolites to the 
individuals' genetic background. 
Future work is required to identify the metabolites with nzlz 495.2 and nzlz 511.2 using 
different hyphenated techniques such as LC-NMR and LC-NMR-MS, by providing 
extra information for identification of unknown metabolites. Fourier transform-mass 
spectrometry (FT-MS) can be of use to characterize metabolites in complex mixtures 
with high sensitivity because of its very high mass resolving power and mass accuracy. 
ffigher mass accuracy generates lower numbers of possible empirical formula, aiding 
the identification of unknown metabolites. Also MS' experiments on an ion trap can 
reveal further fragmentation of complex molecules, which could aid in identification of 
these unknown biomarkers. 
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Table 6.9: The average weight of coffee consumed (Kg) annually by each person in each 
country, obtained from international coffee organisation 
1985 1984 1983 1982 1981 1980 1979 1978 1977 1976 1975 
Cotintry 
China 0 0 0 0 0 0 0 0 0 0 0 
Colombia 3.8 3.4 3.2 3.8 3.8 3.1 3.8 3.6 3.4 3.2 3.2 
Iceland 11.7 10.2 10.3 11.4 11.1 11.1 12.1 9.5 8.9 9.8 11 
India 0 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 
Italy 15 3.9 4.4 4.3 4 3.9 4 3.5 3.3 3.8 3.7 
Japan 2.1 2 1.9 1.8 1.7 1.7 1.7 1 1.3 1.4 1.1 
United Kingdom 2.5 2.7 2.4 2.4 2.6 2.1 2.7 1.9 1.7 2.1 2 
United States 4.7 4.5 
. 
4.3 
. 
4.5 4.3 4.7 5.2 4.9 3.9 5.5 5.6_ 
Zimbabwe 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 
6.6 Conclusion 
The analytical technologies of 1H NMR and UPLC-MS were successfully applied to 
extract latent metabolite information from subset of urine samples from a human 
population which forms part of the INTERSALT study. Chemometric methods such as 
principal component analysis (PCA) and orthogonal projection to latent structure 
discriminant analysis (0-PLS-DA) were applied in order to identify the biomarkers 
which discriminate Iceland from remaining populations. Results from bigger subset of 
urine samples of Iceland were same as the small subset. Therefore, the results 
from this 
scoping study will serve as useful information for human population studies 
in future 
epidemiology studies. 
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Chapter 7: General Discussion, Conclusions and 
Future Directions 
7.1 General discussion 
The overall goal of this thesis was to explore and evaluate the ability of both 1H NMR 
spectroscopy (a well established technique) and the relatively recent addition of UPLC- 
MS in order to maximise the extraction of meaningful biochemical information from 
metabonomic investigations, based on urine metabolite profiles derived from animal 
models of toxicity and from both human epidemiological and inborn errors of 
metabolism studies. 
The strategy of the thesis is discussed in the following order 
1. Development of a UPLC-MS bioanalytical method for profiling urinary organic 
acids 
2. Validation of this method for quantification of organic acids in human urine. 
3. Application of this method to detect organic acids and other classes of 
compounds in urine. 
4. Evaluation of 1H NMR spectroscopy in investigating subtle metabolic changes in 
urine in acid-base as well as caloric restriction studies. 
5. Comparison of IH NMR spectroscopy and UPLC-MS applicability in a clinical 
setting. 
Comparison of 1H NMR spectroscopy and UPLC-MS in the analysis of a large 
population study, i. e. in describing more subtle differences between populations in 
urinary metabolic profiles.. 
This work evaluated urine rather than other biofluids because collection is non-invasive 
and provides adequate sample volume. Urine is produced by the kidneys, which play a 
key role in the maintenance of body homeostasis by excreting unwanted metabolites 
and electrolytes. The composition of urine is complex and varies extremely both 
between species and within species according to lifestyle, the diet being a major factor 
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(Saude, 2007). Thus, urine analysis is enormously diagnostically important since the 
composition of urine is altered in order to maintain the homeostasis of a vast array of 
tissues and organs and it reflects a large number of biochemical processes taking place 
both in the kidneys and other organs in the body. 
Liquid chromatography- mass spectrometry (LC-MS) is one of the analytical techniques 
used in the metabolic profiling of biofluids. The combination of reverse-phase packing 
material with a particle size of 1.7 ýtm and the UPLC chromatographic system 
functioning at high pressure has enabled a remarkable increase in the performance of 
chromatographic separation of lower weight molecules in complex mixtures (Plumb, 
2006). UPLC has higher resolving power compared to conventional HPLC methods, 
resulting in narrower peaks, improved in signal-to-noise, increased peak capacity and 
thereby increased detection of peaks over a shorter time. Additionally, electrospray 
ionisation (ESI) MS is extensively used in metabolic profiling studies since it offers 
many benefits, these comprise higher sensitivity and reproducibility, plus it is easily 
coupled to HPLC or UPLC and has superior quantitation capabilities over other 
ionisation methods. UPLC-MS is thus a complementary technique to NMR 
spectroscopy (Lenz et al., 2007a) and has been used to detect phenotypic and other 
physiological differences such as age, gender and diurnal variation in rats (Plumb et al., 
2005a, Plumb et al., 2006a), analysis of endogenous and exogenous metabolites in 
human serum (Nordstrom et al., 2006) and in a metabonomics study of intestinal 
fistulas (Yin et al., 2006). 
Organic acids are key metabolites used in many of the fundamental metabolic processes 
of the body to generate cellular energy and to provide the building blocks necessary for 
cell function. Chapter 3 described the development and optimisation of a bioanalytical 
method for profiling urinary organic acids using UPLC-MS. An initial study was carried 
out on reference solutions for eighteen selected organic acids which are typical urine 
metabolites. These organic acids encompass a range of structures including simple 
molecules, longer chain molecules, unsaturated molecules and molecules with aromatic 
rings. The same chromatography and mass spectrometry conditions used for the 
reference compounds were then applied to analyse control urine samples after spiking 
with organic acids. The retention time of each organic acid spiked in the urine shifted 
only slightly (maximum 0.08 min) to its standard solution, confirming that overall 
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retention times of selected organic acids were unaffected by matrix effects. The 
developed method was also validated for the quantification of organic acids in human 
urine by evaluating the fundamental parameters of accuracy, precision, matrix effects, 
selectivity and reproducibility as required by the FDA (FDA, 2001). 
Three organic acids methylinalonate, adipate and cis-aconitate were selected, one from 
each category of simple, longer and unsaturated molecules respectively in order to 
assess whether different types of molecule behaved differently under the chosen 
conditions. The calibration curves for each organic acid were linear over the 
concentration range of 10-50 ýtg/ml in both standards and in spiked urine samples with 
different concentration levels. This method passed the FDA validation criteria for 
adipate and cis-aconitate and partially passed for methylmalonate since it shows an error 
higher than 15% in one of the control urine samples. The quantification of these 
metabolites were not significantly affected by matrix effects since the calculated ion 
suppression or enhancement values ranged from 0.3% to 17.2%. with most 
concentration levels less than 15%. which is the cut-off value of the validation criteria 
required by the FDA (FDA, 2001). Additionally., this method showed a good analytical 
reproducibility with repeated analysis of control urine samples, confirming that the 
analytical variation was much smaller than the detected normal physiological variation 
in urine composition of controls. 
The bioanalytical method developed for profiling urinary organic acids was rapid, 
reproducible, reliable and sensitive with respect to the analysis of both hydrophilic and 
hydrophobic metabolites in urine. Although this was optimised for the profiling of 
urinary organic acids, which all eluted in less than 5 mins, the UPLC gradient was 
ramped to a higher percentage of organic solvent over the total time of 12 mins. Thus, 
this method was also used to detect other classes of metabolites apart from organic acids 
in clinical urine samples of patients with unidentified inborn errors of metabolism (IIEM) 
(Chapter 5) and was also used for untargeted metabolic profiling of urine in both 
clinical samples of patients with IIEM and samples from a large human population study, 
INTERSALT. 
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Changes in organic acids, particularly the TCA cycle intermediates citrate, 2- 
oxoglutarate, succinate and furnarate and many other metabolites have been observed 
with numerous types of toxicity including liver (Beckwith-Hall et al., 1998, Bollard et 
al., 2005a, Yap et al., 2006), renal (Gartland et al., 1989) and reproductive organs 
(Nicholson et al., 1989a, Yamamoto et al., 2007). The observed changes in these 
metabolites are related to target organ toxicity. However, inducing high-dose toxicity 
also results in reduced food intake, which is often not reported in toxicology studies. 
The changes of energy metabolism metabolites due to reduced food intake thus may 
correlate with organ toxicity. In Chapter 4, temporal changes in the metabolite 
composition of urine were characterised using 1H NMR spectroscopy in order to 
distinguish the possible confounding physiological effects caused by intervention due to 
metabolic effects of metabolic alkalosis, metabolic acidosis and caloric restriction. 
In all three studies, urinary excretion profiles showed temporal changes in the 
concentration of the TCA cycle intermediates citrate, 2-oxoglutarate, succinate and 
fumarate as well as of other metabolites including hippurate, N-methylnicotinic acid 
(NMNA), N-methyl nicotinamide (NMND) and trans-aconitate. Treatment with 
NaHC03 caused metabolic alkalosis and induced an increase in the excretion rate of the 
TCA cycle intermediates citrate, 2-oxoglutarate, furnarate and succinate, whereas 
treatment with NH4Cl induced metabolic acidosis and showed the opposite effect. 
Caloric restriction elicited a similar effect to that of metabolic acidosis in terms of 
changes in the levels of TCA cycle intermediates, although the urinary pH remained 
stable at a range of 7-7.5. Hippurate, trans-aconitate and NMNA were significantly 
affected by caloric restriction but were not changed with metabolic acidosis or alkalosis, 
suggesting that these metabolites are independent of the effects of metabolic acidosis 
and alkalosis but dependent on the dietary intake. Hippurate is the product of glycine 
conjugation with benzoic acid and the excretion levels of hippurate in the urine are 
highly variable, due to alterations in the gut microbial contents as a result of changes in 
diet (Bollard et al., 2001, Phipps et al., 1998). NMNA is a product of nicotinic acid 
metabolism and also a dietary constituent (Sandhu et al., 1981). The excretion profiles 
of hippurate and NMNA from the metabolic acidosis and alkalosis as well as the caloric 
restriction studies also confirmed that the concentration changes of these metabolites 
could be due to dietary intake. The NMND concentration was not systematically altered 
under any of the three intervention tests and therefore any changes observed in the 
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urinary levels of this metabolite are more likely to relate directly to a toxic effect. The 
application of 1H NMR spectroscopy along with the calculation of urinary excretion 
profiles of metabolites is a useful tool for evaluating metabolic perturbation during 
metabolic alkalosis, metabolic acidosis as well as caloric restriction and can be used to 
investigate the interaction between dose effects and temporal changes in future 
toxicology studies. 
The feasibility of applying the developed UPLC-MS based metabonomics method for 
profiling organic acids approach was initially assessed by using a small study in which 
clinical urine samples from patients with inborn errors of metabolism and age-matched 
controls were assessed for abnormal levels of urinary metabolites, mainly organic acids. 
Both 1H NMR spectroscopy and UPLC-MS were used to characterise metabolic profiles 
of patients with EEMs. Initially the investigation was carried out using the widely 
available standard observation frequency of 400 MHz for 1H NMR spectroscopy 
without any prior knowledge of the diagnosis. All five IIEMs were correctly identified 
through elevated concentrations of particular organic acids such as methylmalonic acid 
for methylmalonic aciduria (MMA), hornogentisic acid for alkaptonuria (ALK), 
isovalerylglycine for isovaleric aciduria (IVG), mevalonic acid for mevalonic aciduria 
(MEV), and orotic acid, uridine and uracil for ornithine transcarbarnylase deficiency 
(OTC). Other typical urinary metabolites detected in both fEM and controls were 
hippurate, creatinine, creatine, p-cresol sulphate, TMA, TMAO, alanine, lactate, 
formate and DMG. Subsequently, the same urine samples of patients with IEM were 
analysed by both 800 MHz 1H NMR spectroscopy and UPLC-MS in order to compare 
the metabolic profiles of urine samples from patients with EEM and controls. Visual 
inspection of spectra generated using 800 MHz 1H NMR spectroscopy showed similar 
peaks to the spectra obtained using conventional 400 MHz 
1H NMR spectroscopy. 
However, increased field strength increased the spectral dispersion of the organic acid 
peaks for each EEM as expected, with more resolved lines becoming visible in the 800 
MHz 1H NMR spectra as compared to 400 MHz for the same samples. The application 
of 800 MHz 1H NMR spectroscopy therefore could facilitate the structural elucidation 
of complex biornolecules in biofluids. 
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From the UPLC-MS analysis, four of the IEM samples were identified using negative 
mode ionisation. They were methylmalonic acid for MMA, isovalerylglycine for IVG, 
homogentisic acid for ALK and orotic acid and uridine for OTC. In positive mode 
ionisation, mevalonolactone for mevalonic aciduria MEV and isovalerylcarnitine, which 
is another marker for IVG, and which had not been detected by NMR spectroscopy in 
this study, were identified. Orotic acid and hippurate were detected in both modes. 
Additionally, negative mode NIS showed a prominent peak at 4.08 min with m/z 187.03. 
This is likely to be p-cresol sulphate, which is a host-bacterial co-metabolite originating 
from Clostridium difficile and other unidentified bugs (Dawson et al., 2008, Selmer et 
al., 2001). The NMR and UPLC-MS revealed complementary biochemical and 
metabolic pathway information of urine samples of IIEM and controls since 
isovalery1carnitine was only detected by UPLC-MS and mevalonolactone did not ionise 
well in UPLC-MS, but it was easily detected by 1H NMR spectroscopy. Urine sample 
preparation for both NMR and UPLC-MS analytical techniques is very simple with 
dilution with water for UPLC-MS and buffer and addition of the internal standard (TSP) 
for NMR analysis, with almost same length of experimental time. Thus, they are 
capable of high throughput biofluid analysis and could be applicable to large scale 
studies. However, UPLC-MS is more sensitive than NMR spectroscopy and the tandem 
mass spectrometry (MS/MS) experiments of UPLC-MS can give additional structural 
information of fragments of molecules of interest. Therefore, they can be used as 
complementary techniques. 
Visual analysis of both NMR spectra and positive and negative UPLC-MS 
chromatograms not only show the distinct difference between disease and controls but 
also show the difference in the biochemical profiles between controls due to age. The 
NMR spectra, UPLC-MS chromatograms and PCA scores plots revealed that the infant 
control had a different biochemical profile from the rest of controls. The PC loading 
plot of NMR data and positive mode MS showed that the separation of the 
infant 
control was attributed to a variation in betaine levels. Additionally, the 
UPLC-MS 
negative chromatogram showed prominent peaks, which were absent or 
low in other 
controls that were likely to be attributable to bile acids, although no standards were 
available at the time for confirmation. Both analytical techniques can provide additional 
information of biochemical profiles of control urine samples due to the physiological 
variations. 
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Chapter 6 extends the initial work developed from the IEM study and explores the 
capability of 1H NMR and UPLC-MS technologies in extracting latent metabolite 
information from a larger number of samples, consisting of a subset of urine samples 
from a large human population that formed part of the INTERSALT study. Urine 
samples from 194 participants from nine different countries were analysed by both 1H 
NMR and UPLC-MS technologies. Exploratory analysis was carried out on datasets 
acquired using both 1H NMR spectroscopy and UPLC-MS using unsupervised PCA 
analysis. The scores plot of 1H NMR spectral data showed that urine samples from 
Icelandic and Chinese participants formed separate clusters from the rest of the 
populations. The loadings plot showed that hippurate and NMNA were highly 
significant for the discrimination of Iceland whereas the China demonstrated greater 
variation in the levels of creatinine/creatine compared to other populations. 
Discriminant analysis was carried out to characterise the biochemical features that 
distinguished China and Iceland from the other populations. A supervised orthogonal 
projection on latent structure discriminant analysis (0-PLS-DA) method was applied to 
1H NMR data to remove variation in the NMR spectra variables that unrelated to the 
countries/populations. The coefficient plot confirmed that hippurate and N- 
methylnicotinic acid were found in higher concentrations in urine samples from Iceland 
and these metabolites were highly significant for the discrimination of Iceland from the 
rest of the populations. Application of statistical total correlation spectroscopy 
(STOCSY) analysis, which generates a pseudo-two-dimensional NMR spectrum that 
displays the correlation behaviour among the intensities of the various peaks of 
molecules, aided the elucidation of the identity of the metabolite N-methylnicotinic acid 
in the urine samples of Icelanders. The O-PLS-DA coefficients plot showed that the 
discrimination of China from rest of populations was due to the metabolites alanine, 
glutamine, taurine and unknown metabolites with NMR peaks at 8H2.78 (singlet),, 8H 
2.81 (singlet), SH2.83 (singlet) and several unassigned resonances between 8H3.0 and 
8H3.2O, 8H6.87 (doublet) and 8H6.9 (doublet). 
Levels of creatinine/creatine in urine are also related to variable consumption of 
products such as meat and fish (Bingham, 1985). A number of publications revealed the 
Chinese and Japanese populations tend to have higher levels of taurine which is rich 
in 
seafood including fresh water fish (Yamori et al., 2001, Zhao et al., 1998). Both alanine 
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and glutamine are found in protein-fich foods such as meat, poultry, fish, eggs, and 
some plants. 
From UPLC-MS analysis, the PCA score plots of negative mode MS data showed a 
clear separation of Iceland from the rest of populations. The O-PLS-DA analysis of 
both Iceland versus all other countries and a pair-wise comparison of Iceland with 
another similar life style western country, the UK, showed several signals to be 
significant for the discrimination of Iceland from the rest of populations. These signals 
were absent in the eastern countries of China, Japan and India. An extensive literature 
and database search of urinary metabolites indicated that these biomarkers were likely 
to be either (i) arachidonic acid metabolite glucuronides (Little et al., 2004, Turgeon et 
al., 2003) from possible dietary origins such as meat, eggs and dairy products or (ii) the 
glucuronide of aglycone of atractylosides isolated from coffee (Cofea arabia) beans 
(Griffiths et al., 2001) or (iii) glucuronide steroids of pregnanediol (nz/z 495.2) and 
pregnanetriol (Wz 511.2), which is a common steroid seen in both male and female 
urine (Griffiths et al., 2001). The statistical analysis of the average weight of coffee 
consumed (kg) annually by each person in each country, obtained from International 
Coffee Organisation (Table 5.9. ) shows that Icelanders were the highest coffee drinkers 
whilst Chinese drank the least for the period between 1975 to 1985, when the urine 
samples were collected for the INTERSALT study. No authentic samples of these 
compounds were available commercially for comparison and the synthesis of these 
compounds would be very expensive and/or time consuming. These biomarkers could 
not be identified in 1H NMR spectroscopy analysis due to their low abundance. 
However, structural identification of these unknown molecules by UPLC-MS and 
MS/MS alone can be difficult as compared to NMR spectroscopy because of the 
lack of 
readily available established databases and literature. High revolution 
MS approaches 
such as FIF-MS could be useful in further characterisation of these unknown metabolites. 
UPLC-MS analysis was repeated with a larger number of samples 
for each population 
in order to calculate the proportion of urine samples with metabolites which 
discriminated Iceland from remaining populations. Results from this large subset of 
urine samples of Iceland confirmed the findings from the small subset, as a 
higher 
proportion of urine samples from the Iceland population (> 
80%) still contained these 
biomarkers than other countries. 
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Both NMR spectroscopy and UPLC-MS analytical techniques provided complementary 
metabolite profile information and this will make the technology useable/robust for 
characterising human diseases in terms of urine and plasma metabolites and also for 
scale-up to larger human epidemiological studies. Other applications of these 
technologies could include nutritional studies and evaluation of the effects of 
interactions between diet, exercise, drugs and stress in life style studies. However, 
metabonomics has some potential disadvantages with regard to these instruments., 
including the need to use multiple instruments with different sensitivities, dynamic 
ranges and metabolite detection ability and the resulting complexity of datasets. This 
can be expensive and requires skilled operators. The data analysis can be time 
consuming and requires trained chemometricians. However, datasets from multiple 
analytical platforms could be integrated using more advanced chemometrics 
methodologies to maximise the infon-nation obtained from these technologies. 
Metabonomics can also be integrated with other -omics datasets such as proteomics, 
transcriptornics to enhance understanding and interpretation. 
Utility of chemometfic techniques 
In all investigations, the unsupervised PCA analysis was used as exploratory analysis of 
datasets in order to overview the 'clustering' trends due to the effects of changes in 
resonances (NMR spectroscopy) or nVz-RT pairs (UPLC-MS) of metabolites on the 
separation of urine samples. The data sets were analysed by mean-centring and applying 
unit variance (UV) scaling for the same mean-centred data. Mean-centring the data 
highlights the effects of major variables, thus it was suitable for the separation of 
samples with IIEM from the controls. UV scaling gives equal weight to all variables, 
treating all variables with equal emphasis irrespective of whether they are present in low 
or high concentrations. The UV scaling was therefore more suitable for the separation of 
urine samples of human population from nine countries. Overall the PCA analysis is a 
good method for the initial analysis of looking at the separation of groups and to 
distinguish any outliers from the datasets. 
Application of principal component analysis (PCA) to the data acquired from different 
magnetic field strengths and different analytical platforms showed that four out of 
five 
IEMs were separated from the data acquired using 400 MHz 
1H NMR data, whereas 
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with 800 MHz NMR, all five IEMs were separated. Comparison of the PC loadings for 
the different magnetic field strengths revealed that the higher spectral resolution with 
increasing magnetic field strength did not introduce any new metabolites as key 
discriminators in the PCA models based on the 800 MHz data. UPLC-MS analysis for 
both positive and negative modes shows that four out of five of the IEM were separated 
out. The cause of MEV was not well separated, due in part to the poor ionisation of 
mevalonolactone. 
Although the UV scaling shows better separation of urine samples of populations 
between countries, it is very difficult to interpret the metabolites which are significant 
for the separation between populations since it gives equal weight to all variables. The 
supervised O-PLS-DA analysis maximises separation between countries and aids in 
distinguishing the metabolites which are significant for the separation of populations by 
removing the variation in X (NMR spectra/ NIS spectra variables) which was orthogonal 
(unrelated) to Y (countries/populations). Thus, this would be a better supervised 
chemometric method as compared to projections to latent structure by means of partial 
least squares - discriminant analysis (PLS-DA) to investigate the metabolites which are 
significant for the separation between groups. 
Although other peak picking software for UPLC-MS are available, the UPLC-MS built- 
in software MarkerLynx was a good choice for analysing the datasets since the analysis 
of UPLC-MS data showed the similar separation to that seen using NMR data. 
Complementary biomarker information was obtained to NMR spectroscopy for the 
same samples, again confirming the utility of combining the two platforms. 
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7.2 Conclusion 
The thesis work presented here shows the relative abilities of 1H NMR spectroscopy and 
UPLC-MS analytical platforms for extracting meaningful biological information, 
assessed by metabonomics investigations based on complex biofluid matrices derived 
from animal models of toxicity and from human studies. Both 1H NMR spectroscopy 
and UPLC-MS are excellent analytical platforms and straightforward to apply on urine 
samples with minimal sample preparation and a short experimental run time. In these 
studies, these technologies provided complementary biochemical information of urine 
samples from patients with unidentified inborn errors of and population differences in 
urinary metabolite profiles from a large scale human population epidemiological study. 
The use of MS/MS aided identification of metabolites such as isovalery1carnitine and 
provided some information on unknown compounds. The structural identification of 
unknown compounds using UPLC-MS could be improved through the expansion of 
readily available MS databases. 
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7.3 Future work 
Future work should be carried out to further extract latent biological information from 
the complex biofluids using both 1H NMR spectroscopy and UPLC-MS strategies and 
identify unknown biornarkers. 
Rat urine samples of metabolic alkalosis, metabolic acidosis as well as caloric 
restriction studies should be analysed by UPLC-MS in order to obtain complementary 
information regarding temporal changes of possible non-toxic or confounding 
physiological effects of intervention using toxic agents. The range of urinary 
metabolites profiled should be increased by constructing excretion profiles of other 
metabolites from both 1H NMR spectroscopy and UPLC-MS datasets. 
The complementary 1H NMR spectroscopy and UPLC-MS analytical techniques can be 
used to investigate other IIEMs for a larger dataset. Reproducibility could be evaluated 
by analysing a larger number of urine samples for each IIEM. Additionally, these 
techniques can be applied to identification of metabolites and thereby understanding the 
metabolic pathways of other metabolic and disorders. 
Identification of biomarkers which discriminated the Icelandic population from the rest 
of the populations from UPLC-MS analysis should be carried out using alternative 
analytical methods. Fourier transform mass spectrometry (FT-MS) would be the most 
suitable choice due to its higher nilz accuracy and resolution. Furthermore, it offers 
multiple collision MS/MS experiments (MS') of fragment ions of interest biomolecules 
with higher accuracy, thereby aiding the structural elucidation of complex molecules 
(Siuzdak, 2006). 
Pre-clean up sample preparation methods such as solid phase extraction (SPE) could be 
used to isolate and concentrate the lower abundance metabolites of interest in order to 
improve analysis by 1H NMR spectroscopy. This might not be a suitable choice for high 
through-put sample analysis particularly within a large sample set, but it could be 
performed on pooled samples/specific samples. Sometimes the concentration of an 
isolated unknown compound by SPE might not be adequate for the detection by NMR 
spectroscopy. Cryogenic probe technologies allow the detection of lower abundance 
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metabolites in the biofluids than could be expected of conventional NMR techniques 
(Keun et al., 2002a). Therefore, the hyphenated techniques such as UPLC-cryo-NMR 
and UPLC-cyro- NMR-MS will be an extremely powerful tool for qualitative and 
quantitative analysis of unknown compounds in complex matrices. Complementary 
infon-nation from NMR and MS can be obtained simultaneously for metabolites in 
biofluids as they elute from UPLC in a single chromatographic run by using a 
hyphenated UPLC-NMR-MS approach. This gives far more structure elucidation power 
than available previously to solve the structures of components in complex matrices 
rapidly and efficiently. 
Despite the derivatisation sample preparation methods required along with longer 
analysis, GC-MS analysis have advantages such as reproducible, established methods 
for analysing biofluids and comprehensive databases. It also provides complementary 
information about different metabolites, and therefore can be applied to all urine 
samples of toxicity, epidemiological and IEM. Use of robotic systems can speed up 
sample preparation time. 
Integration of 1H NMR spectroscopic data and UPLC-MS data should be carried out in 
order to maximise the biochemical infon-nation recovery from urine samples and to 
enhance the overall interpretability of metabonomics data from both analytical 
platforms. Statistical HeterospectroscopY (SHY) is a relatively new approach that 
allows the analysis of intrinsic covariance between signal intensities in the same and 
related molecules measured by different techniques across samples and successfully 
applied in toxicology study (Crockford et al., 2006). The application of SHY analysis to 
IH NMR spectroscopy and UPLC-MS data of human urine samples from INTERSALT 
study should reveal cross correlation between parameters from both analytical 
technologies, leading to improved efficiency of biomarker identification. 
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Appendix 1: Materials and Suppliers 
Materials Suppliers 
2-hydroxybutyrate Sigma-Aldrich 
2-ketoglutarate Sigma-Aldrich 
3-hydroxy-3-methylglutarate Sigma-Aldrich 
3-hydroxybutyrate Sigma-Aldrich 
3-hydroxyisovalefic acid Sigma-Aldrich 
3-ureidopropionic acid Sigma-Aldrich 
5-hydroxyindoleacetate Sigma-Aldrich 
96-well plates Waters 
Acetonitfile (Riedel-de-Haýn) Sigma-Aldrich 
ACQUITyTM 1.79M C18BEH column Waters 
Adipate Sigma-Aldrich 
Azelaic acid Sigma-Aldrich 
Betaine Sigma-Aldrich 
Cis-aconitate Sigma-Aldrich 
D20 Goss Scientific 
Formic acid Sigma-Aldrich 
Furnarate Sigma-Aldrich 
Hippuric acid Sigma-Aldrich 
Homocystine Sigma-Aldrich 
Homogentisic acid Sigma-Aldrich 
Isovaleric acid Sigma-Aldrich 
Synthesised and donated By Prof. Ron 
Isovalerylglycine Wevers, Radboud University Nijmegen 
Medical Centre, Nijmegen, The Netherlands 
Lysine Sigma-Aldrich 
Malate Sigma-Aldrich 
Mesaconic acid Sigma-Aldrich 
Methanol (Riedel-de-Hadn) Sigma-Aldrich 
Methyladipic acid Sigma-Aldrich 
Methylmalonate Sigma-Aldrich 
Methylmalonic acid Sigma-Aldrich 
Methylsuccinate Sigma-Aldrich 
Mevalonolactone Sigma-Aldrich 
Orotate Sigma-Aldrich 
Orotic acid Sigma-Aldrich 
Pirnelic acid Sigma-Aldrich 
Suberate Sigma-Aldrich 
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Suberylglycine 
Succinate 
Succinate- 1,4- 13C" 
Tryptophan 
UPLC grade water (Riedel-de-Hadn) 
UPLC Screw cap vials 
Uracil 
Uridine 
Urocanic acid 
Sigma-Aldrich 
Sigma-Aldrich 
Cambridge Isotope Laboratories 
Sigma-Aldrich 
Sigma-Aldrich 
Waters 
Sigma-Aldrich 
Sigma-Aldrich 
Sigma-Aldrich 
Address of suppliers and instrument manufactures 
Bruker Biospin 
Silberstreifen 
D-76287 Rheinstetten 
Karlsruhe 
Germany 
Cambridge Isotope Laboratories 
50 Frontage Road 
Andover MA 0 1810-5413 
USA 
Goss Scientific Instruments Ltd 
100 Vicarage Lane 
Great Baddow 
Chelmsford 
Essex 
CM2 8JB 
Micromass UK Ltd 
Atlas Park 
Simonsway 
Manchester 
M225PP 
Sigma-Aldrich Company Ltd 
Dorset 
UK 
Waters Corporation 
34 Maple Street 
Milford 
MA 01757 
USA 
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Appendix 2: Composition of phosphate buffer for 
urine sample preparation for NMR spectroscopy 
Chemicals Weight 
Na2HP04 (0.2M) 28.85 g Phosphate buffer Made up 
NaH2PO4(0.04 M) 5.25 g to I litre H20/D20 
TSP 0.172 g (I mM) (80: 20 v/v) 
NaN3 (sodium azide) 0.193 g (3 mM) 
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Appendix 3: MS and MS/MS Spectra of Unknown 
Metabolites 
Sample 1 
100 
[M+HI 
-nA nA ý- 
1468 
144.1275 100-1 1 
129.1038 
; 4ý 
130.0545 1145.1221 
103.1050 130.9304 
145.8986159.0645 
208.4090 218.1091 
,, 
163.0488 196.9940,,, 
01 111111111 1,1ý1 
1111 
.1 'ji 1 11 ,I........ iI. 7.10 
!1.... I. III!,,. I... 'I'm m/z 
100 120 140 160 180 200 220 
Name Molecular weight (MW) 
Propionyl carnitine (See Chapter 5, section 5.4.4) 217.1314 
Possible biomarkerfrom http., -Ilwww. hmdb. ca 
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Sample 2 
[M+H] 
100 
89 
IJ 
226.0870 
198.0932 
196.0779 
129.0700 168.0765., 
104.0342 
PT.... . 1.11 ... I 
254.0830 
270.0753 
1 
L71.0876 
284.0974 
285.0943 
331.0970 
1,332.0967 
M/z 
75 100 125 150 175 200 225 250 276 300 326 350 
Possible biomarkersfrom http., -Ilwww. hmdb. ca 
Name Molecular weight (MW) 
Picrocrocin 330.168 
Camosol 330.183 
Furosemide 330.007 
No endogenous compound matched the MW. 
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Sample 3 
145.0913 
167.1581 
127.0838 
11 
100.1244 
128.0196 
146.0019 
101.0603 
109.0951 146.9345 
100 120 140 160 
68.0694 229.1459 
211.1402 
185.1530 212.0895 
........ 
ll,, 187.0205 
180 200 220 
31.0160 
M/Z 
240 
Possible biomarkerfrom http., -#www. hmdb. ca 
Name Molecular weight (MW) 
Dodecanedioic acid 230.151 
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Sample 3 
Q 
)303 
. 8906 
107.0310 
208.0680 
124.0522 
107.8127 125.0163 
111.8762le' 
0 
142.1325 
144.4501 209.1206 
195.199 
151.5054 165.9776 180- 194 212.2914 
Ili Ill., 1.4 11.11111.111 
1 
w.; ý,; J. !;, 
m/z 
110 120 130 140 150 160 170 180 190 200 210 
Possible biomarkerfrom http., -Ilwww. hmdb. ca 
Name 
Hydroxyphenylacetyl glycine 
Molecular weight (MW) 
209.069 
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Appendix 4: Abstract I 
Abstract for Second Scientific Meeting of the 
Metabolomics Society 
Harvard Medical School 
Boston, USA 
June 24-29,2006 
Title: Profiling of Urinary Organic Acids by 
Ultra Performance Liquid Chromatography 
- Mass Spectrometry (UPLC-MS) 
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Profiling of Urinary Organic Acids by Ultra Performance 
Liquid Chromatography 
- Mass Spectrometry (UPLC-MS) 
Vinothini Sivarajah, Cinzia Stella, Hector Keun, Jeremy K Nicholson 
Biological Chemistry, Biomedical Sciences Division, Faculty of Natural 
Sciences, Imperial College London, South Kensington SW7 2AZ, United 
Kingdom 
Profiling of urinary organic acids (OA) using reliable and reproducible analytical 
techniques can yield infori-nation on the pathophysiological status of many different 
metabolic pathways and allow early diagnosis and treatment for inborn errors of 
metabolism. Derived from dietary protein, fat and carbohydrate, OA are used by the 
body to generate cellular energy and provide the building blocks necessary for cell 
function. The measurement of organic acids in urine allows the simultaneous 
assessment of mitochondrial energy production efficiency, neurotransmitter metabolism, 
clinically significant microflora imbalances in the gut, and metabolic toxicity problems. 
The aim of this study was to develop a novel bioanalytical method for the profiling of 
OA in human urine using UPLC-MS. The analysis was performed on an ACQUITY 
UPLCTm BEHC18 column (1.7 [tm, 2.1 mm x 50 mm) using a gradient elution profile 
and a mobile phase consisting of 0.1% formic acid in water and acetonitrile. The 
analytes were detected using electrospray ionisation (ESI) mass spectrometry in both 
negative and positive modes. Initially, a reference study was carried out on standard 
solutions of the selected OA with the aim of recording retention times and mass spectra. 
The same chromatographic and mass spectrometry conditions were then applied to 
urine samples following a sample preparation step. This proposed method is rapid, 
reliable and sensitive and could be successfully applied for the profiling of urinary OA. 
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Appendix 5: Abstract 11 
Abstract for Advances in Metabolite Profiling 
conference 
Strand Place Hotel London 
November 1" -2 
nd 2005 
Title: Development of a Novel Ultra 
Performance LC-MS-NMR Platform For 
Human Metabolic Phenotyping 
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Development of a Novel Ultra Performance LC-MS-NMR 
Platform For Human Metabolic Phenotyping 
Vinothini Sivarajah, Dr Hector Keun and Prof Jeremy Nicholson 
Biological Chemistry, Biomedical Sciences, Imperial College, Sir 
Alexander Fleming Building, Exhibition Road, South Kensington, London 
SW72AZ 
Multivariate metabolic profiling and modelling are underpinned by hyphenated 
techniques such as Nuclear Magnetic Resonance coupled to High Performance Liquid 
Chromatography (HPLC-NMR), HPLC coupled to Mass Spectrometry (HPLC-MS) 
Ultra Performance LC coupled to MS and UPLC-MS-NMR. Physical combination of 
these techniques is an extremely powerful tool in carrying out qualitative and 
quantitative analysis of unknown compounds in complex matrices. A case study was 
carried out to develop a new integrated UPLC-MS-NMR platform for metabolic 
analysis using urine samples from a patient with an unknown lysosomal storage disease. 
Results show (Beta)-aminoisobutyrate (BAIB) is a potential new marker. Future work is 
to set up a metabonomic database of normal human variation and to develop 
chemometric tools for structural assignments. This together will make the technology 
useable for characterising human diseases in terms of urine and plasma breakdown 
products. 
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